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Abstract	  
 
These studies present the identification of the first parasite secreted ubiquitin 
pathway enzyme, and report a system for the characterisation of the role of 
Trichinella spiralis secreted proteins in the context of mammalian muscle cell re-
programming. 
T. spiralis invade terminally differentiated myofibres, secreting proteins (SP) into the 
host cell and inducing dedifferentiation and cell cycle re-entry. Since myogenic 
differentiation and the cell cycle are heavily influenced by the ubiquitin pathway, this 
study used T. spiralis as a model to investigate the extent to which parasites 
specifically manipulate the ubiquitin pathway during infection.  
Ubiquitin is ligated to protein substrates by E1, E2 and E3 enzymes, and removed by 
deubiquitinating enzymes (DUBs). This ubiquitin 'tag' regulates the fate and function 
of the substrate protein. A DUB expressed by T. spiralis, TsUCH37, was 
characterised as a conserved proteasome interaction partner, however no evidence 
was found of the presence of this, or any other T. spiralis DUB in the muscle larvae 
SP. Upon further investigation an E2 enzyme, TsUBE2L3, was identified. The 
ubiquitin conjugation activity of T. spiralis SP was confirmed, and was only possible 
in the presence of human E1 and E3 enzyme partners. The effect of TsUBE2L3 on 
mammalian muscle cells was investigated by expressing the T. spiralis protein in a 
mouse muscle cell line. Although no significant effect on the cell cycle or 
differentiation state of the muscle cells was observed, TsUBE2L3 expression led to a 
significant reduction of the tumour suppressor protein, p53 that was confirmed to 
occur at the protein level. 
T. spiralis strikes a delicate balance between host cell modulation and host 
protection. This thesis builds on the proposal that the host-targeted muscle cell 
modulators of T. spiralis may inspire the development of parasite-derived 
therapeutics for the treatment of disease. 
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Chapter	  1:	  Introduction	  
 
The purpose of the PhD project was to investigate the role of the ubiquitin pathway in 
host-parasite interactions. This investigation was carried out using Trichinella spiralis 
infection of mammalian muscle cells as a model system. 
1.1.	  The	  ubiquitin	  pathway	  
 
The ubiquitin pathway is functional in all eukaryotic organisms and, as the name 
suggests, the focal point of the pathway is a protein that is expressed ubiquitously in 
all cell types, ubiquitin. It is a highly conserved biochemical pathway that modifies 
and regulates proteins at the post-translational level. The ubiquitin pathway was first 
discovered by Aaron Ciechanover, Avram Hershko, and Irwin Rose in the 1980s, 
who went on to characterise the role of the ubiquitin pathway in the regulation of 
protein degradation [4]. This major function of the ubiquitin pathway is to regulate the 
abundance of intracellular proteins by controlling their degradation via the direct 
communication with the proteolytic complex, the 26S proteasome. We now know that 
the ubiquitin pathway plays a vital role in the regulation of a great number of tightly 
regulated biological processes, from transcription and the cell cycle to trafficking and 
apoptosis [5]. As a testament to the importance of this pathway in cell biology, the 
work of Ciechanover, Hershko and Rose was awarded the Nobel Prize in Chemistry 
in 2004. 
Ubiquitin (Ub) is a 76 amino acid protein (8.5 kDa) that is known as a small modifier 
[6]. This is because protein substrates of the ubiquitin pathway become modified with 
(or conjugated to) a ubiquitin ‘tag’. This tag serves as a signal that directs the 
substrate protein towards a particular fate depending on the timely requirements of 
the cell during the maintenance of healthy homeostasis. Other small modifier 
proteins similar to Ub have also been discovered and this thesis will discuss one 
other, Nedd8 (Neural Precursor Cell Expressed, Developmentally Down-Regulated 
8). There is no evidence that Nedd8 is directly involved in protein degradation. It 
does however play an important role in processes such as the regulation of the cell 
cycle [7]. In humans Nedd8 is 53.4% identical in amino acid sequence and shares a 
common tertiary structure to ubiquitin [8]. Nedd8 and ubiquitin are processed in a 
similar manner, resulting in the Neddylation or ubiquitination of substrate proteins. 
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1.2.	  Ubiquitin	  conjugation	  
 
Ubiquitin is transcribed as a polyubiquitin precursor. The first step in the process of 
ubiquitination is therefore the proteolytic cleavage of polyubiquitin to form 
monoubiquitin. This is now ready to be conjugated to substrate proteins. The event of 
conjugation is catalysed by 3 ubiquitin-specific enzymes that function with one-
another in a cascade of activity [9] (Figure 1.1). The first enzyme is a ubiquitin 
activating enzyme, called E1. This 110 kDa enzyme forms an E1-S-ubiquitin 
intermediate complex upon the formation of an ATP-dependent thioester linkage 
between the sulfhydryl group of the active site cysteine of the E1 and the C-terminal 
glycine carboxyl group of the ubiquitin. The E1 enzyme then passes the highly 
activated thiol-linked ubiquitin onto the active site cysteine of a ubiquitin conjugating 
enzyme (E2), forming an E2-S-ubiquitin intermediate. The E2 enzyme then 
specifically recognises the final protein in the enzymatic cascade, the ubiquitin ligase 
(E3). The specific E3, and sometimes the E2-E3 pair, is responsible for recognising a 
specific protein substrate. The E3 then mediates the ligation of the ubiquitin to the 
amino group of a lysine (K) residue of the protein substrate via a covalent isopeptide 
bond with the C-terminal glycine of the ubiquitin (Figure 1.1).  
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Figure 1. 1 The ubiquitin pathway 
Schematic showing the cleavage of the ubiquitin (Ub, lilac) precursor by deubiquitinating 
enzymes (DUBs). Followed by ubiquitin conjugation to a substrate protein (S) as catalysed by 
the E1, E2 and E3 enzyme cascade. The active-site cysteine of the E1 enzyme activates Ub 
by forming an ATP-dependent E1-S-Ub intermediate with the C-terminal glycine of Ub. 
Activated Ub is then passed onto the active-site cysteine of an E2 enzyme, which also forms 
a thioester bond with the C-terminal glycine of Ub. The E2 passes Ub onto an E3 ligase. 
RING E3 ligases bring the E2-S-Ub intermediate into contact with the substrate protein, 
allowing the substrate lysine amino group to attack the C-terminal glycine of Ub forming an 
isopeptide bond. E2 enzymes pass Ub onto the active site cysteine of HECT E3 ligases first, 
and then the E3 interacts with the substrate protein, which forms an isopeptide bond with Ub. 
Ub conjugation is reversed by DUBs to recycle ubiquitin and deubiquitinate the substrate 
protein. DUBs attack the C-terminal glycine of Ub to hydrolyse the isopeptide bond. Figure 
modified from Kerscher et al. 2006, Annu. Rev. Cell. Dev. Biol. [7]  
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Eukaryotes express only one E1 enzyme but express a large number of E2s (10s in 
humans) that contain the ubiquitin conjugating domain (UBCc) and an even larger 
number of E3s (100s in humans) [10]. There are a number of different types of E3 
domains, the best-described being the HECT domains (Homologous with the E6-AP 
C-Terminus) and RING (Really Interesting New Gene) finger domains [11,12]. During 
ligation, ubiquitin is transferred from an E2 to the active-site cysteine of a HECT 
domain E3, forming an E3-S-ubiquitin intermediate before the ligation to the 
substrate takes place. In contrast, RING finger E3s catalyse the transfer of ubiquitin 
directly from the E2 to the protein substrate, thus associating with the substrate and 
the E2 simultaneously (Figure 1.1). Together, the specific E2-E3 partnership and the 
recognition of particular protein substrates by the E3, confer an extremely high level 
of specificity in the pathway.  
In addition to lysine residues of substrate proteins, ubiquitin can be ligated to 7 
possible lysine residues (K6, K11, K27, K29, K33, K48 and K63) on other ubiquitin 
proteins, forming chains of polyubiquitin [13]. These polyubiquitin chains are also 
found conjugated to substrate proteins. There is a large variation in the possible 
length of the chain, and the residue via which each ubiquitin is linked to another, 
providing many possible different ubiquitin tags (Figure 1.2). Proteins can also be 
monoubiquitinated at multiple lysine residues (multiubiquitinated) and polyubiquitin 
chains can also be branched. Each particular ubiquitin tag serves as a signal to 
direct the substrate protein towards a different fate. For example, monoubiquitin often 
leads to changes in the sub-cellular localisation of the substrate protein, 
multiubiquitin has been shown to affect protein interactions and associations, 
whereas K48-linked polyubiquitin chains generally target proteins to the 26S 
proteasome for their degradation [7,14,15].  
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Figure 1. 2 Different ubiquitin tags 
Ubiquitin has 7 lysine residues that can be linked to other ubiquitin modifiers. Each type of 
ubiquitin tag serves as a signal for a different biological fate of the substrate protein. Figure 
modified from Wang et al. 2012, Front. Oncol. [16]. 
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1.3.	  The	  26S	  proteasome	  
 
The 26S proteasome is a protein complex located in the cytoplasm and the nucleus. 
It is composed of 2 multi-protein subunits, the 20S catalytic core and the 19S 
regulatory particle. The assembly of the 20S and the 19S subunits is reversible. 
Disassembly is induced by various stresses such as oxidative stress or starvation 
[17,18]. The 19S regulatory particle can associate with either or both ends of the 20S 
core and is composed of a lid structure and a base structure (Figure 1.3). The 19S lid 
comprises proteins Rpn3, 5-9, 11, 12 15 plus Rpn10, Rpn1, Rpn2 and Rpn13, which 
is also known as ADRM1. These proteins are responsible for the recognition and 
binding of the polyubiquitin tag of a substrate protein. Once the substrate protein is 
associated with the 19S lid, it begins to enter the 19S base, which links the 20S core 
to the 19S lid. This is composed of a ring of Rpt proteins (1-6). These proteins are 
ATPases that possess chaperone-like activity and are thought to be responsible for 
unfolding the substrate protein, allowing its passage into the 20S core [19]. The 20S 
subunit is cylindrical and is made up of alpha and beta subunits arranged in 
hexameric ring structures forming a hollow core. These proteins possess protease 
activity (caspase-like, chymotrypsin-like and trypsin-like) and catalyse the 
degradation of the unfolded protein as it passes through the proteolytic core [20]. The 
substrate protein is processed into short peptides and amino acids that pass out of 
the other end of the proteasome. Ubiquitin does not pass through the proteasome. 
This is cleaved from the substrate upon binding and entry of the substrate to the 19S 
regulatory particle. The cleavage and subsequent recycling of ubiquitin from protein 
substrates is mediated by proteasome-associated ubiquitin hydrolase (or 
deubiquitinating-DUB) enzymes. 
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Figure 1. 3 The structure of the 26S proteasome 
The 26S proteasome is composed of a 19S subunit, also known as the regulatory particle, 
and the 20S subunit, also known as the catalytic core. The 19S subunit is made up of a lid of 
Rpn proteins and a base Rpt protein ring. This regulates substrate protein association, 
deubiquitination and unfolding. The 20S catalytic core is made up of alpha and beta subunits 
arranged in hexameric rings forming a hollow core through which the unfolded protein passes. 
The 20S core possesses ATP-dependent protease activity that degrades the protein, 
releasing short peptides and amino acids. Image modified from Weissman et al. Nat. Rev. 
Mol. Cell. Biol. 2011 [21]. 
Chapter 1: Introduction 
 24 
1.4.	  Ubiquitin	  hydrolysis	  by	  DUBs	  
 
Enzymes responsible for the cleavage of the ubiquitin precursor, the recycling of 
monoubiquitin from un-associated polyubiquitin chains and the removal of ubiquitin 
from substrate proteins are called deubiquitinating enzymes (DUBs) [22]. The 
enzymes that hydrolyse Nedd8, deNeddylating enzymes, function in a similar 
manner. It is thought that there may be in excess of 100 different mammalian DUBs, 
each of which usually recognises highly specific protein substrates. Many have been 
characterised and for some the crystal structures have been resolved [23-25]. DUB 
enzymes can be divided into 5 families based on their functional conserved domains: 
the Ub C-terminal hydrolase domain (UCH), Ub specific protease domain (USP), 
ovarian tumour domain (OTU), Machado-Josephin domain (MJD) and the 
JAB1/MPN/Mov34 domain (JAMM). The UCH, USP, OTU, and MJD enzymes are 
cysteine proteases and the JAMM family comprises metalloprotease enzymes [26]. 
The catalytic domains of the cysteine protease DUBs contain a highly conserved 
active site consisting of 4 amino acid residues essential for the cleavage of a specific 
substrate. For example, the catalytic site of the UCH domain enzymes comprise a 
glutamine, cysteine, a positively charged histidine and a negatively charged aspartic 
acid [25]. During ubiquitin hydrolysis, the active site cysteine thiol (sulfhydryl group) 
forms a thioester bond with the carbonyl of the C-terminal carbon of ubiquitin. The 
isopeptide bond between ubiquitin and the substrate is subsequently hydrolysed, 
releasing ubiquitin, the deubiquitinated substrate and the regenerated enzyme 
(Figure 1.4).  
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Figure 1. 4 The mechanism of DUB-catalysed hydrolysis 
A DUB (beige) recognises a specific protein substrate (dark green) and catalyses the 
hydrolysis of the isopeptide bond between the substrate and ubiquitin. The active-site cleft 
contains a histidine (His), an asparagine (Asn), an aspartic acid (Asp) and the catalytic 
cysteine (Cys). The histidine maintains the nucleophilicity of the cysteine, which attacks and 
hydrolyses the isopeptide bond of ubiquitinated substrate. Kessler, 2006, [27]. 
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In humans there are 3 DUBs shown to specifically interact with the proteasome. The 
first, Rpn11 is an integral part of the 19S lid structure of the regulatory particle. 
Rpn11 is a JAMM domain metalloprotease that removes ubiquitin from protein 
substrates as they pass into the proteasome. The removal of ubiquitin, which 
otherwise sterically hinders the entry of the substrate into the proteasome, promotes 
the translocation of the substrate into the 20S core for degradation [28,29]. The 
second proteasome-associated DUB is the ubiquitin-specific protease domain 
enzyme, USP14 (Ubp6 in yeast). Unlike Rpn11, this protein is not always associated 
with the proteasome and association is reversible. USP14 associates with the 19S lid 
via Rpn1 and Rpn2 and catalyses the cleavage of ubiquitin from proteins as they 
bind to the proteasome [30]. This inhibits the activity of the regulatory particle, 
suggesting that the cleavage of the tag frees the substrate from the original fate of 
proteasomal degradation [31]. The final proteasome-associated DUB, whose function 
is a focal point of this thesis, is the ubiquitin-C-terminal hydrolase domain enzyme, 
UCH37 (or UCH-L5). UCH37 is nuclear and cytoplasmic and its interaction with the 
proteasome is also reversible. The binding of UCH37 to the proteasome significantly 
enhances its ubiquitin hydrolysis activity by relieving UCH37 of the auto-inhibitory 
effect of its C-terminal tail [32,33]. UCH37 binds to Rpn13/ADRM1, which in turn 
binds to Rpn2, thus competing with USP14 for proteasome association. UCH37 
cleaves ubiquitin from the distal end of polyubiquitin chains of protein substrates 
[34,35]. Koulich et al. showed that RNAi of UCH37 speeds up protein degradation in 
HeLa cells suggesting that UCH37 also acts as a checkpoint for the fate of the 
substrate protein. Interestingly, UCH37 knockout in mice caused embryonic defects 
and prenatal death illustrating that the regulation of proteasomal protein degradation 
by UCH37 is essential [36]. 
 
In summary, ubiquitin conjugation is highly regulated by the balance of the 
abundance and activity of ubiquitin conjugation machinery; E1, E2 and E3 enzymes. 
Likewise ubiquitin hydrolysis is highly regulated by the balance of the abundance and 
activity of DUBs. Although in mammals many of these proteins have now been 
characterised, in almost all cases their specific protein substrates remain to be 
determined. The transient nature of the interaction of these enzymes with their 
substrates makes this a challenging task. However in order to further characterise 
the specific pathways and biological processes in which they function, this is an 
important angle of investigation. 
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1.5.	  The	  ubiquitin	  pathway	  in	  disease	  
 
Considering the important role of the ubiquitin pathway in maintaining the healthy 
homeostasis of a cell, and therefore of the healthy physiology of the organism, it is 
not surprising that the disruption of the ubiquitin pathway is directly implicated in a 
variety of diseases. These include cystic fibrosis, Liddle’s syndrome, Angelman 
syndrome, muscle wasting disease and many neurodegenerative disorders and 
cancers [37-40].  
1.6.	  Muscle	  wasting	  disease	  
 
The terminal differentiation of skeletal muscle cells, from immature myoblasts to 
mature muscle fibres, will be discussed in more detail later (section 1.14). The 
processes of muscle differentiation, growth and homeostasis require the function of 
the ubiquitin pathway [41]. The ubiquitin pathway is also implicated in the disruption 
of these processes that can lead to muscle wasting diseases caused by skeletal 
muscle atrophy (the degeneration of skeletal muscle tissues). This can occur as a 
result of other diseases such as cancer, chronic obstructive pulmonary disease 
(COPD) and sepsis. During these disease states, the ubiquitin system in muscle cells 
is highly activated by a lack of physical activity, a loss of nervous communication to 
the muscle tissues and by malnutrition [40]. This leads to the rapid ubiquitin-
mediated degradation of muscle proteins and thus the loss of the mass and function 
of the muscle tissue. This effect has been linked to the up-regulation of 2 muscle-
specific atrophy-related (atrogen) genes that encode the MuRF1 (Muscle RING 
finger 1) protein that contains an E3 RING finger domain, and the MAFbx (Muscle 
Atrophy F-box) protein that contains an E3 RING finger domain similar to that of the 
cell-cycle specific E3, the SCF complex [42]. These muscle specific E3 ligase 
enzymes ubiquitinate and target myofibre proteins for proteasomal degradation 
[43,44]. MuRF1 and MAFbx have been shown to be activated in many different 
animal models of muscle wasting disease, suggesting that a common ubiquitin-
related pathway controls muscle atrophy in various disorders. 
1.7.	  Neurodegenerative	  disease	  
 
Neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and 
Huntington’s disease all involve the build up of toxic aggregates of abnormal proteins 
in neuronal cells. As well as regulating the degradation of specific proteins for 
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specific requirements, the ubiquitin-proteasome system is also responsible for the 
degradation of misfolded or abnormal proteins [45]. It is thought that the disruption of 
this process may lead to their build up and play a role in the formation of these 
aggregates [46]. Not only have these aggregates have been found to contain 
ubiquitin but mutations in various genes encoding ubiquitin pathway proteins have 
been linked to the development of these diseases [47-49]. For example mutations in 
the PARK2 gene that encodes the E3 ligase parkin, is found in autosomal recessive 
juvenile Parkinsonism, and mutations in the ubiquitin gene itself are associated with 
Alzheimer’s disease [50] [51]. 
1.8.	  Cancer	  
 
The regulation of the abundance or location of a cell cycle protein or an oncoprotein 
often relies on proteasomal degradation [52,53]. The disruption of this process can 
therefore lead to a disruption of the cell cycle and tumourigenesis. These disruptions 
can arise from within the cell, for example by mutagenesis of cell cycle related genes. 
Degradation of the G1 phase-specific cyclin-dependent kinase inhibitor, p27kip1 is 
highly regulated by ubiquitination. The increased proteasomal degradation and 
therefore down-regulation of this protein leads to cell cycle progression. The down-
regulation of p27kip1 has been found in many cancers such as breast and prostate, 
implicating a role for the ubiquitin pathway in the development of these malignancies 
[54]. In addition, the cell cycle regulator proteins, cyclins, are also highly regulated by 
the ubiquitin pathway [55,56]. The over-expression of cyclin B, cyclin E and cyclin D1 
has been observed in many different types of tumours [57-59]. Whether or not the 
up-regulation of these proteins in tumour cells is a result of the inhibition of their 
proteasomal degradation remains to be determined, but mutations in cyclin-specific 
ubiquitin conjugation machinery have been found in several cancers [60]. SCF (Skp, 
Cullin, F-box containing) is a cell cycle-specific complex that controls the transition of 
the G1/S phase and the G2/M phase of the cell cycle. This is achieved through the 
E3 ligase activity of SCF which ubiquitinates specific cell cycle factors. Similarly, the 
anaphase promoting complex (APC) is an E3 ligase that ubiquitinates specific cell 
cycle factors to initiate the progression of metaphase and anaphase of the M phase 
of the cell cycle [61,62]. The regulation of cell cycle factor ubiquitination by SCF and 
APC is therefore important for maintaining a healthy level of proliferation, and 
alterations in the genes encoding these complexes have been found to correlate with 
a number of cancers [63]. 
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Cancer development may also be initiated by the disruption of the ubiquitin pathway 
and subsequent disruption of the cell cycle by viruses. High-risk strains of the human 
papillomavirus (HPV) express an E6 oncoprotein that associates with the human 
HECT domain E3, E6-AP (E6 Associated Protein, also known as UBE3A) in infected 
cervical epithelial cells [64]. Through an interaction with the host E2, UBE2L3 
(UbcH7), this leads to the specific ubiquitination and subsequent degradation of the 
tumour suppressor protein p53 [65-67]. The suppression of p53 promotes the 
propagation of the virus via the uncontrolled proliferation of these cells, leading to the 
development of cervical cancer [68,69]. This is also an example of how the disruption 
of the ubiquitin pathway is implicated in infectious disease, which will be discussed in 
more detail in the next section.  
Due to the discovery of the direct link between the ubiquitin pathway and disease, 
the proteasome has been recognised as a potential drug target for disease therapy 
for some time [70-72]. Some proteasome inhibitors are in clinical trials for human use 
including bortezomib, which in 2006 was approved by the Food and Drug 
Administration to treat multiple myeloma and mantle cell lymphoma [73-76]. However, 
because the proteasome is so highly expressed in all tissues, many proteasome 
inhibitors are non-selective and show toxicity. In order to develop inhibitors with 
greater selectivity, there has been an expansion in the interest in targeting other 
members of the ubiquitin pathway that are differentially expressed or activated, such 
as ubiquitin conjugation enzymes or DUBs [77]. Although as yet none have entered 
clinical trials, there are some recent examples of small molecule DUB inhibitors that 
show therapeutic benefits in cancer [78]. For example, Chauhan et al. showed that a 
specific inhibitor of USP7/HAUSP (herpesvirus-associated USP) induces apoptosis 
of multiple myeloma cells and inhibits tumour growth in mice [79]. Other DUBs, such 
as the proteasome-associated UCH37, have been directly linked to the 
deubiquitination and stabilisation of oncogenic proteins leading to the proliferation of 
cancer cells. UCH37 stabilises transforming growth factor-β (TGF-β) by targeting 
Smad transcription factors for proteasomal degradation via ubiquitination. Inhibiting 
UCH37, reverses this effect, and inhibits cancer cell migration [80,81]. In addition, a 
drug that specifically inhibits UCH37 was observed to induce apoptosis of a number 
of different types of tumour cells in mice [82]. Amongst other ubiquitin pathway 
enzymes, these DUBs may therefore prove as promising new targets for the 
development therapeutics for cancer, and ubiquitin-related diseases. 
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1.9.	  The	  ubiquitin	  pathway	  in	  infectious	  disease	  
 
In addition to the disorders discussed, the ubiquitin pathway is also implicated in 
infectious disease. Immunity to infection is highly dependent on the function of 
antigen presentation as carried out by antigen presenting cells (APCs, predominantly 
dendritic cells and macrophages, but also B lymphocytes). This is the process by 
which pathogen-derived antigens are degraded into short peptides and presented on 
the surface of APCs in complex with the major histocompatibility complex, MHC. 
These APCs then present the antigen-associated MHC complexes to T lymphocyte 
cells. T cells become activated to respond appropriately to the infection, either by 
killing the pathogen or mounting an adaptive immune response. The ubiquitin-
proteasome system is involved in antigen uptake by B lymphocyte cells, 
proteasomal-mediated antigen degradation for peptide presentation by APCs, and 
the proteasomal regulation of levels of MHC protein by proteasomal degradation 
[83,84]. A functional ubiquitin-proteasome system is therefore crucial for managing 
immunity to infection. 
Many pathogens specifically target the ubiquitin pathway in order to evade an 
immune response that threatens their survival [85,86]. For example, the lymphoma 
associated Epstein Barr virus (EBV) expresses a protein EBVNA1 (EBV Nuclear 
Antigen 1) that evades proteasomal degradation thus evading antigen presentation 
and a subsequent immune response. Similarly, the cytomegalovirus (CMV) proteins 
US2 and US11 evade antigenic presentation by preventing the translocation of the 
MHC complex to the cell surface. They do so by directing the MHC complex to the 
proteasome for degradation [87]. The disruption of antigen presentation during 
infection is not exclusive to viruses. Pathogenic bacteria have also developed 
mechanisms of manipulating ubiquitin pathway-mediated regulation of antigen 
presentation to evade immunity. For example Salmonella bacteria inhibit the 
translocation of MHC to the surface of APCs thus preventing the activation of a T cell 
mediated response [88]. The modulation of the host ubiquitin pathway by pathogens 
is not restricted to antigen presentation. Many pathogens target the ubiquitin pathway 
in order to enhance their virulence by disrupting other host cell functions such as the 
cell cycle. This can involve the specific targeting of deubiquitinating enzymes by 
pathogens [89]. For example, the Epstein Barr virus EBNA1 protein directly interacts 
with and inhibits the human (tumour suppressor) p53-specific DUB, USP7/HAUSP. 
This leads to the destabilisation of p53 and the disruption of the host cell cycle 
[90,91]. The widespread bacterial pathogen,  Pseudomonas aeruginosa , chronically 
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infects the lung mucosal cells of patients with diseases such as COPD, cystic fibrosis 
and pneumonia. P. aeruginosa secretes an effector protein Cif, which targets and 
inhibits the host DUB USP10. This inhibits the removal of ubiquitin by USP10 from 
the cystic fibrosis transmembrane conductance regulator (CTFR) causing an in 
increase in the proteasomal degradation of the CTFR. CTFR is an ion channel that 
transports chloride across the cell membrane. This internalization and degradation of 
CTFR inhibits the transport of chloride across the cell membranes of infected 
mucosal cells, causing a build up of thick mucous outside the cell. This prevents the 
clearance of the pathogen by the mucosal cell surface cilia, thus aggravating the 
infection [92].  
Interestingly, some of the viral and bacterial proteins that hijack the host ubiquitin 
pathway are ubiquitin pathway enzymes themselves. These proteins can be 
completely pathogen specific (novel), or they can mimic host ubiquitin enzymes. This 
was a surprising discovery, since prokaryotes, viruses and bacteria, do not have a 
functional ubiquitin proteasome pathway of their own. These proteins have therefore 
evolved to act like host ubiquitin enzymes to specifically target the host ubiquitin 
pathway to their advantage. An example of a novel pathogen ubiquitin enzyme is the 
herpes simplex virus 1 (HSV-1) deubiquitinating enzyme encoded by the UL36 gene. 
This protein shows little homology to mammalian DUBs but can hydrolyse human 
ubiquitin in vitro [93]. Homologues of this protein are also expressed by murine CMV 
(cytomegalovirus) and gammaherpesvirus 68 [94,95]. Although little is known about 
the function of these UL36 homologues, for other pathogen-derived DUBs, their 
effects on host cells have been characterised. The pathogenic bacterium Chlamydia 
trachomatis, that causes one of the most common sexually transmitted diseases in 
the UK, expresses 2 DUBs, ChlaDUB1 and ChlaDUB2. Both can hydrolyse human 
ubiquitin and human Nedd8 in vitro. ChlaDUB1 has been shown to inhibit ubiquitin-
mediated degradation of IκBα leading to a down-regulation of the pro-inflammatory 
protein, NFκB. A function that may lead to the suppression of an immune response 
required to clear the pathogen [96]. The mechanisms that underlie the effects of the 
ChlaDUBs are yet to be determined, however for other pathogen-derived ubiquitin 
enzymes, the direct interaction with the host ubiquitin pathway has been 
demonstrated. For example, Salmonella express an effector protein that mimics host 
HECT E3 ligases. This E3 enzyme, SopA, specifically collaborates with the host 
ubiquitin conjugation (E2) enzymes UbcH5 and UBE2L3 (UbcH7) in HeLa cells [97]. 
It is thought that this also leads to the ubiquitination and subsequent degradation of 
proteins involved in infection-induced inflammation. Salmonella also express a 
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deubiquitinating enzyme, AvrA, that is able to deubiquitinate host IκBα and β-catenin, 
leading to an inhibition of the host inflammatory response to infection, a common 
target of immune-evasive pathogens [98].  
Targeting the ubiquitin pathway to treat non-infectious diseases such as cancer has 
emerged as a viable strategy. Therefore, drugs that target pathogen-derived ubiquitin 
pathway enzymes may also be useful for combatting infectious diseases. Efforts are 
being made to characterise for example, pathogen derived DUBs, for this very 
reason. SARS coronavirus causes severe acute respiratory syndrome. The drug 
GRL0617 targets the SARS coronavirus DUB, Papain-like protease (Plpro). This 
inhibits virus replication, thus illustrating the potential of DUB inhibitors in the 
treatment of infection [99-101].  
This leads us to the first point in question: If there is potential in viral and bacterial 
ubiquitin pathway components as drug targets in infection, is there also potential for 
the development of parasite therapeutics that target the parasite ubiquitin pathway 
during infection? 
1.10.	  The	  ubiquitin	  pathway	  in	  infection	  by	  parasites	  
 
Parasites are most often eukaryotes and therefore express their own ubiquitin 
pathway. Considering the importance of this pathway in eukaryotic cell biology, and 
its conservation throughout evolution, the first hypothesis was proposed that the 
ubiquitin pathway at least plays a role in host-parasite interactions during infection by 
parasites.  
Ubiquitin pathway enzymes have now been characterised in various parasites. For 
example DUBs are expressed by the human apicomplexan parasites P. falciparum 
and T. gondii and the mammalian parasitic worm Trichinella spiralis [1,102-104]. 
These DUBs, UCHL3 orthologues in T. gondii and P. falciparum and UCH37 
orthologues in P. falciparum and T. spiralis, were discovered using reagents based 
on human ubiquitin. Due to the high level of conservation of ubiquitin, even between 
mammals and parasites, it is unsurprising and yet interesting that these parasite 
enzymes can hydrolyse human ubiquitin. Furthermore, drugs that specifically target 
the human ubiquitin system, the majority of which are proteasome inhibitors, have 
also been shown to kill parasites. For example, proteasome inhibitors have been 
shown to kill the human malaria parasite Plasmodium falciparum and the zoonotic 
parasite, Toxoplasma gondii [105-110]. Studies have shown that P. falciparum 
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express a functional proteasome that is essential for the survival of both the infective 
and transmission stages of the parasite (reviewed by Aminake et al. [111]). Due to 
the demand of new drug targets for the treatment of human malaria, and the 
importance of the proteasome in P. falciparum cell biology, the ubiquitin pathway of P. 
falciparum is now being considered by as a potential drug target. To this end, efforts 
are being made to further characterise the P. falciparum ubiquitin proteasome 
system [112-114].  
Although this shows promise in targeting parasite ubiquitin pathways to kill parasites, 
in the interest of developing more specific drugs, and vaccines to prevent infection, 
the main perpetrators of host-parasite interactions during infection must be identified. 
This prompted the second question: in addition to viruses and bacteria, can parasites 
specifically target the host ubiquitin pathway to their advantage during infection? To 
date, no parasite ubiquitin pathway enzymes have been shown to be specifically host 
targeted. This is not necessarily because they do not exist, but due to the fact that 
separating the proteins that are specifically host-targeted from those that are 
parasite’s ‘own’ is a major challenge. This is especially difficult for intracellular 
parasites such as P. falciparum. For example, the blood stage P. falciparum, a major 
cause of the pathogenesis of malaria, cannot be cultured without the host blood cells. 
It is therefore extremely difficult to differentiate host proteins from parasite proteins 
and parasite-derived host-targeted proteins. 
Parasitic nematode worms (also known as helminths) however, provide somewhat of 
a solution to this problem. 
1.11.	  Parasitic	  worms	  and	  their	  secreted	  proteins	  
 
This solution lies within the study of the secretions of parasitic worms. Parasite-
derived secretions are often referred to as the excretory-secretory fraction (ES). 
Parasite ES is released into the host during most life cycle stages of all helminths. 
Helminth ES contains a mixture of proteins, lipids and polysaccharides [115]. The 
term ‘ES’ does not distinguish between molecules that are actively secreted and 
those might be released as a consequence of biological processes such as digestion, 
egg laying or moulting. Because this study focuses on the actively secreted protein 
component of ES, this thesis continues to refer to the ‘secreted proteins’ (SP) of 
helminths. The composition of the helminth SP adapts to the changing external 
environment and the developments in the life cycle stage of the parasite. Along with 
the parasite surface proteins, the secreted proteins are the main mediators of host-
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parasite interaction, thus communicating with the host in an attempt to ensure 
optimal immune evasion and survival. 
For some helminths, characterising the secreted proteins and the host-parasite 
interactions in which they are involved is a major challenge, as the natural life cycle 
of the parasite cannot be successfully modelled in vitro. Studies on these parasites 
therefore rely on mouse models and ex vivo studies. In some cases, it is impossible 
to access certain life cycle stages of the parasite whereas other stages prove 
accessible [2]. Pure SP can only be collected from parasites that have been removed 
from their natural niche and cultured in optimised conditions. Therefore parasites in 
culture exist in a suspended phase of development void of the biochemical cues that 
would be present in the natural environment. In this case studying the SP is highly 
informative, but not necessarily determinative of the proteins that are secreted during 
natural infection. One such example is the food borne parasite Trichinella spiralis. 
Adult T. spiralis parasites can be extracted from the intestine of a host, as can L1 
larvae that have been enzymatically digested out of the muscle tissue of a host 
animal. The muscle larvae can be cultured for 4-6 days. Once in culture, the secreted 
proteins can be collected from the culture supernatants without host protein 
contamination, thus allowing the study of actively secreted and presumably host-
targeted proteins [116]. Furthermore, T. spiralis is an interesting helminth in the 
context of the role of the ubiquitin pathway in host-pathogen interactions. T. spiralis is 
unique in that during the chronic phase of infection the parasite exists inside skeletal 
muscle cells. Proteins expressed by the muscle larvae are secreted directly into the 
host cell. This does not kill the cell, rather mediates the complete re-programming 
and transformation of the cell cycle and differentiation state of the muscle cell. 
Because T. spiralis muscle larvae are intracellular, they have direct access to the 
host ubiquitin pathway and many of the host cell processes that are disrupted during 
this stage ordinarily rely on the ubiquitin pathway for their regulation (discussed in 
more detail in sections 1.14 and 1.15). Furthermore, T. spiralis infects all mammals 
indiscriminately, passing through the same life cycle stages and eliciting similar 
pathogenicity. The infection is therefore analogous in humans and rodents, allowing 
us to study mouse and rat models with confident extrapolation of what might be 
happening in the human host. 
For these reasons, the infection of skeletal muscle cells by T. spiralis was chosen as 
a model system for investigating whether or not parasites can deliberately target the 
host ubiquitin pathway during infection. 
Chapter 1: Introduction 
 35 
Trichinella	  spiralis	  
1.12.	  History	  and	  epidemiology	  
 
Trichinella is a promiscuous parasitic roundworm (nematode) that infects mammals, 
birds and reptiles causing trichinellosis (also known as trichinosis). Species of 
Trichinella are differentiated between those that become encapsulated in host 
muscle tissue during infection: T. britovi, T. murrelli, T. nativa, T. nelsoni, and T. 
spiralis, and those that do not: T. papuae, T. pseudospiralis and T. zimbabwensis 
[117]. Trichinellosis infection in humans has been found on all continents except 
Antarctica making it the most widespread helminth in the world [118]. The most 
common perpetrator of human infection is the species Trichinella spiralis. T. spiralis 
was named after the characteristic spiral structure that the worm adopts inside 
muscle tissue (Figure 1.5). These microscopic worms were first described in 1835 in 
London by Jim Paget, who observed coiled larvae in the diaphragm of an autopsy 
subject. The discovery was later reported and claimed by Richard Owen [119]. 
Infection in the UK and the US was common at the time. Between 1860 an 1877, 150 
trichinellosis epidemics were reported [120]. It was later discovered that Trichinella is 
food borne, and advances in farming standards and in food hygiene preparation led 
to the near eradication of the disease in humans in the UK and the US. However 
significant outbreaks still occur today. The most recent have affected parts of Eastern 
Europe, Russia, China and south East Asia [121-123].  
In many cases the parasite is transmitted via the consumption of undercooked, cured 
or raw meat, which is frequently of a wild origin rather than commercially farmed. 
Muscle stage Trichinella can even survive temperatures below freezing, especially in 
the tissues of arctic mammals that demonstrate resistance to freezing temperatures, 
such as polar bears [124]. In fact this is one theory for the cause of death of Salomon 
August Andrée and his artic explorers in 1897. During an attempt to be the first 
discoverers of the North Pole, the sudden demise of the group is thought to have 
followed their consumption of raw high-arctic bear meat. The only way to ensure the 
destruction of T. spiralis muscle larvae is to heat the contaminated meat throughout, 
above 70°C [118]. Although today trichinellosis in humans still contributes to 
helminth-related morbidity and disability adjusted life years, perhaps more 
importantly it is considered a serious agricultural problem due to the transmission 
from wild animals to livestock, and is therefore still considered a significant yet 
possibly neglected tropical disease [125]. 
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Figure 1. 5 T. spiralis infection of skeletal muscle tissues 
Diagram shows T. spiralis muscle larvae coiled up inside skeletal muscle tissue, as would 
have been observed by Jim Paget in 1835. Photograph taken by S. J. Upton of Kansas State 
University Biology Division. 
Chapter 1: Introduction 
 37 
1.13.	  The	  life	  cycle	  of	  Trichinella	  spiralis	   
 
Although many other helminths pass through a free-living stage, or have 2 hosts, the 
transmission of Trichinella occurs directly from host to host. The life cycle of 
encapsulating species such as T. spiralis is even more unique in that it exists in both 
extracellular and chronic intracellular stages in the same host. During the chronic 
intracellular stage T. spiralis become encapsulated in muscle tissues, where they can 
persist for decades.  
Encapsulated T. spiralis L1 larvae are ingested in contaminated meat and released 
from infected muscle tissue following digestion of the meat by gastric enzymes, to 
which the parasite itself is resistant thanks to its strong outer cuticle (Figure 1.6). L1 
larvae invade the epithelia of the small intestine, inducing inflammation and causing 
symptoms that are similar to those experienced during various intestinal infections 
such as vomiting and diarrhoea. For this reason the condition is often misdiagnosed 
[126]. L1 larvae moult through 4 larval stages before developing into adults 
approximately 30-34 hours after ingestion [127]. Adults reproduce and after 5-7 days 
females release newborn larvae. After this the adult parasites are cleared from the 
gut by the host immune system. The newborn larvae cross the intestinal epithelia, 
entering the lymphatic and vascular circulation, within which they are transported 
around the body. The number or dose of newborn larvae and their path taken around 
the body determines the potential for acute illness. Infection of the eyes, heart or 
CNS may result in oedema, vasculitis, myalgia, myocarditis and encephalitis, which 
can lead to fatality [122]. At approximately 28 days after ingestion the newborn larvae 
establish chronic infection in their final target tissue, skeletal muscle. Here they 
invade fully differentiated skeletal muscle cells (myofibres). A single larva usually 
invades a single muscle fibre, although in acute infection as many as 4 larvae have 
been observed to invade a single myofibre. It is thought a terminally differentiated 
skeletal myofibre may be the only cell in the animal large enough to accommodate 
the parasite, and hence the specificity of the target tissue. Here, the phenotype of the 
host cell is modified completely. As the T. spiralis newborn larvae develop into L1 
larvae, the host cell develops into a unique complex that harbours the parasite. The 
worm can reside in this complex relatively undetected by host immunity and for this 
reason the complex has been named the nurse cell.  
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Figure 1. 6 The life cycle of T. spiralis 
Diagram showing the full life cycle of T. spiralis inside an animal (mammal/bird/reptile) host. 
Severe pathology can occur if newborn larvae infect the central nervous system (CNS) or the 
heart. In acute cases this can lead to death. Image taken from Worm Book, courtesy of John 
W. Karapelou [127]. 
Chapter 1: Introduction 
 39 
Since the target tissue of T. spiralis is skeletal muscle, understanding the biology of 
this tissue of choice is important for understanding the development of the nurse cell. 
The next section therefore introduces the process of skeletal muscle formation and 
maintenance in vertebrates. 
1.14.	  Muscle	  cell	  differentiation,	  and	  T.	  spiralis	  induced	  dedifferentiation	  
 
The development of skeletal muscle tissues (myogenesis) in vertebrates initiates in a 
division of the developing embryo called the somite [128,129]. Progenitor cells in a 
region of the somite respond to muscle specific signals and develop into myoblast 
cells. These signals include the myogenic regulatory factor (MRF) family of 
transcription factors, MyoD, myogenin, Myf5 and MRF4. In fact, in double knockout 
MyoD and Myf5 in mice, no skeletal muscle tissue forms, illustrating how key these 
proteins are to the process of myogenesis [130]. This family of proteins are also 
required for the next step in myogenesis, the differentiation of the myoblasts into the 
myofibre. Firstly, myoblast cells become programmed to develop into myocytes 
(Figure 1.7). This involves the activation of muscle specific genes that commit the 
myoblast to exit the cell cycle [131]. Dramatic changes in transcription and 
ubiquitination lead to the repression of cell cycle factors such as cyclin D1, E and A, 
the induction of cyclin-dependent kinase inhibitors such as p21, and the up-
regulation of tumour suppressor proteins such as the retinoblastoma protein pRb and 
p53. These events lead to terminal cell cycle exit in the G0 phase of the cell cycle 
[132-134]. Multiple myocytes then fuse with one another and further differentiate, 
forming myofibres [135]. The up-regulation of muscle cell-specific genes then leads 
to the maturation of the skeletal muscle fibre [136]. Myofibres are long thin 
multinucleated cells that can no longer divide and have the ability to contract. 
Skeletal muscle tissue is composed of multiple myofibres that have lined up in 
orientation, forming contractile bundles [137]. 
As briefly mentioned, the ubiquitin pathway plays an important role in myogenesis. 
For example, the MRF MyoD (myoblast determination factor) is a short-lived protein 
required for the commitment of myoblasts to differentiation. Inhibition of MyoD (only) 
inhibits the differentiation of myoblasts [138,139]. Although MyoD, and the MyoD 
interaction partner E2A (another transcription factor), are detected at the protein level 
in immature myoblasts (and thus expressed), their activity is down-regulated by post-
translational mechanisms including proteasomal degradation [140-142]. During the 
differentiation of myoblasts into mature muscle cells, ubiquitin-mediated degradation 
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of MyoD and E2A is reduced, leading to their stabilisation. In turn this leads to the 
transcriptional activation of target genes required for the development of the mature 
muscle identity. After the differentiation process has taken place, MyoD is again 
down-regulated by proteasomal degradation.  
During embryogenesis and beyond, not all of the progenitor cells in the 
aforementioned region of the somite become differentiated. These cells that do not 
differentiate are referred to as satellite cells and remain amongst the surrounding 
muscle tissues, even when fully formed in adulthood. Satellite cells have the ability to 
either remain quiescent, self renew or proliferate and develop into myoblast cells 
[143,144]. These cells are responsible for the growth, repair and regeneration of 
muscle fibres. Satellite cells become activated to differentiate into myoblasts and 
myocytes in response to growth factors, stress, aging or injury [145,146]. These new 
myocytes fuse with existing myofibres, thus replenishing the muscle tissue. This 
process is crucial for the maintenance of skeletal muscle homeostasis, since there 
are very few examples in nature of terminally differentiated skeletal muscle cells that 
can dedifferentiate, or re-enter the cell cycle, and it has never been observed in to 
occur spontaneously in mammalian skeletal muscle cells [147,148]. 
In vitro however, the mitotic reactivation of mammalian skeletal myofibres can be 
induced by the small molecule myoseverin, infection by oncogenic DNA viruses (SV-
40 and Polyoma), the down-regulation of the MRF myogenin and by the adenoviral 
oncogene E1A [149-153]. These studies indicate that despite their terminal 
differentiation state, mammalian skeletal myofibres do possess the potential to re-
enter the cell cycle. Indeed when T. spiralis newborn larvae invade host myofibres, 
this is exactly what happens. T. spiralis invades the muscle cell without killing it, and 
induces the formation of the nurse cell. The nurse cell is the result of the 
dedifferentiation and cell cycle re-entry of the terminally differentiated host muscle 
cell. 
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Figure 1. 7 Schematic of myogenesis 
The development of a myofibre from muscle satellite cells and the involvement of muscle 
regulatory factors (MRFs), Myf5, MyoD, myogenin and MRF4. Quiescent muscle satellite cell 
are activated by growth factors, stress, aging or injury to develop into cycling myoblasts. 
Myoblasts commit to differentiate into myocytes, which exit the cell cycle and fuse. The fusion 
of multiple myocytes forms an elongated multinucleated terminally differentiated myofibre. 
Image adapted from Le Grand and Rudniki, 2008, Curr. Opin. Cell. Biol. 
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1.15.	  Trichinella	  spiralis	  and	  the	  nurse	  cell	  
 
T. spiralis newborn larvae break into and enter host skeletal muscle cells. The 
development of the nurse cell then begins with a significant morphological change of 
the host cell, where the myofibre shortens and becomes rounded and enlarged, 
partitioning itself from adjacent muscle fibres (Figure 1.8). One of the first 
biochemical changes that is detected is host cell mitochondrial dysfunction that leads 
to hypoxia [154,155]. The parasite then induces a significant change in host cell gene 
transcription. A down-regulation of terminally differentiated muscle specific genes 
such as actin, myosin light and heavy chain and tropomyosin is observed, and by 
day 9 after invasion, no host muscle markers can be detected [156,157]. In addition 
an up-regulation in cell cycle-related genes is observed. This re-programming of host 
protein expression leads to the reversal of the differentiation state of the muscle cell 
[158-161]. Between day 2 and 8 after invasion, the host cell re-enters the cell cycle 
by replicating DNA, before becoming arrested in the G2/M phase where the enlarged 
nuclei remain as 4n thereafter [162,163]. Between day 10 and 12, the expression of 
host collagen is induced, which is required for the formation of a protective capsule 
that surrounds the nurse cell complex [162,164-166]. Around day 11-12, proteins that 
play a role in angiogenesis are up-regulated, such as vascular endothelial growth 
factor, leading to the formation of a network of circulatory vessels around the nurse 
cell [167]. It is believed that this circulation provides a mechanism for the delivery of 
nutrients and removal of waste products from the complex. These vessels are 
described as venous sinusoids, as they are larger than normal capillaries and carry 
only deoxygenated blood [167,168]. Since the muscle larvae does not require 
oxygen, and a hypoxic environment in the nurse cell is induced, the parasite it 
thought to be anaerobic, requiring the blood for other nutrients such as glucose. As 
well as the cell cycle re-entry of terminally differentiated skeletal muscle cells, the 
stimulation of sinusoid growth is rarely observed elsewhere in nature. 
[156,162,163,169,170]. Approximately 15 days after the invasion of the myofibre the 
nurse cell is fully formed (Figure 1.9) [171]. 
The specific characteristics of the nurse cell are not observed anywhere else; they 
are unique to T. spiralis infection. Although similarities are observed, the 
dedifferentiation profile of a nurse cell is not akin to that induced by SV40 and 
Polyoma infection [153,172]. The mechanisms underlying nurse cell formation still 
remain undetermined. It is proposed that the parasite (rather than the host cell, 
surrounding cells or infiltrating cells) is responsible for the changes that result in this 
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transformation and there have been many studies that support this hypothesis. Firstly, 
the changes in host muscle and cell cycle factors occur at the transcriptional level, 
indicating a direct effect on the host cell genes [156,157]. Secondly, the nuclei that 
replicate their DNA, becoming enlarged and chronically 4n, are derived from the 
myofibre itself, and not from infiltrating activated satellite cells [163]. Furthermore, T. 
spiralis antigens can be located in the nurse cell nuclei and cytoplasm [173] 
[174,175]. The secreted proteins are therefore the prime candidates for the 
mediators of the reprogramming of muscle cells during nurse cell formation. 
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Figure 1. 8 The formation of the T. spiralis nurse cell 
Terminally differentiated host skeletal myofibres are invaded by T. spiralis newborn larvae. 
This causes a change in morphology, a loss of host cell muscle specific proteins leading to 
dedifferentiation and cell cycle re-entry as characterised by DNA synthesis and nuclear 
enlargement. T. spiralis secreted proteins are detected inside the host cell, and host collagen 
expression is up-regulated. This forms a capsule around the parasite-harbouring cell that 
becomes segregated from the original muscle bundle. Angiogenesis is induced characterised 
by a formation of a network of circulatory vessels that surround the new complex, termed a 
nurse cell. The cell then remains in G2/M cell cycle arrest. Meanwhile, the T. spiralis develops 
from a newborn larva into an L1 stage muscle larva. 
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Figure 1. 9 The T. spiralis nurse cell complex 
A. Photograph of a nurse cell isolated from infected muscle tissues, by Eric Grave. B. 
Hematoxylin and eosin stained paraffin section of T. spiralis infected rat muscle tissue, 1 
month post infection. 
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1.16.	  Treatment	  of	  trichinellosis	  
 
Current treatment of Trichinellosis largely involves the use of wide-spectrum 
anthelmintics such as albendazole, mebendazole and thiabendazole that are 
effective during the early intestinal stages of infection (5-7 days after ingestion) [176]. 
However, due to the frequent misdiagnosis of Trichinellosis, this window is often 
missed. After this, the newborn larvae enter the circulation where successful 
treatment now relies on intestinal absorption of the drug. General anthelmintics show 
poor solubility and therefore low efficacy in treatment of circulating stage T. spiralis 
[177,178]. Furthermore, due to the protective characteristics of the nurse cell, muscle 
stage larvae cell are extremely resistant to treatment [179]. 
During the initial intestinal phase of infection, T. spiralis induces a T helper 1 (TH1) 
immune response [180]. This mediates the eventual clearance of the adult parasites, 
but not before reproduction has taken place and the newborn larvae are on their way 
to the muscle. In the muscle tissues, T. spiralis muscle larvae stimulate an overall T 
helper 2 (TH2) immune response followed by an induction of regulatory cytokines 
such as TGF-β and IL-10 [181] [182-184]. This response is protective to both the 
parasite and the host as it prevents elevated and potentially pathogenic pro-
inflammatory cytokine activation. Sustained TH2 immunity and the induction of 
regulatory cytokines is characteristic of helminth infection, whereas TH1 immune 
responses can be characteristic of allergy and autoimmune disease and TH2-based 
disorders such as asthma, do not observe the induction of regulatory cytokines. Thus 
helminth infection, including T. spiralis, can in some cases provide relief from chronic 
autoimmune and inflammatory diseases. Using T. spiralis, this has been 
demonstrated in animal models of colitis, multiple sclerosis (experimental 
autoimmune encephalomyelitis), and asthma (experimental airway allergic 
inflammation) [185-187].  
Despite the overall TH2 response, during the invasion of muscle tissues by T. spiralis 
newborn larvae a T-cell-mediated inflammatory response is observed, illustrated by a 
failure of immune cell recruitment to nurse cells of T cell deficient mice [188]. The 
invasion event by newborn larvae is physically damaging to the muscle cells. 
Together with newborn larvae antigens, this stimulates inflammation with the 
infiltration of innate immune cells, primarily macrophages and eosinophils. Together 
the invasion and the subsequent inflammation (myositis) can cause muscle damage. 
The collagen capsule of the nurse cell eventually protects the parasite from this 
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response but the surrounding host tissue is susceptible. Symptoms of nurse-cell 
induced myositis include cachexia, edema, and dehydration presenting as muscle 
pain, fatigue, weakness and loss. The immune-related symptoms are often 
effectively treated using corticosteroids, however these drugs do not target the 
parasite [176]. It is therefore of importance to investigate new T. spiralis-specific 
targets for the development of drugs or vaccines that show improved efficacy in the 
treatment of the muscle phase of infection. The identification of new targets will 
undoubtedly involve the characterisation of the proteins directly involved in host-
parasite interactions: the secreted proteins. 
1.17.	  The	  secreted	  proteins	  of	  T.	  spiralis	  muscle	  larvae	  
 
Trichinella muscle larvae are approximately 1mm in length. Adult females grow to 
between 1.4 and 4 mm and adult males to between 1.4 and 1.8 mm in length [189]. 
They can just about be seen with the naked eye as tiny flecks. Using techniques 
such as histology and electron microscopy, Despommier and later Takahashi 
described an organ in T. spiralis called the stichosome [190-192]. This organ is found 
in the upper part of the body of all nematodes, both parasitic and free living, and is 
composed of stichocyte cells (Figure 1.10). These cells contain secretory granules 
and are analogous to mammalian granulocytes. The T. spiralis secreted proteins are 
stored in these granules before being released into the host. This is illustrated by the 
binding of antibodies from T. spiralis infected animals to stichocyte cells within the 
muscle larvae [193,194]. There are thought to be in excess of 100 proteins secreted 
from the stichocyte cells by T. spiralis muscle larvae. These proteins can be detected 
in both the cytoplasm and nucleus of the nurse cell using antibodies against an 
immunogenic T. spiralis-specific glycan tyvelose, which decorates the secreted 
glycoproteins [175].  
Many of the changes in host cell transcription of muscle cells during nurse cell 
formation have now been reported using microarray [158,159]. We therefore have a 
good idea of the molecular basis of the changes that occur to form nurse cells from 
the point of view of the muscle cell, but very little idea of the molecular role of the 
parasite. In 1993, Jasmer et al. attempted to determine the source of the induction of 
muscle cell transformation. They did so using a technique that had been previously 
shown successful for creating a synchronous T. spiralis infection. This involves the 
collection of newborn larvae released by pregnant adult T. spiralis in culture and the 
injection of the newborn larvae directly into the muscle tissue [195]. Before injection, 
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Jasmer et al. irradiated the newborn larvae, causing an inhibition of their growth and 
an inhibition of the development of the α and β stichocyte cells (Figure 1.10). The 
irradiated newborn larvae were able to invade the host muscle cells, but their cell 
cycle re-entry was markedly delayed. In addition, once the nurse cell did eventually 
form, it was significantly smaller than those formed by healthy T. spiralis. Results 
showed that the healthy development of some of the secretory cells was, in part, 
required for normal nurse cell formation. These experiments therefore suggest that 
the secretion of proteins by T. spiralis newborn larvae, underlie at least some of the 
mechanisms involved in nurse cell formation as it is observed during infection. In 
order to maintain the chronic status of the nurse cell for prolonged periods of time 
(years), it is plausible that the parasite continues to secrete proteins into the nurse 
cell, long into its development into L1 (muscle) stage larvae. Indeed, Guiliano et al. 
discovered novel T. spiralis secreted proteins in the nurse cell nuclei of rat muscle 
tissue 2 months after infection, where the parasite has long existed as an L1 stage 
larvae. It is therefore strongly suggestive that the direct communication between 
host-targeted T. spiralis secreted proteins and the host cell stimulates the 
transformation of skeletal muscle cells. 
To investigate how the secreted proteins achieve this, they must be characterised 
and functions must be assigned. To date, only a small proportion of T. spiralis 
secreted proteins have been identified or characterised [196,197] [198-200]. These 
proteins include proteases, nucleotidases, antigens and novel T. spiralis proteins. 
Some of those that have been characterised have also been found located inside the 
nurse cell and inside the nurse cell nuclei [201-204]. However the role of these 
proteins in the host-parasite interactions that lead to nurse cell formation remains to 
be determined [205].  
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Figure 1. 10 The morphology of a T. spiralis muscle larva 
The morphology of a T. spiralis muscle larva. Drawing by Villella, J.B., 1970, Life cycle and 
morphology, in: Trichinosis in Man and Animals (S.E. Gould, ed.), Charles C. Thomas, 
Springfield, Illinois, pp. 19-60, taken from Trichinella.org/biology. 
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1.18.	  T.	  spiralis	  as	  a	  model	  for	  investigating	  the	  ubiquitin	  pathway	  in	  host-­‐
parasite	  interactions 
 
The ubiquitin pathway is heavily implicated in cell cycle control, myogenesis, the 
terminal differentiation of skeletal muscle cells, and when it is disrupted can lead to 
muscle wasting disorders [40,42]. Using models of muscle cell reprogramming such 
as T. spiralis infection, and by studying the host-targeted secreted proteins of T. 
spiralis, this project aimed to investigate whether or not parasites target the ubiquitin 
pathway during infection. The purpose of this was two-fold: firstly to help us to 
understand muscle physiology, and secondly to highlight potential vaccine or drug 
targets for the development of novel anthelmintics.  
By characterising the proteins that are expressed and secreted by T. spiralis and, 
most importantly, investigating the biological systems in which they function, this 
investigation aimed to shed light on the complex processes of skeletal muscle 
deregulation. This may help us understand the molecular basis of muscle 
differentiation, dedifferentiation, cell cycle regulation and in turn, muscle tissue 
disorders, muscle cell cycle-related diseases and the process of induced 
angiogenesis. From here, ideas may arise of how to find ways to deliberately 
manipulate these processes for therapeutic purposes. This information may 
contribute to efforts that are being made to understand the process of muscle cell 
dedifferentiation in order to explore the possibilities of induced muscle tissue repair 
and regeneration [206,207].  
During my MRes project that preceded the PhD investigation, I identified a number of 
putative DUBs expressed by T. spiralis muscle larvae [1]. One of these DUBs, 
TsUCH37, is the orthologue of human UCH37 (UCH-L5) a proteasome-associated 
DUB that, as mentioned previously, is currently receiving attention for its potential as 
a drug target for the treatment of cancer. Being the only UCH domain proteasome-
associated DUB in mammals, UCH37 plays a critical role in protein degradation and 
is essential for survival [36]. The characterisation of TsUCH37 therefore provided an 
interesting starting point for the investigation of the ubiquitin pathway in T. spiralis 
muscle larvae, its evolution and potential as a drug target. 
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1.19	  Aims	  of	  the	  project	  
 
Main aim:  
To investigate the role of the ubiquitin pathway during the infection of host muscle 
tissues by Trichinella spiralis. 
Aim 1. To characterise TsUCH37, a DUB expressed by T. spiralis muscle larvae  
A. To characterise the function of TsUCH37 
B. To investigate the role of TsUCH37 as a drug target 
Aim 2. To investigate whether parasites specifically target the host Ub pathway 
during infection using Trichinella spiralis as a model system 
 A. To look for TsUCH37, and other T. spiralis ubiquitin pathway enzymes, in 
the secreted proteins of the muscle larvae 
 B. To characterise the function of secreted T. spiralis ubiquitin pathway 
enzymes in mammalian skeletal muscle cells
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Chapter	  2:	  Materials	  and	  methods	  
2.1.	  Bioinformatics	  analyses	  	  
 
The T. spiralis contig database was downloaded (August 2010) from the University of 
Washington Genome Centre [208]. Contig 1.2, between bases numbered 30000 to 
40000, was analysed using the following programmes: For alignments: Geneious 
software using either the MUSCLE or the Geneious alignment algorithm [209]. For 
homology and conserved domain identification: NCBI BLAST and SMART (Simple 
Modular Architecture Research Tool, [210,211]). For Gene prediction: AUGUSTUS 
[212,213], FGENESH [214], SNAP [215] and GenemarkHmm [216]. Gene 
predictions were carried out in collaboration with Eliseo Papa (Harvard/MIT). Initial 
mass bioinformatics analyses of T. spiralis annotated proteins (RefSeq) were carried 
out by Derek Huntley, Bioinformatics Support, Imperial College London. Programmes 
were used to identify protein localisation motifs and signal sequences using 
wolfPSORT [217], iPSORT [218], and signalP [219]. Sequences were further 
analysed using SMART and InterPro to identify conserved domains. 
2.2.	  Parasite	  isolation,	  culture,	  re-­‐infection	  and	  collection	  of	  secreted	  
proteins	  
 
Ethics statement: All procedures involving care and maintenance of animals were 
approved by the Imperial College Ethical Review Committee and performed under 
license from the UK Home Office. 
 
T. spiralis parasites were maintained in female Sprague-Dawley rats and L1 stage 
muscle larvae were isolated from infected tissue by digestion of skeletal muscle with 
acidified pepsin as described by Arden et al. [116]. Briefly, muscle larvae were 
isolated from infected rats by digestion of skeletal muscle with 1% v/v HCL and 1% 
w/v pepsin in tap water at 37°C for 1.5 hours shaking before being filtered through 
muslin cloth.  Muscle larvae were pelleted by gravity, and pellets were washed in 
sterile 1x PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4.2H2O, 2 mM KH2PO4 
pH 7.4) and cultured in sterile serum-free RPMI (Gibco) supplemented with 1% w/v 
glucose, 100 U/ml penicillin, 100 µg/ml gentamycin, 20 U/ml nystatin and 2 mM 
glutamine at 37ºC and 5% CO2 with a daily change of medium for a maximum of 6 
days. Culture supernatants were collected and filtered through a 0.2 µm membrane. 
The secreted proteins were then dialysed into 25 mM Hepes buffer pH 7.4 and 
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concentrated using 10 kDa molecular weight cut-off (MWCO) vivaspin columns 
(Sartorius Stedim). Protein concentrations were measured using the BCA assay 
(Pierce). For re-infections, 3500 muscle larvae in 300 µl of PBS were used to infect 
each rat orally by gavage feeding.  
Mammalian	  cell	  culture	  
2.3.	  HEK	  293T	  cells	  (adherent)	  
 
HEK 293T (Human Embryonic Kidney 293T cells) cells were used for human cell 
lysate protein control samples and for lentivirus production. Cells were cultured in 
DMEM supplemented with 10% v/v foetal bovine serum (Gibco), 100 U/ml penicillin 
100 µg/ml streptomycin and 4 mM L-glutamine (Sigma-Aldrich) at 37ºC and 5% CO2. 
Cells were grown in vacuum gas plasma treated flasks or petri dishes and routinely 
split 1:20 every 3 days using 0.05% w/v trypsin-EDTA. For experiments were 
harvested by directly lysing in NP-40 lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM 
NaCl, and 1% NP-40 v/v). Cell stocks were frozen in liquid nitrogen in growth 
medium supplemented with 10% v/v DMSO. 
2.4.	  C2C12	  myoblasts	  (adherent)	  
 
Mouse C2C12 myoblasts were originally established by Yaffe and Saxel and 
produced by Blau, et al. [220,221]. Cells were cultured in high-glucose DMEM (Life 
Technologies Cat # 41965, without pyruvate, without HEPES) supplemented with 
20% v/v foetal bovine serum (Gibco), 100 U/ml penicillin 100 µg/ml streptomycin and 
4 mM L-glutamine (Sigma-Aldrich) at 37ºC and 5% CO2. Cells were grown in vacuum 
gas plasma treated flasks or petri dishes and split 1:10 every 2 days using 0.5% v/v 
trypsin-EDTA and never allowed to grow beyond 60-70% confluency. For 
experiments (apart from immuno-fluorescence and flow cytometry), cells were 
harvested in cold 1x PBS and pelleted by centrifugation for 10 minutes at 5,000xg. 
Cell stocks were frozen in liquid nitrogen in growth medium supplemented with 40% 
FBS v/v and 10% v/v DMSO. 
2.5.	  C2C12	  differentiation	  (adherent)	  
 
C2C12 myoblast cells were grown to 90% confluency, washed in sterile 1x PBS and 
media was changed to starvation/differentiation media (high-glucose DMEM (Life 
Technologies Cat # 41965, without pyruvate, without HEPES) supplemented with 2% 
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v/v horse serum (Gibco), 100 U/ml penicillin 100 µg/ml streptomycin and 4 mM L-
glutamine. Media was changed every day and cells were differentiated for 3-4 days 
(or when fully matured myotubes were observed) before using for subsequent 
experiments. Cells were harvested in cold 1x PBS and pelleted by centrifugation for 
10 minutes at 5,000xg. 
2.6.	  Lentivirus	  production	  
 
HEK 293T cells have been modified to express the simian virus 40 (SV40) large T 
antigen. This allows the replication of episomal (non-integrated) plasmids that 
contain the SV40 origin of replication (oriC). Lentiviral accessory plasmids were 
kindly donated by Hidde Ploegh. HEK 293T cells were seeded into 15 cm petri 
dishes 24 hours before transfection. Fresh HEK 293T growth media was added. A 
mixture of the mammalian (lentiviral) expression vector (either pCSGW tdTomato 
TsUBE2L3-HA, pLVX Tet On Advanced, pLVX TsUBE2L3 or pLVX HA-Ub) and the 
lentiviral accessory plasmids was prepared, (pCMV-VSVG, pCMV-Gag/Pol, pCMV-
TAT and pCMV-REV) using the relative amounts listed in Table 2.1. Cells were 
transfected with the plasmid mixture using TransIT-293 Transfection Reagent (Mirus 
Bio) according to the manufacturer’s instructions, using Opti-MEM I reduced serum 
media (Gibco). Growth media (supernatant containing lentivirus particles) was 
collected every 24 hours for 72 hours and fresh growth media was added. 
Supernatants were pooled and sterile-filtered (0.45 µm pore size) before 
concentration of lentivirus by centrifugation at 20,000xg for 90 minutes. Lentivirus 
was resuspended in fresh C2C12 growth media and used directly for transduction. 
 
 
 
Table 2.1 DNA mixture for transfection for lentivirus production 
2.7.	  Lentivirus	  transduction	  of	  C2C12	  myotubes	  
 
For C2C12 myotubes, myoblasts cell lines were counted, seeded into a 6-well plate 
and differentiated. Three days after the addition of differentiation media, cells were 
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transduced. Lentivirus (2 ml per well) was supplemented with Polybrene (Sigma-
Aldrich, 8 µg/ml) and added to each well. Cells were centrifuged with the lentivirus for 
90 minutes at 2000xg for “spinfection”. Fresh differentiation media was then added to 
the cells 6 hours post-transduction. Cells transduced with pCSGW tdTomato 
lentivirus were examined 48 and 72 hours post-transduction using a Leica DMR HC 
fluorescence microscope (Leica Microsystems, Germany) to visualise expression of 
the tdTomato fluorescent protein.  
2.8.	  Lentivirus	  transduction	  of	  C2C12	  myoblasts	  and	  generation	  of	  stable	  
lines	  (inducible	  expression	  system)	  
 
For C2C12 myoblasts and generation of stable cell lines, cells were counted and 
seeded into a 6-well plate 24 hours before transduction to ensure 70% confluency for 
transduction. The control vector (pLVX Tet On) lentivirus and the expression vector 
(pLVX Tight Puro) lentivirus were added to the cells (with 8 µg/ml Polybrene) at the 
same time for simultaneous transduction (1 ml each per well). Transductions were 
carried out as described above and 48 hours later, geneticin (G418, 500 µg/ml) and 
puromycin (4 µg/ml) were added to the growth media for selection. Control cells were 
completely dead after 5 days of drug selection. Cells were maintained in growth 
media supplemented with 250 µg/ml G418 and 4 µg/ml puromycin. Stable C2C12 
cell line protein (of interest) expression was induced using 2 µg/ml doxycycline.  
2.9.	  RNA	  preparation	  for	  RACE	  and	  q-­‐RT-­‐PCR	  	  
 
For RNA preparation from T. spiralis pelleted T. spiralis L1 larvae were frozen in 
liquid nitrogen before being shattered in a percussive disruptor. For C2C12 myotubes, 
cell pellets were harvested as described above (section 2.5). RNA was then 
extracted using Trizol reagent (Invitrogen) using the manufacturer’s protocol. All 
procedures involving Trizol and phenol/chloroform were carried out in a fume hood. 
Briefly, 1 ml of Trizol was added to 100 mg of shattered muscle larvae and pipetted 
and vortexed for lysis. Lysate was then cleared by centrifugation at 12,000xg for 10 
minutes. The supernatant containing was transferred to a fresh eppendorf and 0.2 ml 
chloroform was added. Samples were vortexed and centrifuged at 12,000xg for 15 
minutes at 4°C. The upper aqueous phase was transferred to a new eppendorf, 0.5 
ml 100% v/v isopropanol was added and incubated at room temperature for 10 
minutes before centrifugation at 12,000xg at 4°C for 10 minutes. The pellet was then 
washed 3 times in 1 ml 75% v/v ethanol (using centrifugation steps) before being 
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solubilised in 50 µl of RNase free water. To remove genomic DNA, RNA was treated 
with Turbo DNase using the Turbo DNA-free kit (Ambion). For RACE, total RNA was 
used directly after extraction.  
2.10.	  RACE	  (Rapid	  Amplification	  of	  cDNA	  Ends)	  
 
Primers based on the AUGUSTUS algorithm predicted 931 bp coding sequence of 
TsUCH37 were used as a positive control and to test GSRPs. Two RACE kits were 
used (according to manufacturer’s instructions), to process RNA as explained in 
results section 3.1. The FirstChoice RNA Ligase Mediated Rapid Amplification of 
cDNA Ends (RLM-RACE) kit from Ambion and the GeneRacer kit from Invitrogen. 
Nested PCR was then carried out using gene specific primers with the RACE primers 
supplied by the RACE kits.  
 
Gene specific RACE primers: 
GSRP TsUCH37 (FGENESH), primer 1 
CACCGGCACCAACGCCTCGAACGCCACCACACATT 
GSRP TsUCH37 (AUGUSTUS), primer 3 
CGTCGGTCCCAAATCTACGTCCGGGTGGTCGCAGTT 
GSFP TsUCH37 (same for AUGUSTUS and FGENESH) primer 4 
CGGGCGGCTCCACTGCGTCTCGGCACTGTT 
GSRP TsUBE2L3 
CCAATTCTGTACGAAGCGAATGTTCC 
GSFP TsUBE2L3 
ACGGAGCACATTATTGATTCGTTGATC 
 
RACE-PCR amplified products were ligated into pGEMTeasy using TA cloning 
(described in the results section 3.1) and transformed into E. coli XL10-Gold 
competent cells (Agilent Technologies) according to the manufacturer’s instructions. 
Bacteria were plated onto ampicillin and XGal (80 µg/ml) and IPTG 20 mM agar 
plates, incubated overnight at 37°C and blue/white screening was used to select 
positive colonies. To verify the presence of the correct insert, clonal cultures were 
grown and plasmids were purified using the Qiaprep mini-prep kit (Qiagen) according 
to the manufacturer’s instructions. The insert was sequenced in pGEMTeasy 
(Beckman Coulter Genomics) and diagnostic restriction digests using BamHI and 
NotI were carried out. Insert sequences were verified by alignment. 
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2.11.	  qRT-­‐PCR	  
 
For qRT-PCR total RNA (extracted and purified using Trizol/phenol/chloroform, see 
above) was first passed through an RNeasy column using the RNeasy kit (Qiagen). 
Total RNA was used to synthesise cDNA with both random primers and oligo-dT(12-18) 
primers using the Takara PrimeScript First Strand cDNA Synthesis kit (Clontech) 
according to the manufacturer’s instructions. QRT-PCR was carried out using 
TaqMan Gene Expression Assays (p53: Mm01731287_m1, MHC: Mm01332489_m1, 
and GAPDH: Mm99999915_g1) and TaqMan Fast Universal PCR Master Mix (2x) in 
a MicroAmp Fast Optical 96-Well Reaction Plate (all Life Technologies. All qRT-PCR 
samples were analysed in triplicate, using 1 µl of 1/50 dilution of cDNA per reaction. 
PCR was carried out using the ABI Prism 7500 Fast Real-Time PCR System 
(Applied Biosystems) according to the manufacturer’s instructions. The GAPDH 
TaqMan assay was used as “housekeeping” reference to normalise the samples 
according to the amount of total cDNA used. Gene expression in C2C12 myotubes 
expressing TsBE2L3 was quantitated relative to C2C12 myotubes carrying the empty 
vector DNA. The amplification efficiency of the MHC and P53 target genes was 
approximately equal to the amplification efficiency of GAPDH and so Comparative 
CT (ΔΔCT) Method was used (see Applied Biosystems User Bulletin #2).  
Cloning	  
2.12.	  TsUCH37	  
 
Pelleted T. spiralis L1 larvae were frozen in liquid nitrogen before being shattered in 
a percussive disruptor. Samples were thawed and total RNA was extracted using the 
RNeasy kit (Qiagen). The RACE-confirmed sequence was amplified using the One 
Step RT-PCR kit (Qiagen).  
 
Primers: 
Forward  
TGCAGGATCCatggctgaaggaaattggtgtttaa  
Reverse  
ACAGTGCGGCCGCttattcaaagacgaaatcatgtgcaa 
 
Primers were designed to include BamHI and NotI linkers (capitals) against the 5’ 
and 3’ regions (in capitals, respectively). RT-PCR amplification of a 313 bp fragment 
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(121-434) of T. spiralis GM2 activator protein was carried out as a control [199]. The 
PCR product was ligated into the multiple cloning site of pGEMTeasy (Promega) 
using TA cloning (described in results section 3.1) and transformed into E. coli XL10-
Gold competent cells (Agilent Technologies) according to the manufacturer’s 
instructions. Bacteria were plated onto ampicillin and XGal/IPTG agar plates, 
incubated overnight at 37°C and blue/white screening was used to select positive 
colonies. To verify the presence of the correct insert, clonal cultures were grown and 
plasmids were purified using the Qiaprep mini-prep spin kit (Qiagen) according to the 
manufacturer’s instructions. Diagnostic restriction digests using BamHI and NotI 
were carried out and the inserts were sequenced in pGEMTeasy (Beckman Coulter 
Genomics). DNA fragments were separated by agarose (0.8% w/v) gel 
electrophoresis, stained with ethidium bromide and visualised using UV light. The 
correct insert was then gel-purified using the QIAquick spin gel purification kit 
(Qiagen) according to the manufacturer’s protocol (Qiagen), digested using BamHI 
and NotI enzymes (Promega), purified and cloned into pPET28a(+), containing an 
upstream His-tag sequence. Plasmids were transformed into E. coli XL10-Gold 
competent cells (Agilent Technologies) according to the manufacturer’s instructions 
and selected for kanamycin resistance. Plasmids were purified using the QIAprep 
spin mini or midi prep kits (according to the manufacturer’s protocol, Qiagen). 
2.13.	  Site-­‐directed	  mutagenesis	  
 
The mutant 6His-TsUCH37 D12N was generated by mutating the Aspartic acid 
residue at position 12 to an Asparagine residue. This corresponded to codon GAT, at 
nucleotides 34 to 36 where G was mutated to A (small letters, bold). Mutagenesis 
was carried out using the QuickChange Site-directed Mutagenesis kit according to 
the manufacturer’s instructions (Stratagnene).  
 
Primers for mutagenesis: 
Fw TsUCH37 G34A 
AATTGGTGTTTAATAGAAAGTaATCCTGGAATATTTACTGAAATGATTC 
TsUCH37 wild type 
AATTGGTGTTTAATAGAAAGTgATCCTGGAATATTTACTGAAATGATTC 
Rev TsUCH37 G34A 
GAATCATTTCAGTAAATATTCCAGGATtACTTTCTATTAAACACCAATT 
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Diagnostic digests were carried out using Dpn I and inserts were sequenced to 
confirm the presence of the nucleotide substitution (Beckman Coulter Genomics). 
DNA fragments were separated by agarose gel electrophoresis and visualised by 
ethidium bromide staining and UV light. 6His-TsUCH37 D12N was amplified by PCR 
using the primers originally designed to clone the wild-type 6His-TsUCH37. The PCR 
product was cloned into pGEMTeasy (as described above) before being cloned into 
pPET28a+ (as described above). The same expression and Ni-NTA-mediated His-
tagged purification methods were used for 6His-TsUCH37 D12N as were used for 
6His-TsUCH37 wild type (described above). 
2.14.	  TsUBE2L3	  
 
Pelleted T. spiralis L1 larvae were frozen in liquid nitrogen before being shattered in 
a percussive disruptor. Samples were thawed and total RNA was extracted using the 
RNeasy kit (Qiagen). Total RNA was used to synthesise cDNA using oligo-dT(12-18) 
primers (M-MLV Reverse Transcriptase, Life Technologies). The RACE-confirmed 
coding sequence for TsUBE2L3 was amplified by PCR using the following primers: 
 
Forward  
CCGGATCCatgactgcgagtcgtagacttcaaaaagag 
Reverse 
GCGCGGCCGCttaGTCGAGTGCGTAGTCTGGTACGTCaacatcctgacgtttttccgcgtatt 
 
The forward primer was designed to contain a 5’ BamHI linker sequence (bold) and 
the reverse primer was designed to contain a 3’ NotI linker sequence (bold) a stop 
codon (small letters) and a HA-tag (capitals). Both coding sequence portions are in 
small letters. The PCR product was ligated into the multiple cloning site of 
pGEMTeasy (Promega) using TA cloning (described in the results section 3.1) and 
plasmids were amplified in bacterial cultures, and purified as described for TsUCH37 
above. Diagnostic restriction digests using BamHI and NotI were carried out and the 
inserts were sequenced in pGEMTeasy (Beckman Coulter Genomics). Plasmids 
containing the correct insert were then digested using BamHI and NotI enzymes 
(Promega), the inserts were gel-purified using the QIAquick spin gel purification kit 
(Qiagen) according to the manufacturer’s protocol (Qiagen) and cloned into either 
pCSGW tdTomato or pLVX Tight Puro (Table 2.3). Plasmids were transformed into E. 
coli XL10-Gold competent cells (Agilent Technologies) according to the 
manufacturer’s instructions and selected for ampicillin resistance. Plasmids were 
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purified using the QIAprep spin mini or midi prep kits (according to the 
manufacturer’s protocol, Qiagen). 
2.15.	  Recombinant	  protein	  expression	  and	  purification	  
 
Purified pPET28a(+) 6His-TsUCH37 plasmids were transformed into E. coli Rosetta-
2 (BL21 derivatives, Novagen), plated onto agar plates and clones were selected for 
kanamycin resistance. These were then grown overnight in 5 ml Luria-Bertani Broth 
(LB) kanamycin (50 ug/ml) media before inoculating 1 litre LB. At an optical density 
of 0.6 (600 nm) bacterial cultures were induced with 0.5 mM IPTG (Isopropyl β-D-1-
thiogalactopyranoside) and grown for a further 3 hours at 37°C before being 
harvested. Cell pellets were lysed either using BugBuster™ protein extraction reagent 
(Novagen) supplemented with lysozyme and DNase I or by sonication for 4 x 10 
minutes on ice in lysis buffer (50 mM NaH2PO4 pH 8.0, 300 mM NaCl) supplemented 
with lysozyme and DNase I. Lysates were cleared by centrifugation for 20 minutes at 
16,000 xg at 4°C. Samples of the soluble and insoluble fractions were separated and 
analysed by SDS-PAGE. Inclusion bodies were re-solubilised in 50 mM NaH2PO4 pH 
8.0, 300 mM NaCl, 8M Urea at 4°C. Recombinant protein was purified from re-
solubilised inclusion bodies using Ni-NTA resin (Qiagen) under denaturing conditions 
according to the manufacturer’s protocol. Recombinant 6His-TsUCH37 was then 
slowly dialysed using SnakeSkin (Pierce) out of denaturing buffers into native protein 
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl) at 4°C overnight with a change of 
buffer followed by a further 4 hours.  
2.16.	  AMC	  activity	  assays	  
 
Recombinant purified proteins or cell or parasite lysates were used at the 
concentrations indicated in the results. Ub C-terminal 7-amido-4-methylcoumarin 
(Ub-AMC) was used at 250 nM and Nedd8-AMC was used at 500 nM (both from 
Boston Biochem) diluted in reaction buffer (150 mM NaCl, 50 mM Tris/HCl pH 7.5, 2 
mM EDTA, 2 mM DTT supplemented with 1 mg/ml bovine serum albumin). All 
assays were carried out at room temperature. Negative control samples were 
incubated with 2 mM NEM for 20 minutes before addition of the AMC substrate. AMC 
cleavage was measured by fluorescence at 368 nm excitation and 467 emission 
wavelengths on a FLUOstar microplate reader (BMG LABTECH). All measurements 
were made in a 384 well plate (Nunc, black, Thermo-scientific) in a total volume of 20 
µl, in triplicate. All protein concentrations were measured using the BCA assay 
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(Pierce). For inhibition assays, protein samples were incubated with either LDN-
57444 or WP1130 for 1 hour at 37ºC prior to the addition of Ub-AMC.  
2.17.	  Co-­‐precipitation	  with	  6His-­‐TsUCH37	  
 
For co-precipitation analyses T. spiralis muscle larvae or HEK 293T cells were lysed 
using lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, and 1% NP-40 v/v) and 
dounce homogenisation. Lysates were cleared by centrifugation at 16,000 xg and the 
cleared supernatant lysate protein concentration was determined by BCA assay 
(Pierce). Lysates (3 mg per sample) were pre-cleared using wash buffer (Tris-HCl pH 
7.4, 150 mM NaCl, and 0.1% NP-40 v/v) equilibrated-Protein G sepharose beads 
(Sigma-Aldrich) at 4°C for 2 hours. Recombinant purified 6His-TsUCH37 (500 µg) 
was bound to Ni-NTA agarose beads (Qiagen) in binding buffer (1x PBS pH 8.0, 300 
mM NaCl, 0.1% NP40 v/v, 50 mM imidazole and 2 mM β-mercaptoethanol) for 2 
hours at 4°C and beads were then washed 3 times in binding buffer. Pre-cleared T. 
spiralis lysates were incubated with either 6His-TsUCH37-bound Ni-NTA resin or 
native Ni-NTA (no protein bound control) overnight at 4°C. Resin was washed 3 
times in wash buffer before boiling in 2x protein (SDS) loading buffer for SDS-PAGE 
analysis of co-precipitated proteins. Proteins were visualized either by immuno-blot 
analyses or by staining with colloidal coomassie G-250 for LC/MS/MS. 
2.18.	  PNGase	  treatment	  
 
The removal of N- and O-linked glycans from T. spiralis secreted proteins was 
carried out using Peptide-N-Glycosidase F (PNGase F, New England Biolabs) 
according to the manufacturer’s instructions. Briefly, T. spiralis secreted proteins 
were heated at 94°C with glycoprotein denaturing buffer (0.5% w/v SDS, 40 mM 
DTT, 1 µl of 10x buffer per 20 µg protein) before adding G7 reaction buffer (500 mM 
NaH2PO4 pH 7.5) and NP-40 (1% v/v) and 2 µl PNGase F and incubating at 37°C for 
3 hours. 
2.19.	  Tandem	  mass	  spectrometry	  (LC/MS/MS)	  
 
Proteins for analysis by tandem mass spectrometry were separated by SDS-PAGE 
and manually extracted from the gel.  
All samples analysed in collaboration with Eric Spooner (Whitehead Institute for 
Biomedical Research) were processed as follows: protein samples were digested by 
trypsinisation as described by Kinter et al. [222], and analysed by MS/MS by as 
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described by Borodovsky et al. [223]. Briefly, samples were separated using a 
nanoflow liquid chromatography system (Waters Cap LC). The LC system was 
directly coupled to a tandem mass spectrometer (Q-TOF micro, Micromass). 
Analysis was performed in survey scan mode and parent ions with intensities greater 
than 6 were sequenced in MS/MS mode using MassLynx 3.5 Software (Micromass). 
LC/MS/MS data were then searched against the T. spiralis protein database (NCBI 
RefSeq) using two independent algorithms, Mascot [224] and SEQUEST [225] as 
stated in the results.  
All samples analysed in collaboration with Michael Weekes and Steve Gygi (Harvard 
Medical School) were processed as follows: proteins were digested with trypsin using 
standard protocols and peptides were analysed on an Orbitrap XL2 mass 
spectrometer equipped with an Agilent 1100 binary pump and a Famos 
microautosampler. Peptides were separated using a gradient of 6 to 28% v/v 
acetonitrile in 0.125% v/v formic acid over 90 minutes. Peptides were detected in the 
Orbitrap by means of a data-dependent top 10 method. Each full scan was followed 
by the selection of the most intense ions, up to 10, for collision-induced dissociation 
(CID) in the linear ion trap. MS2 spectra were searched using SEQUEST v.28 
against a composite database derived from the UniProt Trichinella spiralis proteome, 
its reversed complement and known contaminants. Peptide spectral matches were 
filtered to a 1% false discovery rate (FDR) using the target-decoy strategy combined 
with linear discriminant analysis. Peptides from all fractions in each experiment were 
combined and assembled into proteins. Protein scores were sorted by rank, and 
filtered to 1.7% FDR. 
2.20.	  UCH	  inhibitor	  compounds	  
 
WP1130 was kindly provided by Dr William Bornmann (University of Texas, M.D. 
Anderson Cancer Center, Houston, TX). The compound was solubilised in DMSO 
and used at concentrations between 5 µM and 500 µM as indicated in the results. 
LDN-57444 (Sigma Aldrich) was solubilised in DMSO and used at concentrations 
between 10 µM and 1 mM as indicated in the results. DMSO alone was used as a 
negative control for inhibition assays. HsUCHL1 and HsUCH37 were provided by 
Katerina Artavanis-Tsakonas and used at 100 nM and 500 nM respectively as 
positive controls for inhibition. 
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2.21.	  MTT	  viability	  assay	  
 
Parasite viability was measured by a quantitative colorimetric assay with the 
tetrazolium salt 3-[4,5-diethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, MTT 
(Sigma-Aldrich). Following treatment in culture, 1000 T. spiralis muscle larvae were 
incubated in 5 mg/ml MTT in phenol red free RPMI 1640 (Sigma-Aldrich) for 4 hours 
at 37ºC. Formazan crystals were solubilised by shaking larvae in 200 µl of 100 % v/v 
DMSO for 1 hour at room temperature. Parasites were removed by centrifugation 
and the absorbance of the supernatant at 575 nm was determined. Parasites that 
had been killed by heat treatment (65ºC for 10 minutes) were used as a positive 
control for drug inhibition. All measurements were made in triplicate. Data was 
statistically analysed by Students t test.  
2.22.	  Crystallisation	  and	  structure	  determination	  of	  TsUCH37	  
 
Crystallography and structure determination was carried out by Marie Morrow at 
Purdue University. The materials and methods for protein are reported by Morrow et 
al., 2013, Biochemistry [3]. 
2.23.	  Ubiquitin-­‐based	  inhibitor	  probe	  production:	  
HA-­‐Ub-­‐VME,	  HA-­‐Ub-­‐TF3BOK	  and	  HA-­‐Ub-­‐Lac	  
 
Human Ub with an upstream HA tag cloned into pTYB1 was kindly donated by Hidde 
Ploegh (Whitehead Institute for Biomedical Research). PTYB1 contains a C-terminal 
intein/chitin-binding domain. HA-Ub-intein/chitin fusion protein was expressed in 
BL21 Rosetta 2 E.coli (Novagen) with a 2-hour induction using 0.5 IPTG at 30°C. 
Bacteria were harvested, centrifuged at 5,000xg for 20 minutes and pellets were 
resuspended in 25 mM MES (2-(N-morpholino)ethanesulfonic acid) pH 6.0, 100 mM 
NaOAc supplemented with protease inhibitor cocktail (Roche) and 1 mM MgCL2, 10 
µg DNase I, 1 mM DTT and lysozyme, 10 µg /ml. Bacteria were lysed by sonication 
for 4 x 10 minutes on ice. Lysate was cleared by centrifugation at 4°C for 30 minutes 
at 15,000xg. The cleared lysate was then purified using a chitin affinity column (New 
England Biolabs) and a protocol modified from Borodovsky et al. [223]. The lysate 
was loaded onto a chitin column (15 ml packed resin per 50 ml of lysate). The 
column was washed using lysis buffer supplemented with 0.5M NaCl (200 ml) and 
then using lysis buffer (400 ml). HA-Ub-MESNa was then eluted by incubating the 
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column in lysis buffer supplemented with 50 mM β-mercaptoethanesulfonic acid 
sodium salt (Mesa) overnight at 37°C. The HA-Ub-MESNa thioester was 
concentrated using 3 kDa molecular weight cut-off (MWCO) vivaspin columns 
(Sartorius Stedim). HA-Ub-MESNa was converted to HA-Ub-VME/ TF3BOK/Lac 
probe using either glycine-VME that was kindly donated by Hidde Ploegh (generated 
as described by Borodovsky et al., supplemental data) or glycine 2,6-
trifluoromethylbenzyloxymethyl-ketone (TF3BOK) or alpha-amino-beta-lactone (Lac) 
(both produced in collaboration with Jennifer Ward as described in her MRes 
research manuscript 2012). The probe (500 µl of 2 mg/ml HA-Ub-MESNa) was mixed 
with 300 µl of 2M NHS (N-hydroxysuccinimide), 1M NaHCO3 pH 8 and 800 µl of 
0.25M of either warhead (glycine-VME, glycine 2,6-trifluoromethylbenzyloxymethyl-
ketone (TF3BOK) and alpha-amino-beta-lactone (Lac), 1M NaHCO3 pH 8 and 
incubated at 37°C overnight. The mixture was then diluted out into 50 mM NaOAc pH 
4.5 (buffer A), and loaded onto a Superloop MonoS column. Probe was further 
purified by ion exchange chromatography using buffer B (50 mM NaOAc pH 4.5 + 1M 
NaCl, 0.5 ml/min flowpaths, pressure 2.5 mPa) with the help of Jan Silhan and Frank 
Zhao. Fractions were concentrated using 3 kDa MWCO vivaspin columns (Sartorius 
Stedim) and tested for activity by diluting 1:3 into 50 mM Tris pH 7.4 and 150 mM 
NaCl and incubating for 1.5 hours at room temperature with recombinant purified 
6His-TsUCH37 (1 µM). Control 6His-TsUCH37 samples were pre-incubated with 2 
mM N-ethylmaleimide (NEM, an alkylating agent that irreversibly inhibits active-site 
cysteine activity of enzymes, Sigma Aldrich) for 20 minutes at room temperature. 
Samples were then analysed by SDS-PAGE and visualised by coomassie staining or 
immuno-blot analysis.  
2.24.	  Ubiquitin-­‐based	  inhibitor	  probe	  reactions	  
HA-­‐Ub-­‐VME,	  HA-­‐Ub-­‐TF3BOK	  and	  HA-­‐Ub-­‐Lac	  
 
The secreted proteins of T. spiralis muscle larvae were collected as described in 
materials and methods section 2.2. Protein concentration was determined by BCA 
assay (Pierce). For probe reactions, the reducing agent dithiothreitol (DTT) was 
added (1 mM) to the secreted proteins. The Ub-based inhibitor probes HA-Ub-VME/ 
TF3BOK/Lac (generated as described above) and FLAG-Nedd8-VS (generated by 
Hemelaar et al. [226] and kindly donated by Hidde Ploegh) were added to the 
secreted proteins of T. spiralis muscle larvae. For all reactions 0.3 µg probe was 
used per 20 µg parasite protein. For immuno-blot analyses, 300 µg of T. spiralis 
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secreted protein was reacted with the probes. For the scaled up reaction for HA-
immuno-precipitation and LC/MS/MS, 3 mg of T. spiralis secreted protein was 
reacted with the probes. T. spiralis secreted proteins were reacted with the probe for 
1.5 hours at room temperature. NEM was added (2 mM) to control protein samples 
and incubated at room temperature for 20 minutes before reaction with the probe. 
For immuno-blot analyses, samples were boiled in 4x protein (SDS) loading buffer 
(200 mM Tris-HCl pH 6.8, 8% w/v SDS, 0.4% w/v bromophenol blue, 40% v/v 
glycerol, 200 mM DTT) and separated by SDS-PAGE before immuno-blot analyses 
using anti-HA or anti-FLAG antibodies (as described in materials and methods 
section 2.36). For the scale-up reaction for LC/MS/MS, samples were used for anti-
HA immuno-precipitation experiments (see below).  
2.25.	  HA-­‐Ub-­‐VME	  HA	  immuno-­‐precipitations	  
 
For anti-HA immuno-precipitation experiments SDS was added (0.4% w/v) to each 
sample before diluting out the SDS to 0.1% w/v with wash buffer containing 0.1% v/v 
NP-40, 50 mM Tris-HCl pH 7.4, 150 mM NaCl. Protein G sepharose resin (Sigma-
Aldrich) was used to pre-clear samples at 4°C for 2 hours. Anti-HA affinity matrix 
(Roche) was then added to each sample (25 µl packed resin per ml of protein 
sample) and incubated at 4°C overnight. For eluting immuno-precipitated proteins, 
resin was washed 3 times in wash buffer before being boiled in an equal volume of 
2x protein loading (SDS loading) buffer (100 mM Tris-HCl pH 6.8, 4% w/v SDS, 0.2% 
w/v bromophenol blue, 20% v/v glycerol, 100 mM DTT). Samples were separated 
from the resin by filtration, resolved using SDS-PAGE and visualised followed by 
colloidal coomassie G-250 staining. Protein bands were then manually excised for 
analyses by LC/MS/MS (see materials and methods section 2.19). 
2.26.	  Ubiquitin	  conjugation	  assay	  
 
All reactions were carried out in 25 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) buffer pH 7.4 supplemented with protease inhibitors 
(1 mM phenylmethanesulfonylfluoride (PMSF), 0.3 µg/ml trypsin inhibitor and 0.025 
TIU/ml aprotinin). Ubiquitin conjugation reactions were carried out using the parkin 
auto-ubiquitination kit according to the manufacturer’s instructions (Boston Biochem). 
Reactions were incubated at 37°C for 1 hour. Proteins were separated by SDS-
PAGE and analysed by binding streptavidin-HRP at 1:20000 (Pierce). Horseradish 
peroxidase (HRP) is a plant-derived enzyme that can oxidise chemiluminescent 
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substrates. When enhanced chemiluminescent substrate, ECL is oxidised by HRP, 
light is produced as a by-product. 
2.27.	  Gradient	  ammonium	  sulphate	  precipitation	  of	  ES	  protein	  
 
Ammonium Sulphate (4 M saturated (NH4)2SO4) pH 7.4 was added at room 
temperature to 100 µg of ES (in 25 mM Hepes buffer pH 7.4 supplemented with 
protease inhibitor cocktail (Roche) to achieve incremental increases in salt 
concentration. Precipitated proteins were centrifuged at 13,000 rpm and the 
supernatant was transferred to a new eppendorf containing a specified increased 
amount of ammonium sulphate. This process was repeated until 90% of salt 
saturation (4 M) was achieved. Protein precipitates were resuspended in 25 mM 
Hepes buffer pH 7.4 with protease inhibitors. Proteins were then transferred to PVDF 
membrane and analysed by immuno-blot using anti-NEDD4-L. In a scale up reaction, 
500 µg of ES was fractionated at salt concentrations of 34, 44, 54, 59-70 (1% 
increase each time) and 80% saturation. Protein pellets were resuspended in 80 µl of 
1x SDS loading dye. 6.25 µl was analysed by SDS-PAGE and immuno-blot using 
anti-NEDD4-L to locate fractions containing the reactive protein. Fractions containing 
proteins of interest were then separated by SDS-PAGE (95%) and visualised by 
silver staining using the SilverQuest Silver Staining kit (Life Technologies according 
to the manufacturer’s instructions). These were separated alongside 5% of the same 
samples that were analysed by immuno-blot using anti-NEDD4-L. Proteins of interest 
were manually excised, using the immuno-blot signal as a guide. These were 
analysed by LC/MS/MS as previously described in section 2.19. 
2.28.	  Immuno-­‐fluorescence	  
 
C2C12 myoblasts were seeded into µ-Slide 8 well, ibiTreat, tissue culture treated 
plates (ibidi) and differentiated as described in section 2.5. After induction of 
TsUBE2L3 expression, cells were washed in ice cold 1x PBS (137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4.2H2O, 2 mM KH2PO4 pH 7.4) and then processed for immuno-
fluoresce using a series of treatments: 20 minutes fixation at room temperature in 4% 
paraformaldehyde in 1x PBS, 3 x washes in 1x PBS, 10 minutes permeabilisation at 
room temperature in 0.2% v/v Triton-X and 3 x washes in 1x PBS. Samples were 
then blocked overnight at 4ºC in 3% BSA w/v, 5% goat serum in 1x PBS. Samples 
were then incubated in primary antibodies diluted in antibody buffer (3% BSA w/v in 
1x PBS 0.05% Tween-20 v/v) for 1 hour at room temperature, followed by secondary 
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antibodies diluted in antibody buffer for 1 hour at room temperature. Samples were 
washed 3 times in 1x PBS before incubation with Hoechst 33342 nucleic acid stain 
(Invitrogen) at a 1:20,000 dilution for 15 minutes at room temperature. A small 
volume of 1x PBS was added to each well of the plate and samples were visualised 
using a Leica SP5 MP/FLIM inverted confocal microscope fitted with water 
immersion lenses. 
2.29.	  35S	  Radiolabelling	  of	  C2C12	  proteins	  
 
C2C12 myotubes were induced using doxycycline. At 20 hours post-induction growth 
media without cysteine or methionine was added for 1 hour at 37°C (Gibco). The 
proteasome inhibitor MG132 (25 µM, Z-Leu-Leu-Leu-al, Sigma-Aldrich) and 35S 
labelled cysteine and methionine amino acids (100uCi/ml PerkinElmer) were added 
to the growth media for 3 hours at 37°C. Cells were harvested and lysed and 
radiolabelled proteins were spotted onto Whatman filter paper that was then 
submerged in liquid scintillation cocktail (PerkinElmer) inside glass scintillation vials. 
The amount of 35S radiolabelled protein was measured for 30 seconds as counts per 
minute (CPM) using a Wallac 1400 DSA scintillation counter. Radiolabelled proteins 
were then used for radio-immuno-precipitation experiments as described below. After 
immuno-precipitation experiments, radioactive proteins were separated by SDS-
PAGE. Gels were processed for autoradiography (at room temperature) by 
incubating in 100% v/v DMSO for 1 hour, fresh 100% v/v DMSO for 30 minutes, 
followed by 20% v/v PPO (polyphenyl ether) in DMSO for 30 minutes, then fresh 
20% v/v PPO in DMSO overnight. Gels were then washed multiple times in water 
before being dried onto Whatman filter paper using a Bio-Rad Gel Dryer 583. 
Proteins were visualised by autoradiography. 
2.30.	  Immuno-­‐precipitations	  
 
Cells were lysed in RIPA buffer (1% v/v Triton X-100, 1% w/v sodium deoxycholate, 
0.1% w/v SDS, 50 mM Tris pH 7.4, 150 mM NaCl and protease inhibitor cocktail 
(Roche). For immuno-precipitations protein concentrations were normalised based 
on a BCA assay (Pierce). For radio-immuno-precipitations protein amounts were 
normalised based on radioactivity (CPM). Protein G sepharose resin (Sigma-Aldrich) 
was used to pre-clear 300-500 µg of proteins in RIPA lysis buffer at 4°C for 2 hours. 
Protein G was removed and samples were diluted out to a volume of 1 ml using 
wash buffer (RIPA buffer without deoxycholate). Antibodies were added to Protein G 
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(25 µl packed resin per ml proteins) and incubated for 45 minutes at 4°C. Protein 
G/antibody mixture was added to proteins and samples were incubated for 45 
minutes at 4ºC. Resin containing protein complexes were washed 4 times in wash 
buffer and re-suspended in 25 µl of 2x protein (SDS) loading buffer (100 mM Tris-HCl 
pH 6.8, 4% w/v SDS, 0.2% w/v bromophenol blue, 40% v/v glycerol, 20% v/v, 100 
mM DTT). Proteins were eluted by boiling samples for 5 minutes at 97°C. Proteins 
were separated by SDS-PAGE followed by either immuno-blot analysis or 
autoradiography. 
2.31.	  HA	  immuno-­‐precipitation	  	  
 
Cells were lysed in RIPA buffer supplemented with EDTA-free protease inhibitor 
cocktail (Roche). A BCA assay (Pierce) was used to normalise protein 
concentrations. Samples (300-500 µg) were pre-cleared using protein G agarose 
(Sigma) for 45 minutes at 4°C. Samples were then incubated with anti-HA high 
affinity matrix (25 µl packed resin per ml of protein sample, Roche) for 45 minutes at 
4°C and the matrix was washed in NP-40 buffer (50 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 1% NP-40 v/v) supplemented with protease inhibitors.  
2.32.	  Re-­‐immuno-­‐precipitation	  
 
Proteins were eluted from the precipitation matrix by boiling in 1% SDS w/v, 1 mM 
DTT for 2 minutes at 97°C and resuspended in 1 ml of NP-40 buffer supplemented 
with protease inhibitors. Samples were then incubated with protein G agarose that 
had been pre-incubated with the antibody in NP-40 buffer for 45 minutes at 4°C. 
Protein G was then washed 4 times in NP-40 buffer, re-suspended and boiled at 
97°C in protein (SDS) loading buffer for 5 minutes to elute proteins. Proteins were 
separated by SDS-PAGE and analysed by immuno-blot. 
2.33.	  TUBE	  2	  assays	  
 
Enrichment of polyubiquitinated proteins was carried out using TUBE 2 agarose resin 
(tebu-bio) according to the manufacturer’s instructions. Proteins were then processed 
using the re-immuno-precipitation protocol above before being separated by SDS-
PAGE and analysed by immuno-blot. 
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2.34.	  Click-­‐IT	  EdU	  proliferation	  assays	  
 
EdU (5-ethynyl-2'-deoxyuridine, 10 µM) was added to C2C12 cell growth media for 
the indicated amount of time and incubated at 37°C. For immunofluorescence, cells 
were grown and processed directly in ibidi u-Slide 8-well plates (ibidiTreat, tissue 
culture treated). For flow cytometry myoblast cells were trypsinised and washed in 1x 
PBS before being transferred to a 96-well v bottom plate where after each incubation 
and wash step plates were centrifuged at 500xg for 3 minutes. All samples were 
processed using immuno-fluorescence fixation and permeabilisation techniques 
(section 2.28 and 2.35). The Click-iT EdU Alexa Flour 647 Imaging kit (Life 
Technologies) was then used according to the manufacturer’s instructions. Samples 
were either visualised by confocal microscopy or analysed by flow cytometry. 
	  
2.35.	  Flow	  cytometry	  
 
Cell samples were trypsinised and then transferred to a 96-well v bottom plate. Firstly 
cells were fixed in 4% paraformaldehyde in 1x PBS (in suspension). All following 
treatments were carried out in suspension where after each incubation and wash 
step, plates were centrifuged at 500xg for 3 minutes. Cells were permeabilised at 
room temperature in 0.2% v/v Triton-X and washed 3 times in 1x PBS. Samples were 
then processed using the Click-iT EdU Alexa Flour 647 kit for Flow Cytometry (Life 
Technologies) according to the manufacturer’s instructions. Finally cells were 
washed twice in 0.5 ml FACS buffer (1x PBS, 1% w/v BSA, 0.05% v/v sodium azide, 
2 mM EDTA) using centrifugation at 900 xg at 4°C for 3 minutes between washes. 
They were then resuspended in FACS buffer and transferred to FACS tubes. 
Samples were analysed using a BD Fortessa Analyser with lasers and filters 633-
670/14 for detection of Alexa Flour 647. Data was analysed using FlowJo software 
(TreeStar). 
	  
2.36.	  Immuno-­‐blot	  analyses	  
 
Proteins were transferred onto PVDF membrane using semi-dry transfer 
electrophoresis in transfer buffer (25 mM Tris-HCL pH 7.6, 192 mM glycine, 20% 
methanol). The PVDF membrane was blocked for 1 hour at room temperature in 5% 
w/v non-fat milk with PBS-Tween (0.1% v/v, PBST). Membranes were incubated in 
primary antibodies in 2% w/v non-fat milk with PBST for 90 minutes at room 
temperature or 4°C overnight. Membranes were washed in PBST 3 x 15 minutes at 
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room temperature before being incubated in secondary antibodies in 2% w/v non-fat 
milk with PBST for 90 minutes at room temperature. Membranes were washed in 
PBST 3 x 15 minutes at room temperature. Proteins were visualised using enhanced 
chemiluminescence substrate (ECL, PerkinElmer) on a Bio-Rad ChemiDoc XRS Gel 
Photo Documentation System. Analysis of the presence of biotinylated proteins was 
carried out by binding streptavidin-HRP to proteins transferred onto PVDF 
membranes (as described above for a regular immuno-blot, except membranes were 
blocked with 5% w/v BSA in PBST and probed with streptavidin-HRP diluted in 5% 
w/v BSA in PBST). For the conjugation of horseradish peroxidase (HRP) to 
antibodies, the Lightening Link Horseradish Peroxidase kit (Innova Biosciences) was 
used according to the manufacturer’s instructions. 
2.37.	  Statistics	  
 
Unless otherwise stated data values are expressed as the mean with the standard 
error of the mean (SEM) represented by error bars. Unless otherwise stated the 
Student’s t-test was used to assess statistical significance of data. Results were 
taken to be statistically significant where p<0.05 unless otherwise stated. 
2.38.	  Sodium	  dodecyl	  sulphate-­‐polyacrylamide	  gel	  electrophoresis	  (SDS-­‐
PAGE)	  
Resolving gels (8-12% acrylamide) were prepared using a mixture of the following 
reagents: 1.5M Tris-HCl pH 8.8, 0.4% w/v SDS, 30% acrylamide, 10% w/v 
ammonium persulphate (APS) and TEMED (tetramethylethylenediamine). Stacking 
gels (4% acrylamide) were prepared using the following reagents: 0.5M Tris-HCl pH 
6.8, 0.4% w/v SDS, 30% acrylamide, 10% w/v ammonium persulphate (APS) and 
TEMED. The volume of each reagent varied depending on the percentage of 
acrylamide in the mixture as presented in Table 2.2 below (shows amounts required 
for 1x 1.0 mm Novex cassette). Once prepared, gels were either poured into Novex 
1.0 mm empty gel cassettes (Life Technologies) or, for midi gels, between large 
glass plates. If gradient gels were required, pre-cast 4-12% gradient gels were 
purchased from Life Technologies (NuPAGE 4-12% Bis-Tris Mini Gels). Prepared 
gels were submerged in SDS-PAGE running buffer (25 mM Tris-HCl pH 8.3, 192 mM 
glycine, 0.1% SDS) in an SDS-PAGE tank. Protein samples were boiled in 1x protein 
(SDS) loading buffer (200 mM Tris-HCl pH 6.8, 8% w/v SDS, 0.4% w/v bromophenol 
blue, 40% v/v glycerol, 200 mM DTT) for 6 min at 94°C and loaded into the wells of 
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the gel. PageRuler Plus pre-stained protein ladder (Thermo Scientific) was loaded 
alongside the sample proteins to serve as a protein size marker. Gels were subjected 
to electrophoresis using a constant voltage (V) of 90V, which was then increased to 
120 V after stacking was complete. Gels were then either stained using coomassie or 
silver-stain or transferred onto PVDF membranes for immuno-blot (section 2.36). 
Table for SDS-PAGE gel preparation 
acrylamide 8% 10% 12% 
4% 
(stacking) 
water 2.7 ml 2.3 ml 1.9 ml 1.3 ml 
acrylamide (30%) 1.6 ml 2 ml 2.4 ml 0.265 ml 
1.5M Tris-HCl pH 8.8 
with 0.4% SDS 
1.6 ml 1.6 ml 1.6 ml 0.4 ml 
10% APS 30 ?l 30 ?l 30 ?l 30 ?l 
TEMED 6 ?l 6 ?l 6 ?l 3 ?l 
 
Table 2. 2 Table of SDS-PAGE gel reagent composition 
Table shows the volumes required of each reagent to make one resolving gel (with the 
indicated acrylamide percentage) using Novex 1.0 mm cassettes (Life Technologies) plus the 
4% stacking gel. 
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2.39.	  Antibodies	  
 
 
Table 2. 3 Antibodies and probes used throughout the study 
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2.40.	  Plasmid	  vectors	  
 
 
Table 2. 4 Plasmid vectors used throughout the study
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Chapter	  3:	  
Characterisation	  of	  TsUCH37,	  a	  deubiquitinating	  enzyme	  expressed	  by	  T.	  
spiralis	  muscle	  larvae	  
 
Some of the data discussed in this chapter was published in 2011. After publication the 
project was continued and the results presented here comprise an expanded version [1]. 
This work also led to a collaboration with a group at Purdue University, and some of the 
data from this was published in 2013 [3]. 
During my Masters of Research (MRes) degree at Imperial College London, I carried 
out a 3-month project under the supervision of my PhD supervisor to be, Katerina 
Artavanis-Tsakonas. The main project aim was to investigate the various roles of the 
ubiquitin pathway during the infection of muscle tissue by the mammalian parasitic 
nematode, T. spiralis. I initially set out to look at the ubiquitin pathway of the parasite 
itself. During the project, I found that T. spiralis muscle larvae express various putative 
T. spiralis deubiquitinating enzymes (DUBs). The most abundant T. spiralis DUB 
identified was named TsUCH37 after its orthology to mammalian UCH37 (also known 
as UCHL5). The PhD project followed on from this, and chapter 3 presents the 
subsequent characterisation of TsUCH37.  
Background	  
 
The ubiquitin proteasome system is essential for the regulation of many important 
cellular processes [5]. It is therefore implicated in a great number of diseases, 
especially cell cycle disorders such as cancer [227-229]. Therapeutic drugs that target 
the ubiquitin proteasome system are therefore in demand and some are already in 
clinical trials for human use [73,74]. The ubiquitin proteasome system is also implicated 
during infection by pathogenic organisms, where the pathogen may disrupt the host 
ubiquitin pathway to its own advantage during infection. Despite the absence of their 
own ubiquitin proteasome system, some viruses and bacteria express components of 
the ubiquitin pathway that manipulate host proteins [93,97,98]. Because parasites are 
most often eukaryotic, they have their own Ub proteasome system, the function of 
which is essential for the their homeostasis and survival, thus parasite-derived ubiquitin 
proteasome components potentially make good drug targets for infection [230,231]. 
Most of the examples of drugs that target the parasite ubiquitin system are proteasome 
inhibitors. However, because the structure of the proteasome is so highly conserved, 
many proteasome inhibitors are non-selective and potentially toxic. In order to develop 
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inhibitors with greater selectivity, interest in targeting ubiquitin conjugation and 
hydrolysis enzymes has expanded. 
I was interested in exploring the role of the T. spiralis ubiquitin pathway during the 
muscle stages of trichinellosis in order to use T. spiralis as a model for further 
investigating the potential of parasite-derived ubiquitin pathway proteins as drug targets. 
I began by investigating whether or not T. spiralis muscle larvae express active 
ubiquitin pathway machinery. During the MRes project, I utilised a ubiquitin-based 
inhibitor probe, HA-Ub-VME, that identifies deubiquitinating enzymes (DUBs). A 
detailed explanation of the mechanism of the probe can be found in chapter 4, 
background. T. spiralis muscle larvae were reacted with HA-Ub-VME and probe-protein 
complexes were immuno-precipitated using anti-HA antibodies. These complexes were 
further analysed by tandem mass spectrometry (LC/MS/MS). This method identified 5 
different putative T. spiralis DUBs (MRes report 2010, [1]). The most abundant DUB 
identified was a conserved ubiquitin C-terminal hydrolase domain protein, orthologous 
to the highly conserved 37 kDa DUB, UCH37 (also known in mammals as UCHL5). The 
orthologous T. spiralis sequence is annotated in the draft genome (NCBI Ref Seq) as a 
putative ubiquitin carboxyl- hydrolase ubh-4, GI:339238735 [232]. This sequence did 
not correlate with multiple orthologous sequences, and the accuracy of the annotation 
was disputed. 
Mammalian UCH37 was first identified as proteasome associated DUB [34,35]. UCH37 
can be nuclear or cytoplasmic, and is responsible for the hydrolysis of Lys-48-linked 
polyubiquitin [32,233]. UCH37 is the only UCH domain DUB that has been shown to 
associate with the 19S subunit of the 26S proteasome [33]. UCH37 interacts directly 
with the proteasome subunit ADRM1. In turn, ADRM1 binds to Rpn2, a protein that 
makes up the 19S base of the proteasome. In vitro, the ubiquitin hydrolysis activity of 
the full length human UCH37 is enhanced by the addition of the ADRM1 protein. This 
enhancement of UCH37 activity is not observed when ADRM1 is added to a truncated 
version of UCH37 that lacks the C-terminal portion of the protein that has been shown 
to directly bind to ADRM1 [32,33,233]. Human UCH37 and ADRM1 therefore both play 
a role in the proteasomal degradation of protein substrates. HsUCH37 is expressed in 
many different cell types and tissues and knockout of UCH37 in mice is lethal at the 
embryonic stage [36]. The orthologue of this protein in Plasmodium falciparum 
PfUCH54 (named because it weighs 54 kDa rather than 37) was also identified using 
the human Ub-based inhibitor probe, HA-Ub-VME [102].  
Having identified TsUCH37, an abundant T. spiralis DUB for which a function has been 
assigned for numerous orthologues, it was of interest to characterise the function of the 
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T. spiralis protein, and ascertain whether or not its expression is essential for the 
survival of the parasite. Barring some pioneering studies in carried out in Schistosoma 
mansoni, the majority of parasitic nematodes, including T. spiralis have proven thus far 
largely resistant to common techniques of genetic manipulation [234,235]. As yet there 
is no obvious explanation for the resistance observed [236]. The methodological 
possibilities for studying the functions of T. spiralis proteins are therefore limited. In 
addition, the T. spiralis life cycle does not include a free-living stage. This means that 
the muscle larvae can only be cultured for a limited amount of time after isolation from 
muscle tissues before they die (in my experience 4-6 days). For these reasons 
combined, the endogenous expression and function of a T. spiralis protein cannot be 
studied using genetic manipulation. It was therefore decided that studying the function 
of the T. spiralis DUB, TsUCH37, would largely require the cloning of the TsUCH37 
gene followed by recombinant protein expression and biochemical analyses. 
This chapter presents the analysis of the coding sequence of TsUCH37, followed by the 
expression, purification and functional characterisation of the recombinant protein. The 
potential of TsUCH37 as a drug target was then investigated using drug inhibitor 
assays. Finally, results prompted a collaboration with a crystallography group at Purdue 
University (US) [3]. 
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Chapter	  3	  Results: 
3.1.	  Finding	  the	  true	  open	  reading	  frame	  for	  a	  T.	  spiralis	  DUB	  orthologue	  	  
 
The putative coding sequence of for TsUCH37 translates into a protein sequence of 
900 amino acids (GI: 339238735 - 2703 bp). This was aligned with UCH37 orthologues 
from 6 other species using a MUSCLE alignment algorithm (Figure 3.1) [237]. The 
putative UCH37 sequence from the filarial parasitic nematode Brugia malayi (GI: 
158597396) showed the greatest identity to the T. spiralis. Also aligned were UCH37 
orthologues of (in order of descending identity to the T. spiralis orthologue) the M. 
musculus (GI: 4878011), H. sapiens (GI: 4877999), C. elegans (GI: 71981272), D. 
melanogaster (also known as p37A, GI:17648095) and S. cerevisiae (YUH1, 
GI:151945164). All of which have been confirmed as functional ubiquitin C-terminal 
hydrolases [36,238-240]. Alignment revealed that the annotated putative T. spiralis 
sequence was considerably longer than its orthologues, with an N-terminal extension of 
almost 600 amino acids). When analysed by SMART software (Simple Modular 
Architecture Research Tool, [210,211]) 2 additional Pfam domains were identified: a 
SEC14 domain and a PRP38 domain, both located within the N-terminal extension. The 
peptides identified by LC/MS/MS only aligned within the C-terminal region containing 
the peptidase_C12 domain and not within the N-terminal extension (MRes report 2010 
[1]). This information led into question the accuracy of the gene annotation. To be able 
to clone the gene for TsUCH37, the true open reading frame had to first be confirmed.  
The draft annotation of the T. spiralis genome was carried out using the gene prediction 
algorithm FGENESH without using any prior knowledge of potential gene or transcript 
arrangement in T. spiralis, or ‘hints’ from the gene or transcript arrangement of similar 
organisms (FGENSH ‘de novo’ [214,232]). The T. spiralis genomic contig containing the 
TsUCH37 gene (The Genome Institute at Washington University, contig 1.2, bases 
34000-37000) was therefore re-analysed using 6 additional gene prediction algorithms: 
FGENESHC using the original EST hit (identified by the original LC/MS/MS - 
GI:157958881, before the draft genome was available – [1]) as a hint, FGENESH+ 
using the C. elegans UBH4 as a hint, AUGUSTUS using the EST as a hint, 
AUGUSTUS using the EST and C. elegans UBH4 as hints, GenemarkHMM and SNAP 
(Figure 3.2). Gene prediction analyses were carried out in collaboration with Eliseo 
Papa of Harvard/MIT. Out of all 7 algorithms, 5 predicted the same start codon, which 
aligned well with all 6 orthologous UCH37 protein sequences when translated (Figure 
3.5). This consensus start codon did not agree with the putative annotation in the 
database (GI:339238735, based on FGENSH ‘de novo’ prediction). The consensus 
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prediction did not include any of the upstream portion, which translates to contain the 
SEC14 and PRP38 domains. Within bases 34000-37000 of contig 1.2, AUGUSTUS 
predicted an additional gene upstream of the UCH37 gene, and GenemarkHMM and 
SNAP predicted 2 additional genes in the upstream portion of the contig, rather than 
predicting extra exons of the same gene as was the case for FGENESH de novo. The 
predicted end of the coding sequence varied slightly between each programme. Overall, 
when translated the AUGUSTUS sequence prediction of 930 bp, 7 exons and 6 introns, 
aligned most closely with the other UCH37 orthologues (Figure 3.5). This sequence 
was therefore hypothesised to be the true open reading frame of the T. spiralis UCH37. 
In order to experimentally confirm the true open reading frame for the T. spiralis UCH37, 
rapid amplification of cDNA ends (RACE) experiments were carried out. This technique 
is used to confirm the full sequence of an mRNA transcript for a particular gene. Total 
RNA is isolated from a sample and, for 5’ RACE, the 5’ phosphate group is removed 
from degraded mRNA, rRNA, tRNA and DNA by calf intestinal phosphatase (CIP) 
(Figure 3.3). The CAP structure is then removed from intact mRNA using tobacco acid 
pyrophosphatase (TAP), leaving a 5’ phosphate group on only the intact mRNA 
transcripts. RNA ligase is then used to ligate the 5’ RACE adapter oligo onto the intact 
mRNA transcript. This is reverse-transcribed to cDNA for the amplification by PCR 
using a gene specific reverse primer and a primer that anneals to the 5’ RACE oligo, 
thus amplifying the 5’ end, including the start codon, of the transcript. For 3’ RACE, a 3’ 
RACE adapter oligo is ligated onto the poly-adenosine tail at the 3’ end of an intact 
mRNA transcript. This is reverse-transcribed to cDNA for the amplification by PCR 
using a gene specific forward primer and a primer that anneals to the 3’ RACE oligo, 
thus amplifying the 3’ end, including the stop codon, of the transcript. These DNA 
fragments can then be sequenced to confirm the full coding sequence.  
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Figure 3. 1 Alignment of orthologues and gene predictions of TsUCH37 
The NCBI annotated TsUCH37 (GI:339238735, FGENESH 2703 bp) sequence was aligned with 
UCH-L5/37 orthologous sequences from 6 other species using a Geneious alignment algorithm 
with Geneious software (Drummond, geneious.com). Sequences in order of descending identity 
to the T. spiralis orthologue: M. musculus (GI:229577283), H. sapiens (GI: 312922359), C. 
elegans (GI:71981272), D. melanogaster (GI:17648095) and S. cerevisiae (GI:151945164). 
Blocks indicate nucleotide bases and lines indicate gaps in alignment. The TsUCH37 sequence 
was analysed by SMART software identifying 3 Pfam domains: a SEC14 domain, a PRP38 
domain (both located within the N-terminal extension) and a ubiquitin C-terminal hydrolase 
(UCH) peptidase_C12 domain.  
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Figure 3. 2 Gene predictions for TsUCH37 
The T. spiralis genomic contig (contig 1.2, bases 34000-37000, The Genome Institute at 
Washington University) was analysed using 6 gene prediction algorithms: FGENESHC using the 
EST GI:157958881 as a hint, FGENESH+ using the C. elegans UBH4 as a hint, AUGUSTUS 
using the EST as a hint, AUGUSTUS using the EST and UBH4 as hints, GenemarkHMM and 
SNAP. The FGENESHC predicted start codon agrees with all subsequent gene prediction 
programs employed, and the most common (consensus) gene prediction is highlighted. 
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Figure 3. 3 RNA Ligase Mediated (RLM) RACE-PCR schematic 
Total RNA was isolated from T. spiralis muscle larvae. A. For 5’ RACE, the 5’ phosphate group 
was removed from degraded mRNA, rRNA, tRNA and DNA by calf intestinal phosphatase (CIP). 
The CAP structure was then removed from intact mRNA using tobacco acid pyrophosphatase 
(TAP), leaving a 5’ phosphate group on intact mRNA transcripts. The 5’ RACE adapter oligo was 
ligated onto the intact mRNA transcript using RNA ligase. This was reverse-transcribed to cDNA 
and amplified by PCR using a gene specific reverse primer and a primer that anneals to the 5’ 
RACE oligo, thus amplifying the 5’ end, including the start codon, of the transcript. B. For 3’ 
RACE, a 3’ RACE adapter oligo was ligated onto the poly-adenosine tail at the 3’ end of an 
intact mRNA transcript. This was reverse-transcribed to cDNA and amplified by PCR using a 
gene specific forward primer and a primer that anneals to the 3’ RACE oligo, thus amplifying the 
3’ end, including the stop codon, of the transcript. 
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For RACE analysis of the T. spiralis UCH37 transcript, two gene-specific reverse 
primers (GSRP) were designed, one using the annotated FGENESH-derived sequence 
(primer 1) and the other using the AUGUSTUS-derived sequence (primer 3). All 
theoretical primer-binding sites are illustrated in Figure 3.4 A. Each was designed to 
anneal 332 bp and 321 bp (respectively) from the predicted start codon. The 
AUGUSTUS GSRP however, should also anneal to the FGENESH sequence albeit 
further downstream if the prediction is correct (2094 bp from the predicted start codon). 
A gene-specific forward primer (GSFP) was also designed for amplification of the 3’ end 
(primer 4). This was designed to anneal to a sequence that is in agreement with both 
the FGENESH prediction and the AUGUSTUS prediction. This was predicted to amplify 
a fragment of the gene 396 bp from the AUGUSTUS predicted stop codon, and 425 bp 
from the FGENESH predicted stop codon. Forward and reverse (end-to-end) primers 
were also designed on the 930 bp AUGUSTUS predicted sequence (primers 2 and 5, 
Figure 3.4 A). 
Total RNA was extracted and purified from T. spiralis muscle larvae. Control primers to 
amplify a 313 bp fragment of the transcript of the T. spiralis GM2-activator protein were 
kindly supplied by Murray Selkirk [199]. These were used in a PCR reaction to test the 
quality of the RNA. AUGUSTUS-based gene specific primers were also tested by PCR. 
These reactions were separated by agarose gel electrophoresis and visualised under 
UV light after incubation with ethidium bromide. (Figure 3.4 B). End-to-end primers 2 
and 5 amplified a fragment of DNA of an AUGUSTUS-predicted length just under 1000 
bp. However when using the AUGUSTUS GSRP (primer 3) with the forward primer (2), 
3 bands between 300 and 500 bp were observed. These may have amplified as a result 
of gDNA contamination of the T. spiralis RNA. The fragment amplified by primers 4 and 
5 also appeared slightly longer than the AUGUSTUS-predicted length of 396 bp.  
RACE was then carried out using the FirstChoice RNA Ligase Mediated Rapid 
Amplification of cDNA Ends (RLM-RACE) kit from Ambion. T. spiralis RNA was 
processed as instructed by the manufacturer and reverse transcribed to cDNA (using 
the Superscript II Reverse Transcriptase kit from Invitrogen) before undergoing PCR 
followed by nested PCR. Nested PCR was carried out using the RACE 5’ primers that 
anneal to the 5’ RACE oligo, paired with primers 1, 3 and 5 (Figure 3.4 C). Reactions 
were separated by agarose gel electrophoresis and visualised under UV light after 
incubation with ethidium bromide. No band was observed when the FGENESH GSRP 
(primer 1) was paired with the RACE oligo 5’ primers. Again, 3 bands were observed 
when the RACE 5’ oligo primer was paired with the AUGUSTUS GSRP (primer 3), the 
smallest of which was most abundant and at the expected size of around 300 bp. 
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These PCR reactions were carried out using a 40 second polymerase extension time, 
since the predicted fragments were to be 332 bp and 321 bp. The RACE 5’ primers 
were then paired with the AUGUSTUS predicted end primer (primer 5) and again the 
AUGUSTUS predicted GSRP (primer 3). This time, 2 minutes was used for polymerase 
extension time. This was to allow for amplification of a potentially longer sequence 
predicted by FGENESH. Using primer 5 a band was observed that corresponded to the 
AUGUSTUS predicted full-length sequence of 930 bp, rather than the FGENESH 
predicted full length of 2703 bp. With primer 3 a band that corresponded to the 
AUGUSTUS predicted 321 bp was observed, rather than that of 2094 predicted by 
FGENESH. One additional band was also observed at approximately 700-800 bp that 
may have been a result of T. spiralis RNA or cDNA degradation. The fragment that was 
amplified using primer 3 with a 2-minute extension time was purified and ligated into 
pGEMTeasy using a restriction enzyme free ligation method known as TA cloning. 
Briefly, linearised pGEMTeasy is modified to contain a thymine (T) DNA base overhang 
on each 5’ end of the complementary vector strands. The polymerase used for the PCR, 
leaves adenine (A) overhangs on the 3’ end of the PCR product. Since adenine and 
thymine are complementary DNA bases, the T and A will ligate to one another. 
PGEMTeasy containing the purified insert was sequenced by Beckman Coulter 
Genomics. The sequence obtained was 100% identical to the AUGUSTUS prediction of 
the first 321 bp of the coding sequence for the T. spiralis UCH37. This start site aligned 
well with the other UCH37 orthologues and thus the start codon was confirmed (Figure 
3.5).  
In order to amplify the 3’ end of the transcript, the same gene specific forward primer 
(primer 4) was used for both the AUGUSTUS and FGENESH predictions because both 
gene predictions are in agreement with this part of the coding sequence (Figure 3.4 D). 
PCR reactions were carried out using RNA that had been reverse transcribed for 3’ 
RACE as shown in Figure 3.3 B. As a control, primer 4 was paired with primer 5 to 
amplify the AUGUSTUS predicted end of the transcript. Primer 4 was also combined 
with the RACE 3’ primer and RACE 3’ nested primer to obtain a fragment containing the 
true stop codon. DNA was amplified in each sample. Using primers 4 and 5, a band of 
an expected size larger than 300 bp was observed. The band amplified using primer 4 
and the RACE 3’ primer was very slightly larger than this. This fragment was manually 
excised from the gel, purified and ligated into pGEMTeasy using TA cloning as 
described above. The sequence of the insert was obtained (Beckman Coulter 
Genomics) and confirmed to be 100% identical to the AUGUSTUS predicted coding 
sequence for the 3’ end of the TsUCH37 gene. It was therefore confirmed, that the 
AUGUSTUS prediction, represented the true coding sequence for the T. spiralis UCH37. 
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Figure 3.5 shows how this sequence aligned well with orthologous sequences for 
UCH37, with a good level of agreement at the beginning and end of the protein 
sequence. 
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Figure 3. 4 RACE-PCR of the TsUCH37 gene 
A. Primers 1-5 were designed to bind to either the AUGUSTUS predicted (930 bp) or the 
FGENESH de novo predicted (2703 bp) coding sequences of TsUCH37. RACE adapter oligos 
were ligated onto the 5’ end and the 3’ end of the mRNA transcript. RACE 5’ and 3’ primers 
were provided with the FirstChoice RLM-RACE kit from Ambion. Primer binding sites are 
indicated. Sizes of the expected DNA fragments, based on the distances from the end of the 
predicted transcripts to the primer-binding site, are indicated. RACE-PCR was carried out. All 
PCR reactions were separated by agarose gel electrophoresis and visualised under UV light 
after incubation with ethidium bromide. B. Primers 2-5 were tested on mRNA from T. spiralis 
muscle larvae. Control primers to amplify a 313 bp fragment the transcript of the T. spiralis GM2-
activator protein were used as a positive control. C. 5’ RACE-PCR was carried out using the 
RACE 5’ primer and gene prediction-specific reverse primers 1, 3 and 5. A DNA fragment at a 
size corresponding to the AUGUSTUS-predicted start of the TsUCH37 transcript was purified for 
cloning and sequencing (red box). D. 3’ RACE-PCR was carried out using the RACE 3’ primer 
and gene prediction-specific forward primer 4. The DNA fragment amplified by primer 4 + the 
RACE 3’ primer was purified for cloning and sequencing (red box).
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Figure 3. 5 Alignment of orthologues and RACE-PCR-confirmed coding sequence of 
TsUCH37 
The NCBI annotated TsUCH37 (GI:339238735, FEGENSH, 2703 bp) sequence was aligned 
with UCH-L5/37 orthologous sequences from 6 other species using a Geneious alignment 
algorithm with Geneious software (Drummond, geneious.com). Sequences in order of 
descending identity to the T. spiralis orthologue: M. musculus (GI:229577283), H. sapiens (GI: 
312922359), C. elegans (GI:71981272), D. melanogaster (GI:17648095) and S. cerevisiae 
(GI:151945164). This alignment was then re-aligned with the RACE-PCR-confirmed coding 
sequence for TsUCH37 (the same sequence as predicted by AUGUSTUS gene prediction 
software). Blocks indicate nucleotide bases and lines indicate gaps in alignment. The TsUCH37 
was analysed by SMART software identifying 3 Pfam domains: a SEC14 domain and a PRP38 
domain, both located within the N-terminal extension, and a ubiquitin C-terminal hydrolase-
specific peptidase_C12 domain. 
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With the true open reading frame of TsUCH37 confirmed it was possible to clone the 
coding sequence and express recombinant protein, which would allow further 
biochemical analyses of the function of the parasitic DUB. 
The translated open reading frame of the T. spiralis UCH37 orthologue contains 309 
amino acids, forming a protein with a predicted molecular weight of 35.2 kDa and a pI 
of 4.42 (Figure 3.6 A). Residues 5-209 span the peptidase_C12 domain and residues 
C85, H161 and D176 comprise the catalytic triad that is common to cysteine proteases. 
The positions of these catalytic residues are conserved amongst UCH domain DUBs. 
When aligned with the human UCH37, the sequences are 45.9% identical (Figure 3.6 
B). Primers were designed to clone the confirmed coding sequence minus the start 
codon, with a 5’ BamHI restriction site and a 3’ NotI restriction site from T. spiralis 
cDNA (primer Table). This was digested and ligated into the pPET28a(+) bacterial 
expression vector. The complementary BamHI and NotI restriction sites of the multiple 
cloning site ensured that the sequence could be transcribed in frame with a start codon 
and an N-terminal His-tag (6 x histidine residues). The predicted molecular weight of 
6His-TsUCH37 was 38.8 kDa (Figure 3.6 C). The confirmed coding sequence for 
TsUCH37 with an N-terminal His-tag was cloned for expression in a bacterial system, 
for purification and activity profiling.  
Bacteria do not have a ubiquitin proteasome system, and the laboratory E. coli strain 
used for expression of TsUCH37 does not express DUBs. This allowed the purification 
of 6His-TsUCH37 without contaminating DUB proteins that would confuse activity 
profiling. The His-tag was added to the N-terminal end of TsUCH37, because studies 
have shown that the C-terminus of UCH37 is important for the association with the 
interaction partner ADRM1 and the proteasome. The plasmid was transformed into 
competent E. coli and bacteria were cultured and induced to express the 6His-
TsUCH37 using an IPTG inducible system. Bacteria were then harvested and protein 
was purified from both soluble lysate and insoluble inclusion bodies using His-tag-
binding Ni-NTA resin (Figure 3.7 A and B). Purification fractions were separated by 
SDS-PAGE for analysis, revealing that the protein (observed at the expected size) was 
present in a larger proportion in inclusion bodies than in soluble lysate. Purification from 
inclusion bodies yielded much purer protein than purification from soluble lysate, 
although a contaminant band at around 20 kDa was persistent in most batches. 
Recombinant protein was therefore purified from inclusion bodies under denaturing 
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conditions. Purification in denaturing buffers also ensures that, since all proteins are 
unfolded, contaminating protease enzymes cannot degrade the protein of interest. This 
is important when purifying protease enzymes such as DUBs, because many protease 
inhibitors cannot be included in purification buffers as they may inhibit the activity of the 
protease of interest itself.  
The recombinant protein was then slowly refolded using dialysis into native buffers 
using SnakeSkin dialysis tubing (Pirece). Once concentrated, it was confirmed that 
6His-TsUCH37 was purified under denaturing conditions to a greater level of purity than 
previous purifications from soluble lysate (data not shown). The presence of the smaller 
protein however was persistent (Figure 3.7 B, a and b). As expected, the recombinant 
6His-TsUCH37 did react with anti-His-tag antibodies, further validating the expected 
size of the purified protein (Figure 3.7 C). The persistent smaller protein did not react 
with anti-His antibodies, indicating that this protein is a contaminant that has an affinity 
for Ni-NTA resin, rather than being a breakdown product of 6His-TsUCH37. For a 
protein to be active, it is essential that the native confirmation is adopted upon re-
folding. It was therefore necessary to validate the ubiquitin hydrolysis activity of the 
recombinant re-folded 6His-TsUCH37 before further analyses were carried out. 
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Figure 3. 6 Analysis of the TsUCH37 coding sequence 
A. The 930 bp RACE-confirmed open reading frame of TsUCH37 was translated into a protein 
sequence of 309 amino acids with a predicted molecular weight of 35.2 kDa and an isoelectric 
point (pI) of 4.42. B. The translated protein sequence of TsUCH37 was aligned with the human 
UCH37 protein sequence using Geneious alignment software (Drummond 2012 Bioinformatics) 
showing 45.9% identity. C. The TsUCH37 coding sequence was cloned into the expression 
vector pPET28a+ with an N-terminal 6 x Histidine tag (black box). The recombinant protein 
translation is 343 amino acids long and 38.8 kDa in molecular weight. A, B and C. The UCH 
peptidase_C12 domain is highlighted by a grey box and catalytic residues are indicated with star 
symbols.  
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Figure 3. 7 Expression and purification of TsUCH37 
A. 6His-TsUCH37 was expressed in E coli. Using Ni-NTA resin (Qiagen), 6His-TsUCH37 was 
purified from both the (S) soluble lysate (Ni-NTA resin washes and elutions: W and E) and the (I) 
inclusion bodies (Ni-NTA resin wash buffer at pH 6.3 and elution buffers at pH 5.9 and 4.5). 
Protein that did not bind to Ni-NTA resin is annotated as flow though (FT) B. His-tag purification 
under denaturing conditions was optimised for the purification of 6His-TsUCH37 from inclusion 
bodies. Purified protein was observed at the expected size of 38.8 kDa (a). Another band, 
representing either a degradation product or a contaminant was observed at approximately 20 
kDa (b). C. Anti-His-tag antibodies were reacted with lysate of T. spiralis muscle larvae, purified 
6His-TsUCH37 and HEK 293T cell lysate by immuno-blot (IB). The arrow indicates the 6His-
TsUCH37-reactive band at the expected molecular weight of 38.8 kDa. All protein marker sizes 
are indicated in molecular weight (kDa). 
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3.3.	  Validation	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In order to verify that the recombinant purified 6His-TsUCH37 was an active DUB, a 
Ub-AMC assay was employed. Ub-AMC is human Ub that contains the C-terminal 
modification, 7-amido-4-methylcoumarin (AMC). Cleavage of the Ub-AMC substrate by 
DUB enzymes releases free fluorogenic AMC from the Ub (Figure 3.8 A). The 
fluorescence produced is cumulative, and can be recorded as a measure of Ub 
hydrolysis activity. A Ub-AMC hydrolysis assay provides a convenient and sensitive 
method of testing the activity of a DUB. It also allows for the measurement of real-time, 
physiologically relevant activity of an enzyme, rather than end-point activity. In other 
words, the reaction of a DUB with a reagent such as HA-Ub-VME (used originally to 
identify TsUCH37) demonstrates end-point activity. After a period of incubation time, a 
DUB is able to form a covalent bond with HA-Ub-VME. During this experiment, both the 
DUB and the HA-Ub-VME are provided in saturating conditions. These diagnostic 
results tell us that these two compounds interact, eventually. A Ub-AMC assay however, 
is carried out using a nM-µM range of concentrations of the Ub-AMC substrate and the 
DUB enzyme. Measurements are taken immediately after the mixture of the two 
components, and followed over time, representing a level of activity that will be more 
relevant to the physiological conditions of a cell.  
A series of 6His-TsUCH37 dilutions were reacted with Ub-AMC. Fluorescence was 
measured at 1-minute intervals for 20 minutes (Figure 3.8 B). Purified recombinant 
Plasmodium falciparum PfUCHL3 was also reacted with Ub-AMC (at a saturating 
concentration) as a positive control for activity. The Ub hydrolysis activity of this 
conserved DUB enzyme has been previously reported [103]. NEM is a cysteine 
protease inhibitor that irreversibly binds to the active site cysteine of enzymes such as 
DUBs (see chapter 4 background section for a detailed explanation). For a negative 
control to ensure that activity was cysteine-based, proteins were pre-incubated with 
NEM. Ub-AMC hydrolysis activity by 6His-TsUCH37 was observed as quickly as 2 
minutes after addition of the Ub-AMC substrate. The activity of 6His-TsUCH37 began to 
plateau at 20 minutes after Ub-AMC addition, indicating depletion of the substrate. The 
activities of both TsUCH37 and PfUCHL3 were silenced by pre-incubation with NEM 
confirming that the activity was dependent on an active site cysteine. Results validated 
that the recombinant 6His-TsUCH37 was refolded into an active confirmation and could 
therefore be used as a reliable reagent for the characterisation of the T. spiralis DUB. 
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Figure 3. 8 Ub-AMC hydrolysis by TsUCH37 
A. Schematic of the mechanism of a Ub-AMC hydrolysis assay. The active-site cysteine residue 
of a DUB mediates the cleavage of Ub from AMC. Unconjugated AMC fluoresces at 467 nm. 
The measurement of relative fluorescence units (RFU) over time corresponds to DUB activity. B. 
6His-TsUCH37 (2 µM, 1 µM and 500 nM) was reacted with Ub-AMC for 20 minutes. RFU 
measurements at 467 nm were taken at minute intervals. The hydrolysis of Ub-AMC by each 
sample was measured in triplicate. Points show the mean RFU and the standard error is 
indicated as bars. PfUCHL3 was assayed as a positive control (74 nM). Each protein was pre-
incubated with the cysteine protease inhibitor NEM as a negative control. Data are 
presented as the mean of triplicate values from a single experiment and the error bars represent 
SEM. Consistent data were obtained from similar experiments performed using different 
concentrations of protein and different protein batches. 
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My supervisor, Katerina Artavanis-Tsakonas, has previously shown that the malaria 
parasite Plasmodium falciparum orthologue of TsUCH37, PfUCH54 (GI: 23496100), is 
able to hydrolyse both Ub-AMC and the AMC conjugate of the ubiquitin-like modifier 
Nedd8 (Nedd8-AMC, [102]). Recent data generated by an undergraduate student in our 
lab, Sara Aguilera, suggests that the primate malaria parasite, Plasmodium knowlesi 
UCH37 (PkUCH37) can also hydrolyse both Ub and Nedd8 (GI: 221056068, data not 
shown). UCH37 orthologues of higher eukaryotes such as the human UCH37 however, 
do not demonstrate duaI Ub/Nedd8 hydrolysis activity and are specific for Ub. I was 
therefore interested in testing whether or not this dual function was conserved by the 
parasitic nematode T. spiralis.  
Recombinant purified 6His-TsUCH37 was tested for Nedd8-AMC hydrolysis activity in 
parallel with 3 other recombinant purified proteins: the human Nedd8-specific protease 
1 (NEDP1), the human UCH37 and the P. falciparum UCH54 (Figure 3.9 A, B, C, D). 
As a negative control, proteins were pre-incubated with NEM to confirm cysteine 
specific activity. A reaction with Ub-AMC was also included for NEDP1, HsUCH37 and 
TsUCH37 to confirm that the protein was not degraded or denatured. Fluorescence 
measurements were taken every minute for 20 minutes. HsNEDP1 showed very weak 
Ub-AMC hydrolysis compared to a good level of Nedd8-AMC hydrolysis. Conversely, 
HsUCH37 exhibited good Ub-AMC hydrolysis and very weak Nedd8 hydrolysis. 
PfUCH54 showed a high level of Nedd8-AMC hydrolysis as has been previously 
reported [102]. TsUCH37 showed no Nedd8 hydrolysis activity, but showed good Ub-
AMC activity as demonstrated above in Figure 3.9. All activities were silenced by the 
pre-incubation of the proteins with NEM. 
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Figure 3. 9 Nedd8-AMC hydrolysis by TsUCH37 and orthologues 
In vitro Nedd8 and Ub-AMC hydrolysis assays of recombinant purified proteins. Fluorescence 
(representing the release of free AMC) was measured in relative fluorescence units (RFU) over 
time (minutes) for 20 minutes. A. Nedd8-AMC and Ub-AMC hydrolysis by the human Nedd8 
specific protease 1 (NEDP1, 500 nM). B. Nedd8 and Ub-AMC hydrolysis activity of the human 
UCH37 (1 µM). C. Nedd8 hydrolysis by the Plasmodium falciparum UCH37. D. Nedd8 and Ub-
AMC hydrolysis by 6His-TsUCH37. All enzymes were pre-incubated with the cysteine protease 
inhibitor NEM as a negative control for cysteine dependent activity. The hydrolysis of Nedd8-
AMC or Ub-AMC by each sample was measured in triplicate. Data are presented as the mean of 
triplicate values from a single experiment and the error bars represent SEM. Consistent data 
were obtained from similar experiments performed using different concentrations of protein and 
different protein batches. 
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Given the high level of conservation of the ubiquitin pathway in eukaryotes, it is 
surprising that the Plasmodium falciparum and the Plasmodium knowlesi UCH37 
orthologues have dual Nedd8 and Ub hydrolysis activity but that the mammalian and T. 
spiralis orthologues do not. Orthologues of another conserved UCH domain DUB, 
UCHL3, have also been shown to have dual activity in Saccharomyces cerevisiae (Sc) 
yeast (GI: 1015802), Plasmodium falciparum (Pf, GI: 282403542, Drosophila 
melanogaster (Dm) fruit fly (GI: 17136836), humans (Hs, GI: 5174741) and mice (Mm, 
GI: 7578956). Table 3.1 lists the orthologous UCH37 DUBs and the orthologous 
UCHL3 DUBs that have been tested for ubiquitin and Nedd8 hydrolysis activity. Tests 
for the deNeddylating activity of the Plasmodium knowlesi, Drosophila melanogaster, 
human, and Trichinella spiralis UCH37 proteins and the human and Drosophila 
melanogaster UCHL3 protein, were carried out in our laboratory during the course of 
the project. All other proteins were previously tested and evidence can be found in the 
literature (Table 3.1, [102,103,241,242]).   
To compare the level of sequence conservation between the proteins listed in Table 3.1, 
all sequences were aligned using Geneious alignment parameters [237] (Figure 3.10). 
Patterns of clustering were observed, where some residues were conserved amongst 
the proteins that have dual deubiquitinating and deNeddylating activity only, and the 
same residue at this position differed in the proteins that only have deubiquitinating 
activity. In total, 5 residues were highlighted as being conserved in an activity 
dependent manner, 2 that were 100% conserved, and 3 that were conserved in 
hydrophobicity/hydrophilicity. These residues are listed in Table 3.2. For the first 
residue, an asparagine (N) was found in all the proteins (UCH37 or UCHL3) that have 
dual activity. Whereas, the corresponding residue of the proteins that only have mono 
activity was an aspartic acid (D). For the second residue, an aspartic acid (D) was 
found in all the proteins (UCH37 or UCHL3) that have dual activity. Whereas, the 
corresponding residue of the proteins that only have mono activity was a glutamic acid 
(E) (Figure 3.10). 
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Table 3. 1 Ub and Nedd8 activity profiles of UCH37 and UCHL3 orthologues 
List of UCH37 (UCH-L5) and UCHL3 enzyme orthologues that have been tested for ubiquitin 
hydrolysis activity and/or Nedd8 hydrolysis activity. Accession numbers are displayed as NCBI 
gene ID codes (GI). The RACE-confirmed TsUCH37 sequence as yet does not have a GI ID 
(asterisk). Where applicable, the publication in which the activity was demonstrated is listed. 
Where no publication is listed, protein activity was tested either by myself or other members of 
Katerina Artavanis-Tsakonas' lab (unpublished data). 
Chapter 3: Results  
 99 
 
 
Table 3. 2 UCH37 and UCHL3 residues that cluster with Ub/Nedd8 activity profile 
List of UCH37 (UCH-L5) and UCHL3 enzyme orthologues that have been tested for ubiquitin 
hydrolysis activity and Nedd8 hydrolysis activity. Protein sequences were aligned and their 
residues that cluster based on dual deubiquitinating and deNeddylating activity were identified 
(numbered 1-5). Residues 1 and 2 are conserved in identity. Residues 3-5 are conserved in 
hydrophobicity/hydrophilicity. Residues 2 and 4, highlighted in red, are also important for 
ScYUH1 interaction with Ub (Table 3.3). Residue 1, highlighted in yellow, is also important for 
PfUCHL3 interaction with Nedd8 (Table 1.D). This residue was mutated in 6His-TsUCH37 (D>N).   
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Figure 3. 10 Alignment of UCH37 and UCHL3 orthologues 
Orthologues of UCH37 and UCHL3 DUBs were aligned using MUSCLE parameters [209]. The 
UCH37 orthologous proteins were aligned: P. falciparum GI: 23496100 and, P. knowlesi GI: 
221056068, T. spiralis RACE-confirmed (no accession number), M. musculus GI: 4878011, H. 
sapiens GI: 7706753. The UCHL3 orthologues were aligned: P. falciparum GI: 282403542, S. 
cerevisiae GI: 282403542, D. melanogaster GI: 17136836, M. musculus GI: 7578956, H. 
sapiens GI: 5174741. Residues that cluster in alignment based on dual deubiquitinating and 
deNeddylating activity are numbered 1-5 and boxed in red. Residues predicted by Artavanis-
Tsakonas et al. [104] to be involved in the direct binding of PfUCHL3 to Nedd8 were numbered 
based on the residue and position of PfUCHL3 to which they align (E11, N13, E153 and D157). 
Residues shown to be important for direct contact between ScYUH1 and Ub (by Johnston et al. 
EMBO 1999 [243]) are boxed in blue. The bar graph above the sequence indicates the level of 
identity within the alignment.  
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Further analyses were carried out to try and understand the structural basis of the direct 
interaction between 1. a DUB and Ub and 2. a DUB and Nedd8.  
1. The crystal structure of human UCH37 in complex with Ub has not been solved. 
Instead, the crystal structure of the S. cerevisiae YUH1 in complex with Ub (reported by 
Johnston et al.) was used to identify residues important for direct DUB to Ub contact 
[243]. These residues were then identified in each orthologue of UCH37 and UCHL3 
listed in Table 3.1, using the multi-orthologue alignment in Figure 3.10. Table 3.3 lists 
the residue number of YUH1, and each corresponding residue of each orthologue 
predicted to be involved in the binding of Ub. 11 residues were identified, 2 of which 
were also identified to cluster based on dual deubiquitinating and deNeddylating activity 
(Table 3.2). These were residues D35 and Q153 of YUH1.   
2. Artavanis-Tsakonas et al. used the crystal structure of PfUCHL3 in complex with Ub-
VME to model Nedd8 in the position of the Ub ([104], Figure 3.11). Residues that 
appeared important for direct contact between PfUCHL3 and Nedd8 were identified. 4 
residues of PFUCHL3 were predicted to be involved in direct DUB to Nedd8 contact: 
glutamic acid (E) 11, asparagine (N) 13, glutamic acid (E) 153 and aspartic acid (D) 157 
(Table 3.3). These residues were then aligned with the other orthologues listed in Table 
3.1 for which deubiquitinating and deNeddylating activity has been tested. 
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Table 3. 3 UCH37 and UCHL3 residues predicted to be important for Ub contact 
List of UCH37 (UCH-L5) and UCHL3 enzyme orthologues that have been tested for ubiquitin 
hydrolysis activity and Nedd8 hydrolysis activity. Protein sequences were aligned and the 
residues that are important for the interaction between ScYUH1 and Ub (as identified by 
Johnston et al. EMBO 1999 [243]) were listed. Residue numbers represent the position in the 
ScYUH1 protein. The corresponding residue in the orthologous sequences (when aligned) was 
listed. Residues highlighted in red are also listed in Table 3.2 because they cluster based on 
dual deNeddylating and deubiquitinating activity. 
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Table 3. 4 UCH37 and UCHL3 residues predicted to be important for Nedd8 contact 
List of UCH37 (UCH-L5) and UCHL3 enzyme orthologues that have been tested for ubiquitin 
hydrolysis activity and Nedd8 hydrolysis activity. The residues predicted to be important for the 
interaction between PfUCHL3 and Nedd8 are numbered. Protein sequences were aligned and 
residues of orthologous sequences were listed as they correspond to the PfUCHL3 residue. The 
residue highlighted in yellow was also identified in Table 3.2 as clustering based on dual 
deNeddylating and deubiquitinating activity.  
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Figure 3. 11 Model of Nedd8 interaction with PfUCHL3 
A structural model of PfUCHL3 bound to PfNedd8 was built using the Ub-VME-bound crystal 
structure (Artavanis-Tsakonas et al. JBC 2010 [104]). The structure of PfNedd8-VME (magenta) 
was superimposed onto the Ub-VME (green)-bound PfUCHL3 active site (grey). Four residues 
of PfUCHL3 were predicted to be involved in direct DUB to Nedd8 contact (highlighted in yellow 
and boxed in red): glutamic acid (E) 11, asparagine (N) 13, glutamic acid (E) 153 and aspartic 
acid (D) 157. 
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It was observed that one of these residues was also shown to be important for the 
binding of YUH1 to Ub as shown in Table 3.3 (PfUCHL3 E11 and YUH1 E12). 
PfUCHL3 residue N13, was also identified as being conserved only in enzymes with 
dual deubiquitinating and deNeddylating activity (listed as residue number 2 Table 3.1, 
Figure 3.10). Here, the conserved residue at the corresponding position in the proteins 
that only have deubiquitinating activity is aspartic acid (D). Not only does this residue 
cluster based on dual versus mono activity, it is also predicted to be involved in the 
direct contact between a PfUCHL3 and Nedd8 but not in the direct contact between 
YUH1 and Ub. The question was therefore raised: would the mutation of this residue in 
TsUCH37 from D to N, cause a gain in deNeddylating activity? 
Site-directed mutagenesis (substitution) of 6His-TsUCH37 D12>N was carried out to 
produce a mutant coding sequence (Figure 3.12 A). The mutant protein was expressed 
and purified as described earlier for wild-type 6His-TsUCH37 (section 3.2). Ub-AMC 
and Nedd8-AMC assays were then used to assess whether or not the TsUCH37 D12N 
mutant had gained dual activity for Ub and Nedd8 (AMC assays were described earlier, 
section 3.2). TsUCH37 D12N showed Ub-AMC hydrolysis comparable to TsUCH37 
wild-type, but was not able to hydrolyse Nedd8-AMC (Figure 1.12 B and C). It is 
therefore clear that the residue TsUCH37 D12 is not determinative of dual Ub and 
Nedd8 activity.  
Other members of our group have continued this study. The other residues of the 
UCH37 orthologues that appear to cluster based on activity (listed in Table 3.1) are 
undergoing mutagenesis. These mutants will be screened to identify the structural and 
evolutionary basis of dual Ub and Nedd8 activity in UCH37 and UCHL3 DUBs. 
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Figure 3. 12 Mutagenesis and Ub/Nedd8 activity profiling of TsUCH37 
A. Recombinant 6His-TsUCH37 mutant was cloned, where residue D12 was mutated to N. 
Recombinant mutant protein was expressed and purified. B. The Ub-AMC and C. Nedd8-AMC 
hydrolysis activity of the mutant 6His-TsUCH37 D12N was tested. Reactions were monitored for 
20 minutes. Relative fluorescence unit (RFU) measurements at 467 nm were taken at minute 
intervals. The hydrolysis of Ub-AMC and Nedd8-AMC by each sample was measured in 
triplicate. Data are presented as the mean of triplicate values from a single experiment and the 
error bars represent SEM. Consistent data were obtained from similar experiments performed 
using different concentrations of protein and different protein batches. PfUCHL3 and the wild-
type 6His-TsUCH37 were assayed as positive controls for activity. Each protein was pre-
incubated with the cysteine protease inhibitor NEM as a negative control.  
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Although a lower eukaryote and a parasite, based on these analyses the T. spiralis 
TsUCH37 has more in common with the mammalian orthologues than the Plasmodium 
orthologues. The human and mouse UCH37 are proteasome associated DUBs that 
play an important role in proteasomal degradation of substrate proteins [33,233]. It was 
therefore hypothesised that the association of T. spiralis UCH37 with the proteasome 
may have been conserved throughout evolution to higher eukaryotes. TsUCH37-
associated proteins were therefore analysed, with a focus on T. spiralis proteasome 
subunits. 
3.5.	  Analysis	  of	  proteins	  that	  associate	  with	  TsUCH37	  
 
The structure of the 26S proteasome is displayed in Figure 3.14 C. The 26S 
proteasome is made up of the 19S cap structure that binds the substrate protein, and 
the 20S catalytic core ATP-dependent protease that degrades the substrate protein as 
it passes through the hollow core [21]. The 19S regulatory particle is made up of a lid 
and a base. The lid structure contains the regulatory subunits Rpn3, 5-9, 11,12 and 15. 
In-between this and the catalytic core is the 19S base, which is composed of the 
regulatory subunits Rpn10, 1, 2 and Rpn13, otherwise known as ADMR1 (usually called 
Rpn13 in yeast). The 20S core is made up of proteolytic alpha and beta subunits that 
mediate substrate degradation.  
In human cells, HsUCH37 is often found in direct association with ADRM1, a protein 
that is referred to as the ubiquitin receptor. ADRM1 associates with the proteasome 
19S base subunit Rpn2 [32]. During the MRes project, HA-Ub-VME was reacted with T. 
spiralis muscle larvae lysate, and probe-protein complexes were immuno-precipitated 
using anti-HA antibodies (MRes report 2010, [1]). When the products of immuno-
precipitation were analysed by LC/MS/MS, a number of putative T. spiralis DUBs were 
identified. These included TsUCH37. A number of other putative T. spiralis proteins 
were also identified by LC/MS/MS. Although these proteins had co-precipitated with 
HA-Ub-VME and anti-HA resin, they were not themselves DUBs. These proteins may 
either have been experimental contaminants, other proteins able to specifically 
associate with the ubiquitin component of HA-Ub-VME, or proteins able to specifically 
associate with DUBs that were in complex with HA-Ub-VME. One of these proteins was 
a putative T. spiralis ADRM1 orthologue.  
It was hypothesised that if TsUCH37 were found also to associate with the T. spiralis 
ADRM1 it would also be able to associate with the T. spiralis proteasome. The aim was 
to investigate this by co-precipitating the T. spiralis ADRM1 from lysate of T. spiralis 
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muscle larvae, using commercially available anti-human ADRM1 antibodies. The 
products of co-precipitation would then be analysed for the presence of TsUCH37 using 
anti-human UCH37 antibodies in an immuno-blot. The T. spiralis and human ADRM1 
share 36.6% of the same residues, and the T. spiralis and human UCH37 share 45.9% 
of the same residues making it plausible that the antibodies would cross-react with the 
T. spiralis orthologues. The experiment could also be carried out in the reverse order. In 
other words, immuno-precipitation could be carried out using anti-UCH37 antibodies 
followed by immuno-blot with anti-ADRM1 antibodies (Figure 3.13 A). The antibodies 
had to therefore be tested first for cross-reactivity with the T. spiralis orthologues 
(Figure 3.13 B and C).  
Commercial anti-human UCH37 and ADRM1 antibodies were tested for reactivity with 
lysate of T. spiralis muscle larvae. As a control for reactivity, human embryonic kidney 
HEK 293T cell lysate was also tested. HEK 293T cells are a cell line often used in the 
laboratory because they are robust and easy to culture. They were used throughout the 
project to represent human cell protein expression. 
Although a protein at an expected size (human ADRM1 weighs 42.2 kDa, and human 
UCH37 weighs 35.9 kDa) was observed in the HEK lysate, the antibodies did not cross 
react with recombinant purified TsUCH37 or with T. spiralis lysate (Figure 3.13 B and 
C). These antibodies could therefore not be used for further analyses of T. spiralis 
ADRM1. Instead, recombinant 6His-TsUCH37 was used to analyse the potential 
association of the protein with ADRM1. Because T. spiralis proteins did not cross-react 
with the anti-human ADRM1 antibodies used, lysate from human HEK 293T cells was 
used to investigate whether or not recombinant T. spiralis TsUCH37 could associate 
with the human ADRM1. This interaction could then be monitored using the anti-human 
ADRM1 antibodies. 
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Figure 3. 13 Analysis of TsUCH37 co-precipitation with ADMR1 
A. Schematic of the experimental methods. B. Immuno-blot (IB) analysis of T. spiralis muscle 
larvae (ML) lysate, 6His-TsUCH37 and HEK 293T cell lysate using anti-human UCH37 
antibodies. (a) Approximate size of human and T. spiralis UCH37. C. Immuno-blot analysis of T. 
spiralis muscle larvae lysate and HEK 293T cell lysate using anti-human ADRM1 antibodies. (b) 
Approximate size of human and T. spiralis ADRM1. D. DB71 stain of Ni-NTA 6His-TsUCH37 co-
precipitation with HEK 293T cell lysate. E. Ni-NTA 6His-TsUCH37 co-precipitation with HEK cell 
lysate followed by immuno-blot using anti human ADRM1 antibodies. (a) Approximate size of 
human ADRM1. (b) Approximate size of human 6His-TsUCH37. All protein marker sizes are 
indicated in molecular weight (kDa). 
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Recombinant purified 6His-TsUCH37 was bound to Ni-NTA resin. This was then 
incubated with HEK lysate under conditions that would preserve protein-protein 
interactions. As a control, native Ni-NTA resin, with no 6-His-TsUCH37, was incubated 
with HEK lysate. The resin was then washed, and associated proteins were eluted. To 
assess whether or not any E. coli contaminants remained after the original purification 
process of 6His-TsUCH37 and to observe any non-specific interactions between these 
contaminants and the anti-ADRM1 another control was included. This was purified 
recombinant 6His-TsUCH37 alone, bound to Ni-NTA (with no cell lysate added). All the 
eluates were then separated by SDS-PAGE, transferred to PVDF membrane and 
visualised using a dye called direct blue 71 (DB71) that is similar to coomassie but 
binds to proteins on PVDF membranes (Figure 3.13 D). Proteins were then analysed by 
immuno-blot using anti-(Hs)-ADRM1 antibodies (Figure 3.13 E). No reactivity was 
observed with 6His-TsUCH37 alone. After co-precipitation of 6His-TsUCH37 (bound to 
Ni-NTA resin) with HEK lysate, a band was observed at the expected size for human 
ADRM1 (42.2 kDa). However, the same band was observed after the co-precipitation of 
HEK lysate with naked Ni-NTA resin. It appeared possible that this band was enriched 
(but not significantly) in the 6His-TsUCH37 co-precipitation sample. The binding of 
human ADRM1 to Ni-NTA, both in the absence and the presence of 6His-TsUCH37, 
suggests that human ADRM1 can non-specifically interact with Ni-NTA under 
conditions designed to preserve protein-protein interactions. I propose that human 
ADRM1 is able to non-specifically bind to either the nickel or the agarose of the Ni-NTA 
resin. It was therefore not possible to use these reagents to verify direct interactions 
between ADRM1 and either endogenous TsUCH37, or recombinant 6His-TsUCH37.  
A possible follow-up approach would have been to produce T. spiralis-specific 
antibodies to either the TsUCH37, TsADRM1 or indeed to other T. spiralis proteasome 
components. However, a mass spectrometry-based approach was adopted for 3 
reasons:  
1. The peptide coverage of TsADRM1 identified during LC/MS/MS analysis of HA-Ub-
VME bound T. spiralis proteins was 11%. This did not provide much sequence upon 
which potential immunogen sequences could be mapped.  
2. Since the annotation was only predicted, the TsADRM1 coding sequence would first 
have to be confirmed using RACE-PCR.  
3. A collaboration with Eric Spooner at the mass spectrometry facility at The Whitehead 
Institute was already underway.  
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Mass spectrometry was therefore used to analyse the T. spiralis proteins that co-
precipitate with recombinant 6His-TsUCH37, and search for possible T. spiralis ADRM1 
or proteasome components within the results. 
A large quantity of recombinant purified 6His-TsUCH37 was bound to Ni-NTA resin, 
which was then incubated with lysate of T. spiralis muscle larvae under conditions that 
would preserve protein-protein interactions. Three controls were included: 1. Naked Ni-
NTA resin with no recombinant protein bound was incubated with T. spiralis lysate to 
control for non-specific interactions. 2. purified recombinant 6His-TsUCH37 alone was 
bound to Ni-NTA to control for contaminants of the purification process. 3. Crude T. 
spiralis lysate with no Ni-NTA or 6His-TsUCH37 to observe the SDS-PAGE profile of all 
T. spiralis proteins. Ni-NTA resin was washed, co-precipitated proteins were separated 
by SDS-PAGE and visualised by staining with colloidal coomassie (Figure 3.14 A). 
Proteins were manually excised from the gel that appeared only in the Ni-NTA-6His-
TsUCH37 plus T. spiralis lysate sample, and not in the control samples. Excised 
proteins were analysed by LC/MS/MS. Using SEQUEST, the identified peptides were 
then matched against the annotated draft genome of T. spiralis (Genome Institute at 
Washington University). All mass spectrometry and SEQUEST screening was carried 
out by Eric Spooner at the Whitehead Institute in Boston.  
Matches were made to 12 different putative T. spiralis proteasome components (Figure 
3.14 A and B and appendix 1, and all co-precipitated proteins are listed in the 
supplementary appendix 1) of the 26S proteasome. These 12 proteasome proteins 
were amongst the highest scoring matches (in terms of unique peptide count) of all 
proteins that co-precipitated, suggesting an increased likelihood that they were specific 
to TsUCH37 association. For example, the 4th highest scoring match of all co-
precipitated proteins was the putative T. spiralis 19S base subunit protein, Rpn1. Rpn1 
matched 28 exclusive unique peptides found in band 2 of the gel (only), giving a 
coverage of 39% of a 102 kDa (911 amino acids) protein (data not shown). Including 
this result, the most abundant T. spiralis putative proteasome proteins were those that 
are found in the 19S base of the proteasome, such as Rpn1, Rpn2 and Rpt1. This is 
the part of the mammalian proteasome that interacts with the mammalian UCH37. 
Other matches were made to proteins found in the 19S lid: Rpn3 and Rpn6, and 
proteins of the 20S catalytic core such as the alpha and beta ATPase subunits (Figure 
3.14 B). Results also included a PSME3 orthologue otherwise known as the PA28 
subunit of the immuno-proteasome [244]. Three unique peptides matching the T. 
spiralis putative ADRM1 orthologue were also identified (GI:316977948). The annotated 
TsADRM1 sequence that matched these peptides was the same as that previously 
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identified by HA-Ub-VME immuno-precipitation of T. spiralis muscle larvae lysate during 
the MRes project [1]. In this analysis, the peptides identified by co-precipitation covered 
10% of the putative TsADRM1 sequence of a protein predicted to weigh 46 kDa (data 
not shown). When compiled with peptide data from the MRes project HA-Ub-VME 
immuno-precipitation experiment, peptides identified by mass spectrometry covered 
14.4% of the putative T. spiralis ADRM1 sequence. Proteins were often found to 
migrate during SDS-PAGE in a similar manner to human proteasome proteins as 
previously reported by Lee et al. [245] (Figure 3.14 D). For example, 2 of the largest 
subunit proteins, Rpn1 and Rpn2 were found to have the least electrophoretic mobility 
as they are amongst the largest of the proteasome subunits.  
Data suggests that T. spiralis UCH37 can associate with the putative T. spiralis ADRM1 
and with multiple proteasome subunits, but mostly those from the 19S base. This 
association with the proteasome may be via the interaction with ADRM1, as is observed 
in mammalian systems. It is therefore likely that the T. spiralis UCH37 also functions as 
a proteasome interaction partner. If so this function has been conserved throughout 
evolution, from nematodes to mammals. In mammals, proteasome associated UCH37 
is essential for survival. The knockout of mouse UCH37 is lethal at the embryonic stage 
[36]. It was therefore hypothesised that TsUCH37 may also be essential for the survival 
of the parasite, and if so, may be a potential drug target to be considered in the 
development of novel anthelmintics. 
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Figure 3. 14 Analysis of TsUCH37 co-precipitation with the T. spiralis proteasome 
A. Co-precipitation of 6His-TsUCH37 with lysate of T. spiralis muscle larvae. Bands that 
appeared only in the test sample (Ni-NTA, 6His-TsUCH37 and T. spiralis muscle larvae lysate) 
and not in the control lanes, were manually excised (numbered 1-19). These proteins were 
analysed by LC/MS/MS by Eric Spooner (Whitehead Institute). Band 9 is marked in red and was 
the location of peptides that matched the putative T. spiralis ADRM1. Protein marker sizes are 
indicated in molecular weight (kDa). B. Putative T. spiralis proteasome components identified by 
LC/MS/MS are listed with the band that the peptides were found in, the number of unique 
peptides found and the predicted molecular weight (kDa). The putative TsADRM1 is indicated in 
red. C. The structure of the proteasome. The ADRM1 subunit (Rpn13) is red. D. The SDS-PAGE 
profile of the human proteasome. 
Chapter 3: Results  
 114 
3.6.	  Investigation	  of	  the	  potential	  of	  TsUCH37	  as	  a	  drug	  target 
 
T. spiralis cannot be genetically modified. Therefore genetic analyses, such as specific 
gene knockout or gene or transcript silencing could not be carried out. Instead, the 
potential of TsUCH37 as a drug target was investigated using available inhibitor 
compounds that were previously shown to be specific to UCH DUBs. Two small 
compounds were found to be available. The small molecule inhibitor compound 
WP1130 has been shown to inhibit UCH37 in human cells [246]. LDN-57444 has been 
shown to inhibit UCH-L1 and to a lesser extent, UCH-L3 in human cells [247,248]. 
Considering the level of functional conservation of UCH37, and the level of structural 
conservation between UCH domain DUBs, it was hypothesised that WP1130 and LDN-
57444 may also inhibit TsUCH37. This was first tested in vitro using Ub-AMC hydrolysis 
assay. 
WP1130 was kindly supplied by William Bornmann of the University of Texas. WP1130 
(degrasyn) is a small tyrphostin compound that has been shown to inhibit the activity of 
USP9x, USP5, USP14, UCHL1 and UCH37, but not UCHL3 [246], Figure 3.15 A). The 
effect of WP1130 on the in vitro activity of recombinant human TsUCH37 was tested 
using a Ub-AMC assay. The effect on human UCH37 and UCHL1 were also tested to 
confirm in vitro inhibition of the mammalian DUBs using this method. Purified 
recombinant proteins were incubated with WP1130 at the indicated concentrations, 
before adding Ub-AMC (Figure 3.15 B, C and D). As a positive control for inhibition, 
proteins were pre-incubated with NEM only and, as a negative control for inhibition, with 
the drug solvent (DMSO) only. Fluorescence measurements were taken every minute 
for 20 minutes. In contrast to previously reported data, no inhibition by WP1130 of Ub 
hydrolysis activity of either protein was observed by Ub-AMC assay. Since no inhibition 
of TsUCH37 was observed, the second compound LDN-57444 was used for further 
experiments. 
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Figure 3. 15 The effect of WP1130 on TsUCH37 Ub hydrolysis activity 
A. The structure of the small molecule UCH enzyme inhibitor WP1130. The Ub-AMC hydrolysis 
activities of B. human UCH37, C. human UCHL1 and D. 6His-TsUCH37 were tested in the 
presence of WP1130 at the indicated concentrations. Relative fluorescence unit (RFU) 
measurements at 467 nm were taken at minute intervals for 20 minutes. Each protein was pre-
incubated with the cysteine protease inhibitor NEM as a positive control for inhibition. Proteins 
were assayed with DMSO only as a negative control for inhibition. The hydrolysis of Ub-AMC by 
each sample was measured in triplicate. Data are presented as the mean of triplicate values 
from a single experiment and the error bars represent SEM. Consistent data were obtained from 
similar experiments performed using different concentrations of protein and different protein 
batches. 
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LDN-57444 (compound 30) is a cell permeable isatin o-acyl oxime (Figure 3.16 A). 
LDN-57444 exhibits active site-directed inhibition of HsUCHL3 and, with greater 
potency, HsUCHL1 [247,248] Treatment of mammalian neuronal cells with LDN-57444 
causes a build up of highly ubiquitinated proteins [249]. 
Recombinant TsUCH37, and recombinant HsUCH37 as a control, were incubated with 
either 1 mM LDN-57444 (solubilised in DMSO) or with DMSO alone. Proteins were then 
mixed with Ub-AMC, before a fluorescence measurement was taken every minute for 
20 minutes. Pre-incubation of recombinant TsUCH37 with NEM was assayed as a 
positive control for inhibition and to confirm cysteine-specific activity. Samples 
incubated with DMSO alone, showed Ub hydrolysis activity from TsUCH37 and UCHL1 
(Figure 3.16 B). Almost complete inhibition by 1 mM of LDN-57444 of UCHL1 was 
observed, whereas partial inhibition of TsUCH37 was observed. A titration of LDN-
57444 (50, 100 and 500 µM) showed specific, concentration-dependent inhibition of 
recombinant TsUCH37 activity compared to the DMSO control (Figure 3.16 C). 
Although LDN-5744 inhibits TsUCH37 in vitro, it is also able to inhibit mammalian UCH-
L1 and UCH-L3 [247]. It is therefore not a specific inhibitor of UCH37, rather a specific 
inhibitor of UCH domain DUB enzymes. Putative orthologues of the T. spiralis L3 
enzyme (but not UCHL1) can be identified by BLAST analysis of the T. spiralis 
annotated protein database. In addition, a putative T. spiralis UCH-L3 was identified by 
mass spectrometry analysis of proteins immuno-precipitated by the HA-Ub-VME probe. 
T. spiralis muscle larvae therefore express at least 2 UCH domain DUBs. For this 
reason, LDN-57444 could not be used to specifically target TsUCH37 in vivo. It was 
therefore used to investigate whether or not the UCH DUB enzyme family of T. spiralis 
might be essential for the survival of the muscle stage parasite. 
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Figure 3. 16 The effect of LDN-57444 on TsUCH37 Ub hydrolysis activity 
A. The structure of the small molecule UCH enzyme inhibitor LDN-57444. B. The Ub-AMC 
hydrolysis activities of human UCHL1 and TsUCH37 were tested in the presence of 1 mM of 
LDN-57444. As a negative control for inhibition, proteins were incubated with DMSO only. As a 
positive control for inhibition, 6His-TsUCH37 was incubated with the cysteine protease inhibitor 
NEM. C. 6His-TsUCH37 was tested in the presence of a titration of LDN-57444 (concentrations 
are indicated). Relative fluorescence (RFU) measurements at 467 nm were taken at minute 
intervals for 20 minutes. 6His-TsUCH37 was pre-incubated with the cysteine protease inhibitor 
NEM as a positive control for inhibition. 6His-TsUCH37 was assayed with DMSO only as a 
negative control for inhibition. The hydrolysis of Ub-AMC by each sample was measured in 
triplicate. Data are presented as the mean of triplicate values from a single experiment and the 
error bars represent SEM. Consistent data were obtained from similar experiments performed 
using different concentrations of protein and different protein batches. 
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T. spiralis muscle larvae were isolated, cultured and immediately incubated with LDN-
57444 over a total period of 96 hours. Parasite viability was then measured using the 
MTT assay. The MTT viability test is a quantitative colorimetric assay based on the 
tetrazolium salt, 3-[4,5-diethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide [250,251]. 
MTT is yellow in colour. It is reduced by dehydrogenase enzymes of metabolically 
active cells to insoluble purple crystals of formazan. Formation of formazan does not 
occur in dead cells and is directly proportional to the number of live cells. Formazan 
crystals can be solubilised by adding organic solvents to the parasite culture, and the 
absorbance of the purple supernatant represents cell viability. Over a period of 96 
hours, muscle larvae were incubated with either LDN-57444 solubilised in DMSO or 
DMSO alone, providing a negative control for inhibition (100% viability). An MTT assay 
was then carried out for each sample after 24 hours, 48 hours and 96 hours of 
incubation. An MTT assay of heat-killed larvae that cannot produce formazan (larvae 
heated to 70°C for 10 minutes) was taken as a positive control for inhibition for each 
time-point (0% viability). After 24 hours of incubation with LDN-57444, a decrease in 
motility and a change in morphology were observed, with more larvae becoming 
uncoiled and stationary (an early sign of T. spiralis muscle larvae death) than the 
DMSO control sample. When quantified by the MTT assay, a significant reduction in the 
viability of the parasites incubated with 100 µM LDN-57444 was observed, compared to 
the DMSO control sample (Figure 3.17). After 48 and 96 hours of incubation, the 
viability of larvae was significantly reduced by 50 µM and 100 µM of LDN-57444. By 96 
hours, the viability of muscle larvae incubated with 100 µM LDN-57444 was reduced by 
75%. 
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Figure 3. 17 The effect of LDN-57444 on T. spiralis viability 
The viability of T. spiralis muscle larvae was measured using the MTT assay. Larvae were 
incubated with DMSO alone as a negative control for inhibition of viability (100% viability) then 
with 50 or 100 µM of LDN-57444. MTT assays were taken at 24 hours (A), 48 hours (B) and 96 
hours (C) incubation. As a positive control for inhibition of viability, larvae were killed by heat 
treatment (HT) at each time-point. All MTT assays were carried out in triplicate. The mean 
percentage viability of the DMSO control is plotted, with standard error of the mean as error bars. 
Data was analysed using a two-way anova test. Statistically significant data (P<0.005) is 
indicated with an asterisk.  
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Results show that TsUCH37 activity can be targeted with small molecule inhibitors and 
that UCH DUBs, including TsUCH37, may be essential for the survival of T. spiralis 
muscle larvae. This set precedent for the further investigation of TsUCH37 as a specific 
drug target. A useful drug for therapeutic use during parasitic infection must target the 
parasite enzyme but not target the mammalian orthologue. In order to separately target 
the parasite orthologue of a conserved protein, it is useful to have the crystal structures 
of both proteins to identify structural differences that could be exploited in drug 
identification or design. 
In order to find, design or develop effective enzyme inhibitors, crystal structures must 
first be resolved. The crystal structures of the full length and the catalytic domain 
human UCH37 have been previously reported [25] [252], [253]. In order to compare the 
structure of the human UCH37 with TsUCH37, the clone that I had made and used for 
protein synthesis was given to Chittaranjan Das, the supervisor of a crystallography 
laboratory at Purdue University (US). Using protocols developed during my project, 
Marie Morrow, a member of the crystallography group, was able to express and purify 
the full length and the catalytic domain residues (1-226) of TsUCH37. This led to the 
successful determination of the crystal structure of both the full length TsUCH37, and 
the catalytic domain of TsUCH37, each in complex with Ub-VME (appendix 7). This 
angle of the project has continued in the Das laboratory, as the group endeavors to 
investigate the structural basis of the specific functions of deubiquitinating enzymes.  
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Summary	  
 
3.1. The correct open reading frame of the T. spiralis DUB TsUCH37 was hypothesised 
using bioinformatics analyses and confirmed experimentally using RACE techniques.  
3.2. The coding sequence of TsUCH37 was cloned and recombinant His-tagged 
TsUCH37 was expressed and purified.  
3.3. The in vitro Ub hydrolysis activity of recombinant TsUCH37 was validated.  
3.4. TsUCH37 was not able to hydrolyse Nedd8-AMC. The residue D12 was predicted 
to be important for the specific interaction with Nedd8. The substitution of this residue to 
N, the residue found in Nedd8 hydrolases, did not enable Nedd8 hydrolysis by 
TsUCH37. 
3.5. TsUCH37 was co-precipitated with numerous T. spiralis proteasome components, 
including the putative T. spiralis ADRM1. 
3.6. The compound LDN-57444 inhibited TsUCH37 Ub-AMC hydrolysis activity, and 
significantly reduced the viability of T. spiralis muscle larvae in culture. 
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Discussion	  
 
The initial aim of the project was to characterise TsUCH37, a DUB expressed by T. 
spiralis muscle larvae, by cloning the coding sequence and expressing recombinant 
protein. In order to do so, the true coding sequence had to first be confirmed. This was 
achieved using bioinformatics analysis, including gene predictions and alignments, 
followed by RACE-PCR. Once sequenced, RACE-PCR products provided experimental 
evidence that the gene prediction using AUGUSTUS software represented the true 
transcript of the TsUCH37 gene. This sequence did not include the extra 2 protein 
domains annotated in the database as being upstream of the peptidase_C12 DUB 
domain. The RACE-confirmed start and stop codons aligned well with multiple UCH37 
orthologues. These results demonstrate that T. spiralis has a unique genome 
arrangement pattern. During the draft annotation 1 prediction programme, FGENESH 
de novo, was used to identify T. spiralis genes [232]. Because the FGENESH algorithm 
has been developed using other well-studied organisms, when used alone to scrutinise 
the T. spiralis genome, it may not necessarily be accurate for predicting T. spiralis 
genes. 
During expression in E. coli, 6His-TsUCH37 was observed in a greater proportion in 
inclusion bodies of the bacteria. Methods of purification from inclusion bodies under 
denaturing conditions were therefore adopted, allowing an increased level of purity to 
be achieved and ensuring that the denatured enzyme could not be degraded by other 
proteases. On the down side, experimentally refolding proteins from a denatured state 
does not guarantee that they will reach a native and active confirmation. For this reason, 
the activity of TsUCH37 had to be confirmed before any further experiments 
investigating the function of the protein could be carried out. 
6His-TsUCH37 was able to hydrolyse Ub-AMC at a physiologically relevant rate, 
confirming that the protein was refolded into the correct confirmation and that the 
activity was dependent on an active site cysteine. Recombinant 6His-TsUCH37 was 
therefore deemed a reliable reagent for the characterisation of the T. spiralis DUB.  
The yeast, malaria parasite, mouse and human orthologues of the highly conserved 
UCH domain DUB, UCHL3, and the highly conserved human UCH domain DUB 
UCHL1, can process both Ub and Nedd8 [102-104,241,254-256]. Although most 
UCH37 orthologues, are specific to Ub, 2 parasite UCH37 orthologues, the Plasmodium 
falciparum UCH54 and the Plasmodium knowlesi UCH37, are able to hydrolyse both 
Ub and Nedd8. The function of the dual activity of the parasite UCH37 orthologues is 
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unknown. P. knowlesi has a UCHL3 gene and P. falciparum has been reported to 
express PfUCHL3 [102]. Furthermore, when analysed by BLAST both organisms have 
orthologous genes for the mammalian deNeddylating enzymes DEN1 (deNeddylating 
enzyme 1) and NEDP1 but not for SENP8 (SUMO/sentrin specific peptidase family 
member 8). It was hypothesised that the dual activities of the malaria parasite UCH37 
proteins may serve a parasite-specific advantage. The T. spiralis parasite orthologue, 
TsUCH37 was therefore tested for its ability to hydrolyse Nedd8. Like the human 
orthologue HsUCH37, TsUCH37 was not able to hydrolyse Nedd8-AMC.  
To try and explain the structural basis of dual versus mono activity, patterns of activity-
based clustering of UCH37 and UCHL3 residues in multiple orthologues were 
highlighted. Five residues were identified that are conserved in only the enzymes that 
possess dual activity. These analyses were then combined with structural modelling 
analyses that predicted 4 residues to be important for the direct contact between 
PfUCHL3 and Nedd8 [104]. One residue was highlighted by both analyses that was not 
shown to be important for the interaction between YUH1 and Ub, and therefore possibly 
Nedd8-specific [243]. This residue was therefore mutated in the T. spiralis TsUCH37 
coding sequence to match the corresponding residue found in dual deubiquitinating and 
deNeddylating enzymes. The TsUCH37 D12N mutant was unable to hydrolyse Nedd8 
confirming that this residue is not a determinant of Nedd8 hydrolysis. This is not to say, 
however, that this residue is not predictive of dual activity. 
These studies are on-going and the remaining 4 residues of the UCH37 orthologues 
listed in Table 1.A are currently undergoing mutagenesis. Residues will first be mutated 
to an alanine residue (because alanine is chemically inert) to confer the importance of 
the residue in substrate recognition or binding by assessing the effect of the mutation 
on Ub and Nedd8 hydrolysis activity. If found to be essential for activity, the residue will 
then be mutated to match the corresponding residue of the enzymes that have dual 
activity. These mutants will continue to be screened for Ub-AMC and Nedd8-AMC 
hydrolysis activity, with the aim of identifying the structural and evolutionary basis of 
dual Ub and Nedd8 activity in UCH37 and UCHL3 DUBs. S. cerevisiae (yeast) only 
express 1 UCH domain DUB, YUH1 [257]. YUH1 is most closely related to the 
mammalian UCHL3, but also shows homology with mammalian UCHL1 and UCH37 (in 
order of identity). YUH1 also has dual Ub and Nedd8 activity [242]. This may suggest 
that as lower eukaryotes evolved to express a wider range of UCH enzymes, the dual 
activity of the UCH37 orthologue was lost. The functional significance of the dual 
activity of PfUCH54 and PkUCH37 is unknown, and whether or not these DUBs are in 
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involved in the regulation of Nedd8 conjugation in the parasite remains to be 
determined. 
Results suggested that the function of the T. spiralis parasite UCH37 may be more 
related to the function of the mammalian orthologues than the malaria parasite 
orthologues. The interaction of mammalian UCH37 with the proteasome enhances its 
Ub hydrolysis activity [32,258]. This interaction occurs via the direct binding of UCH37 
to the proteasome subunit ADRM1. Alone human UCH37 is able to hydrolyse 
monoubiquitin, with ADRM1 this activity is 2-3-fold increased. Evidence suggests that 
UCH37 contains a C-terminal tail that acts in an auto-inhibitory manner [32,233]. This 
tail contains the binding site for ADRM1, and it is hypothesised that the binding of 
ADRM1 relieves the auto-inhibitory effect of the tail. UCHL1, UCHL3 and YUH1 do not 
associate with the proteasome and can only hydrolyse monoubiquitin 
[24,36,233,243,259,260]. Only in the presence of both ADRM1 and the 19S 
proteasome complex, is UCH37 able to hydrolyse di-ubiquitin [233]. The interaction of 
UCH37 with the proteasome therefore determines the specific function of this DUB as a 
proteasome-associated polyubiquitin hydrolase.   
The co-precipitation of TsUCH37 with proteins of T. spiralis muscle larvae revealed that 
6His-TsUCH37 associates with a large number of proteasome components, including 
the putative T. spiralis ADRM1. For an undetermined reason, human ADRM1 was 
found to non-specifically bind to Ni-NTA resin. It is therefore possible that TsADRM1 
can also non-specifically bind to Ni-NTA resin. Considering that co-precipitation 
analyses were carried out using Ni-NTA suspended 6His-TsUCH37, it cannot be 
concluded that the presence of ADRM1 is due to a specific interaction with TsUCH37. 
However ADRM1 was also identified alongside TsUCH37 after immuno-precipitation of 
HA-Ub-VME with T. spiralis lysate during the MRes project (MRes report 2010, [1]). 
Since the HA-Ub-VME immuno-precipitation method did not involve Ni-NTA, TsADRM1 
may have been immuno-precipitated in association with TsUCH37, or in association 
with the ubiquitin of the HA-Ub-VME probe itself via the pleckstrin like receptor for 
ubiquitin (Pru) domain that is present in ADRM1 orthologues [261]. The direct 
interaction between TsUCH37 and TsADRM1 would therefore require validation. 
Numerous other putative T. spiralis proteasome subunits were co-precipitated with 
6His-TsUCH37, the most abundant of which are found in the 19S base of the 
proteasome. In the mammalian system, ADRM1 associates with Rpn2 (subunit of the 
19S base) anchoring UCH37 to the proteasome. Data therefore strongly suggests that 
TsUCH37 can be proteasome associated. It is therefore likely that the function of 
TsUCH37, as a proteasome associated DUB has been conserved throughout evolution.  
Chapter 3: Results  
 125 
Controlled proteasomal degradation of polyubiquitinated proteins is essential for cell 
homeostasis. Silencing UCH37 in human adenocarcinoma cells leads to apoptosis and 
the knockout of mouse UCH37 in vivo is lethal [36,262]. Knockdown of the drosophila 
UCH37 orthologue, which is also proteasome associated, causes death at an early 
stage of development [240] [263,264]. Deletion of YUH1 however, which is not 
proteasome associated, has no phenotype in yeast [265,266]. Since TsUCH37 is also 
able to associate with the T. spiralis proteasome, it was hypothesised that TsUCH37 
might be essential for the survival of the T. spiralis parasite. TsUCH37 was therefore 
investigated for its potential as a drug target in vitro and then in parasites in culture. 
I was unable to show that WP1130, a small molecule inhibitor previously shown to 
inhibit a number of UCH enzymes, can inhibit UCHL1, UCH37 or TsUCH37 activity by 
Ub-AMC assay. It is possible that this discrepancy in Ub-AMC data to that already 
published is due to differences in concentrations of recombinant protein used for Ub-
AMC assay. A nM range for protein concentration was used by Kapuria et al. whereas a 
µM range was used in my experiments [246]. This was because below the µM range, 
no Ub-AMC hydrolysis activity was observed with DMSO only (negative control for 
inhibition). My protein preparations may have been less active than those reported by 
Kapuria et al. possibly containing a lower proportion of correctly folded protein. I 
therefore decided that LDN-57444 would be tested for the effect on TsUCH37 instead, 
and indeed, a potency of inhibition was observed similar to that for human UCHL1 [249]. 
Although the activity of recombinant 6His-TsUCH37 was specifically inhibited by LDN-
57444, the compound is also known to inhibit the human UCH37, UCHL1 and UCHL3. 
If drugs were to target TsUCH37, or other parasitic DUBs for therapeutic effect during 
infection, they would have to be developed to select only the parasite protein and not 
the human orthologue. Considering that UCHL3 orthologue is annotated in the T. 
spiralis genome, and a putative T. spiralis UCHL3 was identified in muscle larvae lysate 
[1], It cannot be concluded that the inhibitory effect of LDN-57444 on T. spiralis muscle 
larvae viability was solely due to TsUCH37 inhibition. LDN-57444 however, is a specific 
UCH inhibitor, and does significantly reduce the viability of T. spiralis muscle larvae. 
Some UCH inhibitor compounds are able to specifically discriminate between the 
different UCH DUBs, such as the UCHL1 inhibitor 1 which does not inhibit UCHL3 
despite 21% identity between the 2 proteins [267]. This shows that it is possible to 
specifically target different UCH DUBs, despite their level of conservation. Indeed, 
shortly after the experiments presented in this chapter were carried out, a specific 
inhibitor of UCH37, and USP14 (another mammalian proteasome-associated DUB) was 
discovered [82]. This drug has been recently shown to induce apoptosis in bone 
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marrow cancer cells. This drug would make an interesting candidate for following up the 
T. spiralis viability studies, to determine if proteasome-associated DUBs, rather than all 
UCH domain DUBs, are essential for T. spiralis survival. 
To identify structural specificities that can be exploited in drug identification or design, it 
is useful to have the crystal structures of proteins. Both the full length and the catalytic 
domain of TsUCH37 in complex with Ub-VME were solved (Morrow et al.) as a result of 
a collaboration with Chittaranjan Das [3]. This data allowed for the identification of 
differences between the human UCH37 and the T. spiralis UCH37 when the 2 
structures were overlaid (appendix 7). The crossover loop of TsUCH37 remained 
disordered even in a packed crystal, where in the human UCH37 structure the loop was 
ordered. This disorder is not observed in the previously solved substrate-bound 
structures of human UCH-L1, UCH-L3, or in the unbound structure of human UCH37 
[25,268,269]. Evidence suggests that the crossover loop of UCH DUBs, may be 
involved in substrate filtering, where a longer crossover loop allows the entry of larger 
substrates into the active site of the enzyme [270]. Differences in the confirmation of 
crossover loops between UCH37 orthologues, may therefore also confer specificity of 
inhibitors, especially if these inhibitors were active-site targeted. 
Subtle changes in the electrostatic charges of the catalytic cleft were also observed, 
where the active-site cysteine of TsUCH37 flipped in orientation compared to its 
position in the human UCH37 structure. These changes may be TsUCH37-specific, or 
they may occur upon binding to Ub-VME. In which case, the equivalent human 
structure of HsUCH37cat-Ub-VME would have to be solved for direct comparison. So far, 
data is only available for the unbound form of human UCH37 [25,252,253]. It is possible 
that the conformational changes observed and presented here for TsUCH37 would also 
occur in the substrate-bound form of human UCH37. Greater scrutiny of the direct 
comparison would be necessary before any conclusions on selective drug targeting 
could be made. The crystallography group at Purdue University continue to study the 
structure function relationship of deubiquitinating enzymes, using proteins such as 
TsUCH37 as informative models. 
Results presented in chapter 3, demonstrate the initial stages of the project that aimed 
to investigate the role of the ubiquitin pathway during infection by T. spiralis from the 
point of view of the parasite. I then wanted to use the remainder of the PhD project to 
use the tools and skills presented during this chapter, to shift focus and investigate the 
role of the ubiquitin pathway in the direct host-parasite interactions during infection by 
T. spiralis.
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Chapter 3 describes experiments that were designed to study the endogenous 
ubiquitin proteasome system of the parasitic nematode, Trichinella spiralis. A 
successful system for characterising functional T. spiralis DUB enzymes was 
established. This system was used to begin an investigation into the role of the 
ubiquitin proteasome system in the direct host-parasite interactions that occur during 
infection by T. spiralis. To do so, T. spiralis secreted proteins, the main mediators of 
host-parasite interaction, were studied. Following this, a multitude of experimental 
approaches were used to analyse the secreted proteins of T. spiralis muscle larvae for 
deubiquitinating, deNeddylating and ubiquitin conjugation activity.  
Background	  
 
Pathogens use many strategies to directly manipulate host biochemistry to their own 
advantage during infection. One of these strategies involves pathogen-derived 
proteins that target and alter the activity of the host ubiquitin-proteasome pathway. 
This can lead to the modification of host biological processes such as immunity to 
infection, thus promoting the survival of the pathogen [271], [84]. Pathogen proteins 
can target the host proteasome, host deubiquitinating enzymes (DUBs) or host 
ubiquitin conjugation machinery, namely E1, E2 and E3 enzymes [85,89]. Alternatively, 
pathogens can express their own ubiquitin proteasome components that are able to 
mimic, interact with and modify the host ubiquitin proteasome system.  
Prokaryotic organisms do not have their own ubiquitin-proteasome system. It was 
therefore surprising to discover that some prokaryotic pathogens, viruses and bacteria, 
express proteins with ubiquitin-proteasome system activity (Table 4.1, 
[93,96,97,99,100,272-275]). Because there is no ubiquitin pathway endogenous to the 
pathogen with which these proteins can interact, they are thought to specifically target 
the host ubiquitin-proteasome system. It is thought that these collaborations can lead 
to the ubiquitination and subsequent degradation of either host-derived or bacteria-
derived proteins involved in the infection process.  
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Eukaryotic pathogens such as parasites have their own ubiquitin pathway, as was 
demonstrated for the mammalian parasitic nematode, T. spiralis during chapter 3. 
Human apicomplexan parasites also express a functional ubiquitin proteasome 
pathway and parasite-derived DUBs have been characterised for Plasmodium 
falciparum and Toxoplasma gondii [102,103]. It is not clear however whether or not 
these DUBs are specifically involved in the infection process because separating 
proteins that are specifically host-targeted from those that are parasite’s ‘own’ is a 
particular challenge. This is especially true when studying the intracellular stages of 
parasites such as Plasmodium falciparum. For parasitic worms, along with the 
parasite surface proteins, the parasite secreted proteins (SP) are thought to be the 
chief mediators of host-parasite interaction during infection. Although apicomplexan 
parasites secrete proteins into the host cell, it is extremely difficult to isolate these 
proteins from host cell proteins, and not possible to culture the parasite without the 
host cell. 
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Table 4. 1 Pathogen-derived ubiquitin pathway enzymes 
List of pathogen-derived ubiquitin pathway enzymes and the publication in which their 
identification and host-targeting strategy during infection is reported. 
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The parasitic nematode Trichinella spiralis secretes proteins into the host during both 
the extracellular stages of infection and the intracellular stage of chronic infection, 
where larvae invade and reside inside mature skeletal muscle cells [169,171]. T. 
spiralis muscle larvae can be isolated from infected muscle tissue and cultured 
without host tissue. The secreted proteins can then be collected from culture 
supernatants and studied separately to host proteins [116,276]. Since these proteins 
are actively secreted by the parasite it is hypothesised that they are specifically host 
targeted. Furthermore, during the muscle stage of infection, T. spiralis induces 
changes in host cell transcription that lead to changes in the host cell cycle and 
differentiation state [159,162,163,165]. The ubiquitin-proteasome system heavily 
regulates the proliferation and differentiation of eukaryotic cells [5,52]. It was therefore 
hypothesised that T. spiralis muscle larvae SP contains proteins that are able to 
interact with and modulate the host ubiquitin-proteasome system. 
The experiments carried out during my MRes project showed that the inhibitor probe 
HA-Ub-VME can be successfully used for identifying functional T. spiralis DUBs [1]. 
The inhibitor probe HA-Ub-VME is composed of the human Ub protein with an N-
terminal haemagglutinin (HA) epitope tag and a C-terminal electrophilic group, VME 
[223,226]. Due to the high level of conservation of ubiquitin amongst eukaryotes, 
these probes have been used to successfully identify DUBs from a number of 
pathogenic organisms of medical importance, including the human apicomplexan 
parasites Plasmodium falciparum and Toxoplasma gondii [102,103]. They have also 
been used to identify Ub-proteasome components expressed by bacteria and viruses 
[93,96]. These probes were therefore used to look for DUB activity in the secreted 
proteins of the muscle larvae of T. spiralis.  
Most DUB enzymes are cysteine (thiol) based in activity. When a protein sample 
containing a cysteine (thiol)-based DUB(s) is reacted with HA-Ub-VME, the ubiquitin is 
recognised by the DUB, and the electrophilic group (or ‘warhead’), VME reacts with 
the thiol of the DUB active-site cysteine, forming a covalent thioether bond and 
‘trapping’ the DUB(s) ([223,226] Figure 2.1). These electrophilic warheads may vary, 
and for each warhead a specific affinity for different DUB enzymes is observed. Some 
even show affinity for E2 and E3 enzymes [277]. To control for cysteine-specific 
activity, the protein sample of interest can be pre-incubated with N-ethylmalemide 
(NEM). NEM also reacts with the thiol group of the active site cysteine, rendering the 
cysteine protease inactive. Once a sample has been reacted with the probe, in the 
presence and absence of NEM, anti-HA epitope tag antibodies can then be used to 
immuno-precipitate or immuno-blot probe-enzyme complexes for further analyses. 
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In this chapter T. spiralis secreted proteins were analysed for DUB and deNeddylating 
activity using HA-Ub-VME, and using an additional probe based on the ubiquitin-like 
protein Nedd8. Following this, a number of techniques including modified inhibitor 
probe assays, in vitro ubiquitin conjugation assays, bioinformatics and tandem mass 
spectrometry were then used to investigate the presence of E1, E2 or E3 activity in 
the T. spiralis secreted proteins. 
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Figure 4. 1 The mechanism of the HA-Ub-VME probe 
A. HA epitope tag and an N-terminal electrophilic group (VME). A DUB recognises the Ub of 
HA-Ub-VME and the warhead, VME, reacts with the active site cysteine, forming an 
irreversible covalent thioether bond and creating a HA-Ub-DUB complex. Curly arrows indicate 
the movement of an electron pair. To control for cysteine-specific activity, the protein sample of 
interest can be pre-incubated with N-ethylmalemide (NEM). NEM reacts with the active site 
cysteine rendering the DUB inactive. B. Once a sample has been reacted with the probe, in 
the presence or absence of NEM, anti-HA tag antibodies can then be used to immuno-
precipitate HA-Ub-DUB complexes.  
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The vector for expression of the inhibitor probe was prepared previously as described 
by Hemelaar and Borodovsky et al. and kindly donated by Hidde Ploegh (Whitehead 
Institute for Biomedical Research) [223,256]. Briefly, the coding sequence of human 
ubiquitin, lacking both the C-terminal glycine (Ub75) and a stop codon, was cloned with 
an N-terminal haemagglutinin (HA) tag, into the multiple cloning site of pTYB1 vector. 
This allowed for transcription of the coding sequence in-frame with a C-terminal intein 
gene from Saccharomyces cerevisiae and a chitin-binding domain (CBD) from 
Bacillus circulans (Figure 4.2 A). The chitin-binding domain allows affinity purification 
of the fusion protein on chitin resin (Figure 4.2 B). The intein gene encodes an intein 
domain that allows protein cleavage after addition of a thiol reagent like 2-
mercaptoethane sulfonate Na (MESNa). HA-Ub-intein/CBD was expressed in E. coli 
as described (materials and methods section 2.23). A fusion protein of approximately 
60 kDa was observed after SDS-PAGE analysis of the bacterial lysate (Figure 4.2 D 
(a)). The fusion protein was then purified on chitin resin before cleavage of the intein 
domain was induced by adding the thiol reagent MESNa (Figure 4.2 C). This eluted 
HA-Ub-MESNa (approximately 11 kDa) from the column, leaving the chitin binding 
domain on the resin (Figure 4.2 D (b)). HA-Ub-MESNa was concentrated and reacted 
with the electrophilic ‘warhead’ glycine-VME in the presence of the activating reagent 
 N-Hydroxysuccinimide (NHS) to form HA-Ub-VME (Figure 4.1 E).  
In order to remove inactive probe, un-reacted warhead, un-reacted HA-Ub-MESNa 
and impurities, the probe was then further purified by ion exchange chromatography 
(FPLC) using a strong cation exchange (MonoS) column (Figure 4.3 A). HA-Ub-
MESNa was bound to the FPLC MonoS column in buffer A. Buffer A is a sodium 
acetate-based buffer at pH 4.5, optimised for the binding of the HA-Ub-VME to the 
MonoS column based on its isoelectric point of 5.85. Once bound and washed on the 
column in buffer A, buffer B (buffer A supplemented with 1M NaCl), was slowly 
introduced to gradually increase the concentration of Na+ ions. This changes the net 
charge of the bound protein resulting in its elution from the column. Protein was then 
collected fraction by fraction. As FPLC fractions were collected, the UV absorbance of 
each fraction at 280 nm (measured in milli-absorbance units, mAU) was taken to 
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determine the protein content. Two small peaks in mAU were observed (Figure 4.3 A). 
FPLC fractions were analysed by SDS-PAGE and coomassie staining to confirm the 
presence of protein at the expected size of 11 kDa (data not shown).  
Fractions containing probe were concentrated and tested for activity. The reactivity of 
T. spiralis TsUCH37 with HA-Ub-VME was previously confirmed during my MRes 
project [1]. Therefore the recombinant purified 6His-TsUCH37 was used as a test for 
probe activity. Complex formation of the probe with 6His-TsUCH37 was analysed by 
SDS-PAGE and coomassie staining (Figure 4.3 B). 6His-TsUCH37-probe complexes 
were observed as an electrophoretic mobility 'up-shift' of approximately 11 kDa. This 
up-shift was not present when 6His-TsUCH37 alone was analysed, however a smaller 
band was consistently observed that is likely to be a breakdown product or 
contaminant in the 6His-TsUCH37 sample. Fraction A15 did not contain any probe. 
Fractions B5 to B1 contained active probe, for which a band of that corresponded to 
the 6His-TsUCH37-probe complex was observed (Figure 4.3 B (a)). An additional 
larger band was observed for fractions B4 to B2. Fraction B11 contained some active 
probe, although some un-reacted probe was still observed at approximately 11 kDa, 
indicating that this peak may represent mainly un-reacted HA-Ub-MESNa, or inactive 
HA-Ub-VME. Fraction C5 did not contain any probe.  
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Figure 4. 2 Production of the HA-Ub-VME probe 
A. Human (Hs) ubiquitin with an N-terminal HA tag was cloned into pTYB1 creating a C-
terminal intein/chitin binding domain fusion protein (CBD). The vector was kindly donated by 
Hidde Ploegh (Whitehead Institute). B. The HA-Ub-intein/CBD fusion protein was purified 
using chitin resin that binds to the CBD. C. The addition of the MESNa mediates the cleavage 
of ubiquitin from the intein/CBD, releasing HA-Ub-MESNa. D. HA-Ub-intein/CBD was 
expressed by E. coli (a) and purified using the chitin column and on-column cleavage 
technique, forming HA-Ub-MESNa (b). E. HA-Ub-MESNa was ligated to glycine-VME forming 
HA-Ub-VME. 
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Figure 4. 3 Purification and testing of the HA-Ub-VME probe 
A. HA-Ub-VME was purified by ion exchange chromatography. The absorbance (mAU) of 
fractions eluted from the column by buffer B was measured as they were collected. The 
shaded fractions were tested for activity: A15 (blue), B11 (green), B5-B1 (yellow) and C5 (lilac). 
B. Fractions were tested for reactivity with 6His-TsUCH37. Reactions were analysed by SDS-
PAGE and coomassie staining. As a control TsUCH37 was analysed alone (b). Probe-
TsUCH37 complexes (a) demonstrate a shift in electrophoretic mobility (a). An unidentified 
signal was observed (c) and probe alone (d). C. The effect of NEM and isopropanol on 
TsUCH37 and HA-Ub-VME reactions was analysed using probe fraction B3. Reactions were 
analysed by coomassie staining and His blot. Probe-TsUCH37 complexes (a) demonstrate a 
shift in electrophoretic mobility (a) above the unreacted TsUCH37 signal (c). NEM also caused 
a shift in electrophoretic mobility of TsUCH37 (b). 
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There is some evidence that Ub is able to dimerise in a non-covalent manner [278]. 
The aggregation of a protein under reducing conditions during SDS-PAGE, would 
imply SDS resistant aggregation. The reducing agent dithiothreitol (DTT) is included in 
both the probe reaction buffer and the protein (SDS) loading buffer and theoretically, 
disulphide linkages are prevented in this buffer. However DTT is not included in SDS-
PAGE running buffer, and there is evidence that some proteins are able to aggregate 
during the stacking stage of SDS-PAGE [279]. If I propose that the probe is able to 
non-covalently aggregate, the extra unexpected bands that were observed may 
represent a probe dimer weighing approximately 22 kDa, and a probe dimer in 
complex with 6His-TsUCH37, weighing approximately 60 kDa (38 kDa + 22 kDa).  
To test for cysteine-specific reactivity, probe fraction B3 was then further tested for 
reactivity with and without the cysteine protease inhibitor NEM. Preliminary 
experiments indicated that either the NEM, or the NEM vehicle isopropanol, was 
having an effect on the electrophoretic mobility of the proteins themselves (data not 
shown). An experiment was therefore set up to verify the activity of the probe fraction 
B3 with 6His-TsUCH37, and to demonstrate the effect of NEM on protein 
electrophoretic mobility (Figure 4.3 C). This time, coomassie stain and anti-His-tag 
antibodies were used to analyse the reactions by immuno-blot. Figure 4.3 C shows 
that isopropanol itself has no effect on the TsUCH37 mobility, and that probe fraction 
B3 indeed reacts with TsUCH37, forming a complex of an expected size. This 
reactivity is silenced by NEM and NEM also causes the un-reacted TsUCH37 to have 
a reduced mobility in SDS-PAGE, even in the absence of the probe. This observation 
had to be taken into account in subsequent experiments so as not to overlook subtle 
changes in the mobility of proteins when testing Ub-based inhibitor probes. 
4.2.	  Reaction	  of	  ubiquitin-­‐based	  inhibitor	  probes	  with	  T.	  spiralis	  secreted	  
proteins	  	  
 
In addition to the HA-Ub-VME probe, another probe that was previously produced by 
Hemelaar et al. was kindly provided Hidde Ploegh [226]. This probe is based on 
another human Ub-like modifier protein, Nedd8. DeNeddylating enzymes remove 
Nedd8 from substrate proteins using the same mechanism as deubiquitinating 
enzymes. The probe contained a FLAG epitope tag for immuno-blot/precipitation and 
the electrophilic warhead, vinyl sulphone (VS), FLAG-Nedd8-VS. The mechanism of 
reactivity of this probe with deNeddylase enzymes is as described earlier for HA-Ub-
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VME in Figure 4.1. The putative T. spiralis Nedd8 orthologue (GI: 339239065) shows 
65.6% identity to human Nedd8 (Figure 4.4 E). 
The secreted proteins from T. spiralis muscle larvae were collected and 300 ug were 
reacted with HA-Ub-VME and FLAG-Nedd8-VS, in the presence or absence of the 
cysteine protease inhibitor NEM as a control. Reactions were then separated by SDS-
PAGE and analysed by immuno-blot using anti-HA-tag antibodies and anti-FLAG-tag 
antibodies (Figure 4.4 B and C). Most bands observed after the reaction of HA-Ub-
VME with T. spiralis secreted proteins were present in both the samples (with and 
without NEM), indicating either probe aggregation, or that reactivity with the probe 
was not cysteine dependent and therefore unlikely to be DUB specific (Figure 4.5 B). 
There were however a few bands that appeared to have been present only in the 
NEM-free sample. No cysteine-dependent reactivity was observed after the reaction 
of T. spiralis secreted proteins with FLAG-Nedd8-VS (Figure 4.4 C).  
To confirm whether or not the signal observed after the reaction of T. spiralis secreted 
proteins with HA-Ub-VME (in the absence of NEM) might be DUB-specific, the 
experiment was scaled-up. A large amount (3 mg) of T. spiralis secreted protein was 
reacted with HA-Ub-VME. Protein-probe complexes were then immuno-precipitated 
and purified using anti-HA affinity resin. These were eluted from the resin and 
analysed by SDS-PAGE. This experiment was repeated a 2nd time. Proteins from the 
1st experiment were visualised by coomassie staining and proteins from the 2nd 
experiment were visualised by silver staining (Figure 4.5 A and B respectively). All 
bands present in the coomassie-stained gel were manually excised for analysis. From 
the silver-stained gel, bands that appeared present in only the NEM-free sample, and 
corresponding areas of the NEM-present sample, were manually excised for analysis. 
This constituted 19 bands from the coomassie-stained gel labelled 1-19 and 13 bands 
from the silver-stained gel labelled A-M (Figure 4.5 A and B respectively). These 
proteins were analysed by tandem mass spectrometry (LC/MS/MS). Peptides were 
then matched against the T. spiralis draft genome annotation database using 
SEQUEST software, [280]. In bands 1-19, a total of 100 putative T. spiralis proteins 
were identified and in bands A-M, a total of 57 putative T. spiralis proteins were 
identified. A list of all the putative T. spiralis protein matches can be found in the 
supplementary appendices 2 and 3. Eric Spooner of the Whitehead Institute, Boston 
carried out the mass spectrometry analysis and SEQUEST searches.  
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Figure 4. 4 Reaction of T. spiralis secreted proteins with the HA-Ub-VME probe 
A. Schematic of the reaction of a DUB with the HA-Ub-VME probe. The DUB recognises Ub 
and the active-site cysteine attacks the modified (VME) C-terminal glycine. An irreversible 
thioether bond is formed between the DUB and the glycine-VME. Curly arrows indicate the 
movement of an electron pair. Anti-HA antibodies with react with the HA epitope tag of the HA-
Ub-DUB complex, allowing immuno-blot (IB) or immuno-precipitation (IP) analyses. B. 
Reaction of the secreted proteins of T. spiralis muscle larvae (T.sp SP) with HA-Ub-VME. C. 
Reaction of T. spiralis secreted proteins (SP) with FLAG-Nedd8-VS. Reactions were carried 
out in the presence and absence of the cysteine protease inhibitor NEM and analysed by 
immuno-blot using anti-HA or anti-FLAG antibodies. A possible enrichment of signal was 
observed after the reaction with HA-Ub-VME in the absence of NEM (red arrows). All 
molecular weights are indicated in kDa. D. Alignment of human (Hs) ubiquitin with T. spiralis 
(Ts) ubiquitin shows 98% identity. E. Alignment of human (Hs) Nedd8 with T. spiralis Nedd8 
shows 59.2% identity.
Chapter 4: Results  
 141 
 
Figure 4. 5 Proteomic analysis of the HA-Ub-VME reaction with T. spiralis secreted 
proteins 
The secreted proteins (SP) of T. spiralis muscle larvae were reacted with HA-Ub-VME, in the 
presence and absence of the cysteine protease inhibitor NEM, followed by immuno-
precipitation (IP) using anti-HA antibodies. Two separate reactions were carried out and 
separated by SDS-PAGE. The first was analysed by coomassie staining (A) and the second by 
silver staining (B). Bands that appeared in the NEM negative sample only were identified and 
manually excised (numbers or letters) along with the corresponding areas of the NEM positive 
sample. Proteins in these bands were analysed by tandem mass spectrometry (LC/MS/MS). 
All molecular weights are indicated in kDa. C. The putative T. spiralis ubiquitin conjugating 
enzyme TsUBE2N (GI: 316965577) was identified in band 5 of the coomassie-stained HA-Ub-
VME/T. spiralis SP experiment. Two peptides covering 21% of the putative protein sequence 
were identified. The UBCc (ubiquitin conjugation) domain is boxed in red. 
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Although many putative T. spiralis proteins were identified (see supplementary 
appendix 2 and 3 for all LC/MS/MS data), none were annotated as DUB or 
deNeddylating enzymes. All protein matches annotated as ‘uncharacterised’ were 
further analysed for conserved domain architecture by BLAST and SMART (Simple 
Modular Architecture Research Tool, [210,211]). No DUB or deNeddylase domains 
were identified. However, 3 ubiquitin-related protein sequences were identified (Table 
4.2). The first match, the ‘Ubiquitin family member protein (fragment, (GI: 339233028), 
is the putative T. spiralis ubiquitin protein itself, which is labelled as a fragment 
because the annotated sequence contains a single (mono) ubiquitin followed 
immediately by a fragment of another ubiquitin whose sequence is incomplete. In 
order to determine the source of the T. spiralis ubiquitin protein, T. spiralis secreted 
proteins and lysate were separated by SDS-PAGE and reacted with antibodies raised 
against human ubiquitin by immuno-blot. For positive controls, HEK 293T lysate and 
lysate of T. spiralis muscle larvae were analysed in parallel. T. spiralis secreted 
protein contained many proteins that were able to react with the anti-Ub antibodies at 
various sizes, and a protein at approximately 10 kDa that would correspond to the T. 
spiralis Ub itself (Figure 4.6). Peptides matching the T. spiralis ubiquitin family protein 
may therefore have derived from the human Ub-based probe itself, since the level of 
identity between the human Ub and the T. spiralis Ub is 97.4%, or from T. spiralis 
secreted proteins that are themselves modified by ubiquitin.
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Table 4. 2 Ubiquitin-related proteins identified by proteomic analysis of the HA-Ub-VME 
reaction with T. spiralis proteins 
Table showing the 3 ubiquitin-related proteins that were identified by LC/MS/MS analysis of the 
proteins that were immuno-precipitated from 2 separate reactions (coomassie-stained or silver-
stained) of the secreted proteins of T. spiralis muscle larvae with the HA-Ub-VME probe. 
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Figure 4. 6 Anti-ubiquitin immuno-blot of T. spiralis proteins 
Human cell (HEK 293T) lysate and T. spiralis lysate were included as controls to analyse the 
secreted proteins (SP) of T. spiralis muscle by SDS-PAGE and immuno-blot (IB) using anti-
ubiquitin antibodies. All molecular weights are indicated in kDa. 
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The 2nd ubiquitin-related protein identified by LC/MS/MS was annotated as a RING 
finger and WD-repeat (RWD) domain protein, GI: 316972581 with a predicted size of 
77 kDa. RWD domains are RING finger and WD-repeat domains, and are often found 
in E3 ligases [281,282]. Although RWD proteins have been shown to interact with 
ubiquitin, their function is not well understood. When further analysed by BLAST 
alignment, the N-terminal portion of the putative T. spiralis RWD protein sequence 
matched another T. spiralis protein, annotated as the 53 kDa excretory-secretory 
antigen (GI: 805126). This protein was previously characterised as a dominant T. 
spiralis antigen whose sequence and size has been confirmed by proteomic analysis 
[196,283,284]. In these studies the authors do not observe an RWD domain as part of 
the sequence. When multi-orthologous alignments were carried out the sequence 
aligned with those from various species as 2 separate proteins. The N-terminal region 
aligned with a T. spiralis sequence that does not contain the RWD domain, the 53 kDa 
excretory-secretory antigen that is conserved amongst other species of Trichinella 
only. The C-terminal region aligned with RWD domain proteins from various other 
species. Peptides identified by LC/MS/MS only aligned with the N-terminal region.  
Reactivity with the probe was found in both the NEM-free sample and the NEM-
present sample, and thus was not cysteine-dependent (Figure 4.5 A and B). 
Furthermore, peptides that matched the annotated RWD protein were found most 
predominantly in bands C and J of the silver-stained gel and bands 2 and 13 of the 
coomassie-stained gel that represents a molecular weight of approximately 55 kDa 
(indicating a protein of 44 kDa in complex with an 11 kDa probe). These peptides only 
matched the N-terminal half of the sequence, and not any of the RWD domain that 
comprises the C-terminal portion of the annotated sequence. It therefore could be that 
this sequence has been mis-annotated.  
The 3rd Ub-related protein was annotated as a putative ubiquitin-protein ligase that, 
when further analysed by BLAST, actually contained a UBCc domain. UBCc domains 
are characteristic of ubiquitin conjugation (rather than ligase) enzymes. The putative T. 
spiralis E2 GI: 316965577 is predicted to weigh 20.5 kDa, but matched 2 unique 
peptides found in band 5 (corresponding to approximately 40 kDa) of the coomassie-
stained gel (Figure 4.5 A). The 2 unique peptides covered 21% of the putative T. 
spiralis E2 sequence (Figure 4.5 C). When analysed by BLAST alignment the 
sequence was found to be orthologous to the human E2 enzyme UBE2N (S. 
cerevisiae UBC13 and C. elegans ubc-1). Mammalian UBE2N is involved in lysine-63-
linked polyubiquitin chain assembly [285,286]. This kind of ubiquitin chain is not 
predominantly involved in protein degradation, rather other proteasome-independent 
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processes such as the transcriptional activation of target genes [287,288]. When the 
experiment was repeated, peptides from the silver-stained gel did not match this 
protein, despite bands D, E, K and L being excised from a region of the gel that could 
correspond to band 5 of the coomassie-stained gel (Figure 4.5 B). 
The sequence was then further analysed by bioinformatics programmes to ascertain 
the likelihood of true secretion of the protein by T. spiralis. The putative T. spiralis 
UBE2N sequence predicts a 179 amino acid protein. When analysed for protein 
architecture and conserved domains by SMART, residues 32 to 176 span the 
conserved UBCc domain (Figure 4.5 C). SignalP is an algorithm that identifies signal 
peptide cleavage sites and therefore signal peptides for membrane localisation, 
translocation or secretion [219]. SignalP analysis of the putative TsUBE2N did not 
identify a signal peptide or cleavage site. WolfPSORT is a programme that predicts 
sub-cellular localisation motifs based on sequence orthology. This includes searching 
for orthology with sequences that are often involved in secretory pathways, and 
proteins that are often located extracellularly [217]. WolfPSORT gives a list of 
potential locations of the protein, in order of a score of likelihood. For example, the 
wolfPSORT score for the human secreted protein insulin is as follows: 
extr: 32.0 (only one possible location for this protein - extracellular) 
WolfPSORT predicted the putative TsUBE2N to be predominantly located in the 
cytoplasm or targeted to the mitochondria or nucleus: 
wolfPSORT score: mito: 22.0, cyto: 7.0, cyto_nucl: 5.0 
The human UBE2N and the putative T. spiralis UBE2N are 87.2% identical. An 
antibody was purchased that was raised against a portion of the human UBE2N that 
shows 75% identity (Figure 4.7 A). The secreted proteins of T. spiralis muscle larvae, 
lysate of muscle larvae and lysate of HEK 293T cells were reacted with the antibody 
(Figure 4.7 B). Proteins were also reacted with antibodies (kindly provided by Kleoniki 
Gounaris) that react with an abundant T. spiralis secreted protein, the 5’nucleotidase 
(5’NT) enzyme, GI: 22656349, previously characterised by Gounaris et al. [197]. Both 
T. spiralis secreted proteins and T. spiralis lysate reacted with the known secreted 
5’NT at approximately 60 kDa. The human UBE2N is 17 kDa. Proteins from HEK 
lysate, of approximately 17 kDa, reacted with the anti-HsUBE2N, confirming specificity 
of the antibody. Although proteins in the T. spiralis lysate reacted with anti-UBE2N 
antibodies, showing a doublet band at approximately 15 kDa, there was no reactivity 
in the T. spiralis SP. Results indicated that although T. spiralis muscle larvae express 
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a UBE2N homologue, it is unlikely that it is secreted. T. spiralis muscle larvae were 
cultured for 4 days and the secreted proteins were harvested at the end of each day. 
By the 4th day, a significant proportion of parasites may have begun to die. Therefore 
peptides matching TsUBE2N may have been released from dead or dying larvae, and 
not present as a result of the active secretion of the protein. 
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Figure 4. 7 Analysis of TsUBE2N 
A. Alignment of human (Hs) UBE2N and T. spiralis (Ts) putative UBE2N showing 87.2% 
identity. To analyse secretion of TsUBE2N by T. spiralis, an antibody raised against a portion 
of the human protein (immunogen sequence shaded in yellow) was reacted with T. spiralis 
secreted proteins (SP), T. spiralis lysate and human cell (HEK) lysate (B). As a control, the 
same samples were reacted with an antibody raised against an abundant T. spiralis secreted 
protein, 5’NT. Anti-5’NT was kindly donated by Kleoniki Gounaris (Gounaris et al. 2004 [197]). 
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4.3.	  Verification	  of	  the	  absence	  of	  DUB	  and	  deNeddylating	  activity	  in	  the	  T.	  
spiralis	  secreted	  proteins 
 
No DUB or deNeddylating activity could be detected in the secreted proteins of T. 
spiralis muscle larvae using HA-Ub-VME and FLAG-Nedd8-VS. To verify the absence 
of DUB and deNeddylating enzymes in T. spiralis secreted proteins, AMC hydrolysis 
assays were carried out. A description of the mechanism of an AMC assay can be 
found in section 3.3. AMC conjugates of the human orthologue of ubiquitin and Nedd8 
were used to test for ubiquitin and Nedd8-specific hydrolysis activity in secreted 
proteins of T. spiralis muscle larvae. Lysate of T. spiralis muscle larvae was tested as 
a positive control, and purified recombinant PfUCHL3, the Plasmodium falciparum 
UCH-L3 orthologue, (at a saturating concentration) was tested as an additional 
positive control because it was previously shown to have both Ub and Nedd8 
hydrolysis activity [103]. HEK lysate, T. spiralis lysate and T. spiralis SP were all used 
at 2 mg/ml. Protein samples were mixed with each AMC substrate and fluorescence, 
corresponding to the release of AMC from the conjugate, was measured every minute 
for 15 minutes (Figure 4.8 A and B). Lysate of T. spiralis muscle larvae gave rise to 
Ub-AMC and Nedd8-AMC hydrolysis activity that was comparable to the activity of 
PfUCH-L3 or HEK lysate (Figure 4.8 A and B). No Ub-AMC or Nedd8-AMC hydrolysis 
activity was observed in T. spiralis secreted proteins, consistent with the lack of 
activity measured by inhibitor probe assays. All activities were silenced by pre-
incubation of the proteins with NEM, denoting cysteine dependent hydrolysis.  
Using the Ub- and Nedd8-based inhibitor probes and Ub and Nedd8 AMC conjugates, 
no DUB or deNeddylating activity was detected in T. spiralis secreted proteins. 
Immunoprecipitation of HA-Ub-VME-SP complexes did however suggest the potential 
presence of a ubiquitin conjugating (E2) enzyme TsUBE2N, the secretion of which by 
T. spiralis could not be confirmed by immuno-blot. This prompted further investigation 
into the possibility of the secretion of Ub-conjugation machinery by T. spiralis muscle 
larvae. 
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Figure 4. 8 Testing for Ub and Nedd8 hydrolysis activity of T. spiralis secreted proteins 
The secreted proteins (SP) of T. spiralis muscle larvae were tested for reactivity with (A) Ub-
AMC and (B) Nedd8-AMC. T. spiralis lysate and the P. falciparum dual deNeddylating and 
deubiquitinating enzyme PfUCHL3 were also tested as controls. All samples were pre-
incubated with the cysteine protease inhibitor NEM as a negative control for cysteine 
dependent activity. Fluorescence (representing the release of free AMC) was measured in 
relative fluorescence units (RFU) over time (minutes). The hydrolysis of Ub-AMC and Nedd8-
AMC by each sample was analysed in triplicate. Data are presented as the mean of triplicate 
values from a single experiment and the error bars represent SEM. Consistent data were 
obtained from similar experiments performed using different concentrations of protein and 
different protein batches. 
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  and	  ligating	  (E3)	  activity	  
in	  T.	  spiralis	  secreted	  proteins	  
4.4.	  Production	  of	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Ubiquitin-based inhibitor probes, including Ub-VME, can interact with E1, E2 and E3 
enzymes as well as DUBs, albeit with a lower affinity, the level of which depends on 
the electrophilicity of the warhead [277]. Ubiquitin activating (E1), conjugating (E2) 
and ligase (E3) enzymes are also reliant on a catalytic cysteine for transient 
interaction with Ub during ubiquitination. The greater the electrophilicity of the 
warhead of a ubiquitin-based inhibitor probe, the greater the affinity for ubiquitin 
conjugation enzymes; E1, E2 and E3s. Therefore, the purpose of these experiments 
was to produce HA-tagged-Ub-based probes with more electrophilic warheads than 
VME. Love et al. demonstrated that 2 warheads, glycine 2,6-
trifluoromethylbenzyloxymethyl-ketone (TF3BOK) and alpha-amino-beta-lactone (Lac) 
have a higher affinity for Ub conjugation enzymes than vinylmethylester (VME, [277]). 
These warheads were also shown to react with a largely different panel of proteins to 
the VME warhead. These warheads were therefore chosen based on their divergent 
affinities to the VME, which had already been tested with the T. spiralis secreted 
proteins. 
The TF3BOK and Lac warheads were synthesised in collaboration with Jennifer Ward 
under the supervision of Ed Tate at the Institute of Chemical Biology, Imperial College 
London (Figure 4.9 and 4.10 A). HA-Ub-MESNa was produced as described earlier 
(section 4.1) and reacted with each warhead at pH 8, under the direction of the 
methods previously reported by Love et al. A significant level of insolubility of each 
warhead was observed, thus reducing the ratio of warhead to HA-Ub-MESNa during 
the ligation step. Ligation samples were then purified by FPLC as described earlier 
(Figure 4.9 and 4.10 B). Fractions with peak absorbance were analysed by SDS-
PAGE and coomassie staining to confirm presence of the probe at the expected size 
(Figure 4.9 and 4.10 C). An additional larger band was also observed, possibly 
representing aggregates/ doublets. Love et al. reported the identification of the human 
UCH37 (UCH-L5) using both TF3BOK and Lac warheads and TsUCH37, the T. 
spiralis UCH37 orthologue, was originally identified using the human Ub-based probe 
HA-Ub-VME. It was hypothesised that the lac and TF3BOK probes would also be able 
to react with TsUCH37 and the His-tagged recombinant protein was used to test for 
probe activity. Probe containing fractions were reacted with 6His-TsUCH37 and 
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analysed by SDS-PAGE and immuno-blot using anti-HA antibodies. The previously 
produced HA-Ub-VME probe (section 4.1) was also reacted with 6His-TsUCH37 as a 
positive control and as a negative control, 6His-TsUCH37 was pre-incubated with 
NEM before addition of the fraction (Figure 4.9 and 4.10 D).  
No probe-6His-TsUCH37 complexes were detected in any fraction, and therefore no 
active TF3BOK or Lac probes were present. In order to try and explain the lack of 
active probe, the warheads were then analysed by mass spectrometry (LC/MS) by 
Jennifer Ward. When the probes are produced they are in a slightly acidic state, they 
are then buffered to pH 8 for the ligation reaction. The stability of the warheads at pH 
8 was therefore analysed (Jennifer Ward MRes research manuscript, Institute of 
Chemical Biology 2012). It was found that significant degradation of the TF3BOK 
warhead occurred within 1 hour of incubation at pH 8. Methods of ligation and FPLC 
were adapted for optimisation, but multiple attempts to produce active HA-Ub-TF3BOK 
and HA-Ub-Lac failed. In order to troubleshoot and optimise the conditions required 
for stabilisation of the warheads, in depth analysis of the composition of the products 
at each production and ligation step would be necessary. This would require extensive 
LC/MS and NMR analysis. Due to time constraints the production of the TF3BOK and 
Lac probes was therefore not continued and other methods were sought to try and 
confirm whether or not Ub conjugation enzymes are secreted by T. spiralis.  
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Figure 4. 9 Production, purification and testing of the HA-Ub TF3BOK probe 
A. HA-Ub-MESNa was ligated to the TF3BOK (glycine 2,6-trifluoromethylbenzyloxy-methyl-
ketone) warhead. B. HA-Ub-TF3BOK probe was purified by ion exchange chromatography. 
The absorbance (mAU) of fractions eluted from the column by buffer B was measured as they 
were collected. C. The following fractions were analysed by SDS-PAGE for the presence of 
probe: the flow through X1, the wash A3, B10-B5 (green), B2 (blue), C3-C6 (yellow), C8-C10 
(lilac), D9 (not shown on trace) and the original ligation reaction that was loaded onto the 
column (load). Fractions contained a protein at the expected size of the probe (b) and a 
possible aggregate protein of double the size (a). The marker (M) shows the molecular weights 
in kDa. D. Fraction B8 was tested for reactivity with 6His-TsUCH37. Reactions were analysed 
by SDS-PAGE and immuno-blot (IB) using anti-HA antibodies. As a control 6His-TsUCH37 
was reacted with HA-Ub-VME probe. (a) A complex larger than the expected probe-TsUCH37 
complex (possible aggregation complex or contaminant), (b) probe-TsUCH37 complex (c), 
possible probe aggregates, (d) expected size of probe. For each probe, 6His-TsUCH37 was 
also pre-incubated with the cysteine protease inhibitor NEM as a control. 
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Figure 4. 10 Production, purification and testing of the HA-Ub-Lac probe 
A. HA-Ub-MESNa was ligated to the Lac (alpha-amino-beta-lactone) warhead. B. HA-Ub-
TF3BOK probe was purified by ion exchange chromatography. The absorbance (mAU) of 
fractions eluted from the column by buffer B was measured as they were collected. C. The 
following fractions were analysed by SDS-PAGE for the presence of probe: the flow through 
X1 and X2, the wash A4, B10-B8 (green), B4 (pink), C1 (yellow), C6-C12 (lilac), D9 (blue) and 
the original ligation reaction that was loaded into the column (load). Fractions contained a 
protein at the expected size of the probe (b) and a possible aggregate protein of double the 
size (a). The marker (M) shows the molecular weights in kDa. D. Fraction B8 was tested for 
reactivity with 6His-TsUCH37. Reactions were analysed by SDS-PAGE and immuno-blot (IB) 
using anti-HA antibodies. As a control 6His-TsUCH37 was reacted with HA-Ub-VME probe. (a) 
A complex larger than the expected probe-TsUCH37 complex (possible aggregation complex 
or contaminant), (b) probe-TsUCH37 complex (c), possible probe aggregates, (d) expected 
size of probe. For each probe, 6His-TsUCH37 was also pre-incubated with the cysteine 
protease inhibitor NEM as a control.  
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An in vitro ubiquitin conjugation assay involves a mixture of all the components 
required for the enzymatic cascade that leads to the ubiquitination of a protein 
substrate. Either the substrate or the ubiquitin can be tagged (Figure 4.11 A). This 
allows detection of the tag by immuno-blot and visualisation of an upward shift in size 
of the substrate protein if ubiquitination has taken place. This may be observed as a 
smear if the protein has multiple ubiquitination sites and/or can be modified with 
polyubiquitin chains of various lengths. The E1 enzyme requires ATP to activate free 
ubiquitin, before passing the activated ubiquitin onto the E2 enzyme. Therefore the 
addition of ATP to the reaction buffer initiates the ubiquitin conjugation cascade. 
Streptavidin is a protein from the bacterium Streptomyces avidinii that binds with a 
high affinity to biotin. Streptavidin-HRP conjugates can therefore be used in a similar 
manner to antibodies to blot for biotin-tagged proteins.  
An in vitro ubiquitin conjugation reaction was carried out to determine if T. spiralis 
secreted proteins contain proteins with E1, E2 or E3 activity, using biotin-tagged 
human ubiquitin. All reactions were then separated by SDS-PAGE and analysed by 
binding to streptavidin-HRP and visualisation of the HRP using chemiluminescence. 
The positive control ubiquitin conjugation mixture contained the human recombinant 
E1 enzyme, the human recombinant E2 UBE2L3 (UbcH7), and the human 
recombinant E3 parkin. In the presence of the UbcH7, parkin is able to ubiquitinate 
itself (auto-ubiquitination). Unmodified parkin is 51 kDa. When all 3 enzymes were 
mixed together, with biotin-Ub and ATP, a smear was observed corresponding to the 
ubiquitinated forms of parkin (Figure 4.11 B, panel a). For a negative control, the E2 
was removed from the reaction mixture and no smear was observed (Figure 4.11 B, 
panel b). T. spiralis SP were then substituted into the reaction mixture for either the 
E1, the E2 or the E3 (Figure 4.11 B, panels c, d and e). A mixture containing T. 
spiralis SP and the E1 but no E2 or E3 was also set up, and a mixture containing only 
T. spiralis SP and biotin-Ub (Figure 4.11 B, panels f and g). Biotin-Ub conjugation was 
observed when T. spiralis SP was used instead of the E2 and the E3 (Figure 4.11 B, 
panels c and d). Conjugation was not observed when T. spiralis SP was used instead 
of the E1. This suggests that proteins in T. spiralis SP have Ub conjugation and 
ligation activities but not E1 activity. There was also no signal observed when T. 
spiralis SP were mixed with the E1 only, indicating that the human E2 is required for 
the T. spiralis secreted proteins to carry out E3 activity and the human E3 is required 
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for T. spiralis secreted proteins to carry out E2 activity (Figure 4.11 B, panel f). In 
other words, T. spiralis SP have E2 and E3 activity, but it appears unlikely that these 
activities can work together without coming into contact with ubiquitin conjugation 
enzymes from an external source. It was therefore hypothesised that ubiquitination of 
substrates by these proteins requires mammalian host E2 or E3 partners. Efforts were 
then made to try and identify the proteins responsible for the E2 and E3 activity.  
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Figure 4. 11 In vitro ubiquitin conjugation assay of T. spiralis secreted proteins 
A. Schematic of the ubiquitin conjugation assay. Using ATP, the E1 enzyme activates biotin-
tagged Ub and passes it on to the E2. The E2 enzyme passes Ub-biotin on to the E3, which 
catalyses the ligation of Ub-biotin to a substrate protein. For this assay the human E1, human 
E2 UBE2L3 and the human E3 parkin were used. HRP conjugated streptavidin can bind to the 
biotin-tag, thus allowing detection of ubiquitinated proteins by blot. B. An in vitro ubiquitination 
assay was carried out using the E1, E2, E3, and Ub-biotin (a) as a positive control. (b) The 
assay was carried out in the absence of the E2. (c) The secreted proteins of T. spiralis muscle 
larvae were assayed in the place of the E2 and the E3 (c). The assay was carried out with T. 
spiralis SP in the absence of the E1 (d), in the absence of the E2 and E3 (e) and in the 
absence of the E1, E2 and E3 (g). All reactions were separated by SDS-PAGE and analysed 
by streptavidin-HRP blot. Proteins sizes are indicated in kDa. 
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4.6.	  Bioinformatics-­‐based	  prediction	  of	  the	  T.	  spiralis	  secretome	  
 
Firstly, a bioinformatics approach was adopted to look at T. spiralis proteins and build 
a list of putative T. spiralis secreted proteins. Within this, searches for candidate T. 
spiralis ubiquitin-related enzymes were carried out. There are a multitude of 
bioinformatics programmes that have been developed to analyse eukaryotic proteins 
and predict secretion signals (signal peptides) or localisation motifs. Analysis of 
proteins by these programmes gives an overall score of the likelihood of secretion of 
the protein. All non-redundant (RefSeq) T. spiralis annotated protein sequences (a 
total of 16404 proteins) were analysed by 3 different sequence-based programmes: 
iPSORT, wolfPSORT and signalP. WolfPSORT was described earlier. SignalP is an 
algorithm that identifies signal peptide cleavage sites and therefore signal peptides for 
membrane localisation, translocation or secretion [219]. IPSORT predicts subcellular 
localisation sites by predicting N-terminal sorting signals. This includes identifying 
signals required for sorting proteins to the mitochondria or externally, i.e. for 
extracellular secretion [289].  
All 16404 putative T. spiralis proteins were systematically searched against each of 
the 3 programmes. Derek Huntley at the Imperial College Bioinformatics Support 
Service carried out initial mass bioinformatics searches. Proteins that gave a positive 
score for one programme, were then searched against the other 2 programmes, until 
all possible combinations of positive score was obtained for each protein. Table 4.3 
lists all combinations of a positive score for all 3 programmes out of all 16404 proteins. 
For example, 321 T. spiralis proteins were identified and listed as positive for iPSORT 
only, 776 proteins were positive for both iPSORT and wolfPSORT, and 750 proteins 
were positive for all 3 programmes: iPSORT, wolfPSORT and signalP. In total, 1948 
out of a total 16404 proteins had a positive score (for an N-terminal sorting signal) 
when searched against iPSORT, 8824 had a positive ‘extracellular’ score according to 
wolfPSORT, and signalP predicted that 1060 proteins have a signal peptide. 
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Table 4. 3 Bioinformatics-based prediction of T. spiralis secreted proteins 
All non-redundant T. spiralis annotated protein sequences were analysed by 3 different 
prediction programmes that predict signal peptides (iPSORT and signalP) or sub-cellular 
localisation motifs (wolfPSORT). The number of sequences that were predicated as positive 
for each programme alone, and in combination with each of the other programmes, is listed. 
For example, 7134 sequences were predicted to be secreted by wolfPSORT only (but not by 
signalP and iPSORT, and 776 different sequences were predicted to be secreted by both 
wolfPSORT and iPSORT (but not signalP) etc. 
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Each list of proteins with a positive score (for all combinations of searches) was then 
further analysed by keyword searches, BLAST for orthology and by SMART for 
conserved domain architecture [210,211]. This identified 130 proteins that are related 
to the ubiquitin-proteasome system or contain domains that can associate with Ub 
and that iPSORT wolfPSORT and/or signalP predict to be secreted (all results are 
found in appendix 2). To refine the list, all proteins whose wolfPSORT score of 
‘extracellular’ was listed as the most likely location (highest score) were identified 
(Table 4.4). This was because a vast number of proteins were predicted to have 
signal peptides by iPSORT and signalP that may not have been signal peptides for 
secretion, rather signal peptides for membrane localisation. Using WolfPSORT in this 
way (taking the highest scoring location only) was considered the most stringent 
prediction algorithm for T. spiralis proteins. 
4.7.	  Further	  analysis	  of	  2	  putative	  T.	  spiralis	  E3	  proteins	  predicted	  to	  be	  
secreted	  by	  bioinformatics	  
 
Searches were carried out to find commercially available antibodies to the mammalian 
orthologues of the Ub-related proteins whose wolfPSORT score of 'extracellular' was 
the highest (listed in Table 4.4). Alignments of the mammalian orthologues with the 
putative T. spiralis sequences identified 2 antibodies that were predicted to cross 
react (Table 4.5). Two antibodies were purchased that were predicted to cross react 
with:  
1. A putative T. spiralis HECT-domain protein, GI: 339253068, orthologous to the 
human Ub E3-ligase, NEDD4-L (neural precursor cell expressed, developmentally 
down-regulated 4-like) [290].  
2. A putative WD domain, G-beta repeat-containing domain protein orthologous to 
human WDR48 [291].  
HECT and domains both have Ub-ligase activity [292]. WD-repeat domains consist of 
short amino acid (approximately 40) repeats and are often found in E3 ligase 
enzymes [293]. 
Anti-NEDD4-L and anti-WDR48 were reacted by immuno-blot with 10 ug of T. spiralis 
SP, T. spiralis muscle larvae lysate and with human cell lysate as a positive control 
(HEK 293T cell lysate). The predicted sizes of each orthologue compared to the 
human protein can be seen in Table 4.5. No reactivity with the anti-WD48 antibody 
was observed in the T. spiralis SP at the predicted size of 115.3 (Figure 4.12 B). Both 
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antibodies showed reactivity with proteins of the predicted size in HEK lysate, 
although additional reactivity was observed at various sizes with the anti-WDR48 
antibodies. Significant reactivity with the T. spiralis SP was observed for the anti-
NEDD4-L antibodies (Figure 4.12 A). The predicted size of the putative T. spiralis 
NEDD4-L is 96 kDa. In T. spiralis SP, a strong band was observed between 55 and 
70 kDa. Reactivity at the same size was observed in the T. spiralis lysate, although an 
additional larger band (just below 100 kDa) was also observed. In HEK lysate, a band 
was observed at an expected size of human NEDD4-L of approximately 100 kDa, 
however 2 additional bands were also observed, one corresponding to the reactive 
band in T. spiralis secreted proteins. Considering that the reactivity in T. spiralis 
secreted proteins was so significant, and that thus far many potential mis-annotations 
in the T. spiralis draft genome had been experienced, the source of the reactivity with 
the anti-NEDD4-L antibody was further investigated. This was done using a method of 
protein fractionation called 'salting out'. 
The solubility of a protein is dependent on the salt concentration of its solvent. Once 
the salt concentration has reached the critical concentration for a particular protein 
with a particular hydrophobicity profile, the protein will precipitate by 'salting out' of the 
solution. Proteins in a mixture can therefore be separated (or fractionated) by 
incrementally increasing the salt concentration of the solution step by step. The 
precipitate is then recovered at each step. This method was used to fractionate T. 
spiralis secreted proteins using a saturated ammonium sulphate solution. Precipitated 
secreted protein fractions were re-solubilised in aqueous buffer, and separated by 
SDS-PAGE. Proteins were analysed by immuno-blot using the anti-NEDD4-L antibody 
described above. This method was repeated a number of times to narrow down the 
range of ammonium sulphate salt concentration required to precipitate the anti-
NEDD4-L-reactive proteins (data not shown). Once optimised, 500 µg of T. spiralis 
secreted proteins was fractionated at the appropriate concentrations of ammonium 
sulphate). A small portion of each of these fractions was analysed by immuno-blot 
using anti-NEDD4-L (Figure 4.12 C). The secreted proteins alone (20 µg) were 
analysed in parallel as a positive control, showing now 3 reactive bands between 50 
and 70 kDa. Of the three reactive bands, the largest and smallest were found to 
precipitate out of a solution of 34% ammonium sulphate, and the smallest again at 
44%. The middle band was found to precipitate in every fraction between 64% and 
80% ammonium sulphate (Figure 4.12 C).  
T. spiralis secreted proteins were then precipitated using 34%, 44% and 69% 
ammonium sulphate. Precipitated fractions were separated by SDS-PAGE and 5% 
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was analysed by immuno-blot using anti-NEDD4-L, and 95% was visualised by silver 
staining (Figure 4.12 D). The immuno-blot was used as a guide to manually excise 6 
protein bands from the silver-stain gel that contained the anti-NEDD4-L-reactive 
proteins. These proteins were then analysed by LC/MS/MS and peptide data was 
searched against all annotated T. spiralis proteins using SEQUEST. Eric Spooner at 
the Whitehead Institute, Boston, carried out LC/MS/MS and SEQUEST analyses. No 
peptides from any of the 6 bands, matched the putative T. spiralis HECT domain 
protein GI: 339253068, the NEDD4-L orthologous sequence (appendix 3). Although 
putative T. spiralis protein matches were made, none of these protein sequences 
contained HECT domains when further analysed by BLAST and SMART.  
WolfPSORT predicted many T. spiralis ubiquitin-proteasome components to be 
secreted, including the putative ubiquitin ligase TsNEDD4L. Because it was not 
possible to experimentally verify the secretion of TsNEDD4L using the fractionation 
and immuno-blot technique, this method was not continued. 
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Table 4. 4 Ubiquitin-related T. spiralis proteins predicted to be secreted by wolfPSORT 
Table shows the ubiquitin-related proteins (containing conserved ubiquitin interaction domains) 
that were predicted by wolfPSORT to be most likely located extracellularly. Commercially 
available antibodies were found for testing 2 of these T. spiralis proteins for secretion 
(highlighted in yellow). 
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Table 4. 5 Antibodies to ubiquitin-related proteins predicted to be secreted by T. spiralis 
Commercially available antibodies that are likely to cross-react with the putative T. spiralis E3, 
NEDD4-L and the putative T. spiralis WDR48 protein. 
Chapter 4: Results  
 165 
 
Figure 4. 12 Analysis of the secretion of NEDD4-L and WDR48 by T. spiralis 
The secreted proteins (SP) of T. spiralis muscle larvae, T. spiralis lysate, and human (HEK) 
cell lysate were analysed by immuno-blot (IB) for reactivity with anti-NEDD4-L antibodies (A) 
and anti-WDR48 antibodies (B). (a) The predicted size of the T. spiralis protein, (b) the 
expected size of the human protein and (c) the observed size of the signal in T. spiralis SP. C. 
Gradient ammonium sulphate (NH)4SO4 precipitation (fractionation) of the secreted proteins of 
T. spiralis muscle larvae. Fractions were separated by SDS-PAGE and analysed by immuno-
blot using anti-NEDD4-L antibodies. Three reactive bands were observed (1, 2 and 3). The 
fractionation by precipitation using 34%, 44% and 69% (NH)4SO4 (circled in red) was scaled up. 
D. Of each fraction, 5% was analysed by immuno-blot using anti-NEDD4-L antibodies, and 
95% was analysed by silver staining. The anti-NEDD4-L signal was lined up with proteins of 
the silver-stained gel. These 6 areas were manually excised (red boxes) for analysis by 
tandem mass spectrometry (LC/MS/MS) by Eric Spooner (Whitehead Institute).
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4.8.	  Proteomic	  analyses	  of	  all	  T.	  spiralis	  secreted	  proteins	  by	  tandem	  mass	  
spectrometry 
 
Thus far, a number of different methods were used to try and identify the proteins 
responsible for the E2 and E3 activity detected in T. spiralis secreted proteins by a 
ubiquitin conjugation assay. None of these methods however proved successful. It 
was therefore decided that the total secreted proteins would be analysed by tandem 
mass spectrometry (LC/MS/MS), and the data would be searched for conserved E2 
and E3 domains.  
T. spiralis muscle larvae were isolated from infected skeletal muscle tissues. Larvae 
were washed multiple times to remove host muscle tissue. When T. spiralis muscle 
larvae die, they become uncoiled and float in culture media. Larvae that are alive 
readily sediment. It is therefore possible to remove dead parasites from a mixture. 
Dead larvae were removed from live larvae to prevent non-secreted proteins being 
released from dead or dying parasites. To ensure a low level of parasite death, larvae 
were cultured for 24 hours only, before the culture supernatant was collected. Day 1 
secreted proteins were purified from the culture supernatant. A large proportion of T. 
spiralis secreted proteins are modified with sugar moieties (glycosylations). The 
dominant moiety on T. spiralis secreted proteins is called tyvelose [294-296]. Muscle 
larvae SP (50 ug) were therefore subjected to treatment with the deglycosylating 
enzyme PNGaseF to remove all N-linked glycosylations from glycoproteins to obtain 
more clarity of the actual size of a protein by SDS-PAGE. Deglycosylated SP were 
separated by SDS-PAGE, alongside 10 ug of untreated, glycosylated proteins, under 
conditions compatible for LC/MS/MS (Figure 4.13 A). The entire lane of proteins was 
manually excised from the gel and dissected as annotated in Figure 4.13 A. Each mid-
section (numbered) portion was analysed by highly sensitive LC/MS/MS. Mass 
spectrometry was carried out by Steve Gygi and Michael Weekes at the Harvard 
Medical School, Boston. Data was then searched against the T. spiralis UniProt 
proteome, its reverse complement and common contaminants of SDS-PAGE and 
mass spectrometry. Matches were made to all of the T. spiralis putative secreted 
proteins identified during a previous study of the T. spiralis secretome by Robinson et 
al. however many additional new matches were also made [196]. Because the larvae 
were isolated from rat muscle tissue, peptides were also searched against the rat 
proteome, and only 3 matches to rat proteins were made. Data was consistent with 
previous T. spiralis secreted protein data found in the literature. For example, the 
most abundantly secreted protein according to this study was analysed by BLAST. It 
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was found to match putative T. spiralis nudix hydrolase enzymes, and so may be 
related to the 5’ nucleotidase (5'NT) enzyme previously characterised by Gounaris et 
al. to be an abundant secreted protein [197].  
Matches were made to 3 ubiquitin-related proteins, shown in Table 4.6. The first 
match, the ‘Ubiquitin family member protein (fragment)’ is the putative T. spiralis Ub 
protein orthologue, which is labelled as a fragment because the annotated sequence 
contains a single (mono) Ub followed immediately by a fragment of another Ub whose 
sequence is incomplete (Uniprot: E5RYP1, GI: 339233028). In many organisms, 
tandem Ub genes exist, where Ub is transcribed in tandem and later hydrolysed by 
DUBs to form mono-ubiquitin [297-299]. This fragment sequence may therefore 
represent an incomplete version of the T. spiralis tandem Ub coding sequence, since 
the annotation was generated from contig scaffolds of the T. spiralis genome. 
Peptides matching this sequence were found in all segments of the gel except number 
3 (Figure 4.13 A). This reinforces the evidence presented in Figure 4.6 that shows 
how T. spiralis proteins are secreted with ubiquitin attached. 
The second match was orthologous to the RING finger domain protein (E3) RNF13 
(Uniprot: E5S4Y0, GI: 339237319) and has a predicted size of 58 kDa. The human 
orthologue of RNF13 is a protein that is found in the membranes of the ER, the golgi, 
the nucleus and lysosomes. Human RNF13 is a RING finger protein that has Ub 
ligase (E3) activity and has been linked to cancer development of pancreatic cells 
[300]. When analysed by BLAST, it was found that the domain architecture of the 
Trichinella spiralis putative open reading frame was slightly different to the consensus 
structure of the orthologues. The T. spiralis sequence contains both an N-terminal 
extension and a C-terminal extension that are not present in the orthologous 
sequences (Figure 4.13 C). The extended Trichinella spiralis N-terminal region 
contains an extra domain that is not present in the orthologues. This is an MIR 
domain, which stands for Mannosyltransferase Inositol 1,4,5-trisphosphate receptor 
(IP3R) and Ryanodine receptor (RyR). There are 3 types of protein in which the MIR 
domain has been found and there are therefore multiple different functions associated 
with these domains [301,302]. Peptides matching the putative TsRNF13 sequence 
were found in segment 2 of the gel, corresponding to a molecular weight of 20-30 kDa 
(Figure 4.13 A). 
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Figure 4. 13 Proteomic analysis of T. spiralis secreted proteins 
A. 50 ug of day-1 secreted proteins (SP) of T. spiralis muscle larvae were treated with the 
deglycosylating enzyme PNGaseF to remove glycosylations, 10 ug were not deglycosylated. 
These samples were separated by SDS-PAGE and the areas (boxed in blue and numbered) 
were manually excised and analysed by tandem mass spectrometry (LC/MS/MS) by Michael 
Weekes and Steve Gygi (Harvard Medical School). B. A separate experiment was carried out 
where 60 ug of day-1 SP (not treated with PNGaseF) was separated by SDS-PAGE. The 
areas boxed in blue and numbered were analysed by LC/MS/MS. Two ubiquitin-related 
enzymes were identified in the bands indicated (red boxes) in both gels, the putative T. spiralis 
RNF13 (E3) and the putative T. spiralis UBE2L3 (E2). C. Schematic of the structure of the 
putative TsRNF13 and (D) the putative TsUBE2L3 showing the conserved domains and their 
locations within each sequence. 
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Table 4. 6 Ubiquitin-related proteins identified by the proteomic analysis of T. spiralis 
secreted proteins 
Table shows 3 ubiquitin-related proteins that matched peptides identified by LC/MS/MS in 
each separate analysis of the day-1 secreted proteins of T. spiralis muscle larvae. Unique 
peptides did not match any other T. spiralis protein. 
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When analysed by localisation prediction programmes, the following results for the 
putative TsRNF13 were:  
signalP: yes - signal peptide 
iPSORT: yes - signal peptide 
wolfPSORT: plas: 20.0, extr_plas: 15.5, extr: 9.0 
WolfPSORT analysis indicates that the plasma membrane is the most likely location 
for the protein, but that it also contains motifs orthologous to proteins that are 
secreted. SignalP and iPSORT also predict a signal peptide. This may be a signal for 
translocation to a plasma membrane or for secretion. SMART also predicts that the 
protein contains a mid-sequence single transmembrane domain (Figure 4.13 C). 
Another protein domain prediction programme, InterPro, predicts that the N-terminal 
half (containing the MIR domain) may be non-cytoplasmic, whereas the C-terminal 
half (containing the RING domain) may be cytoplasmic.  
The final ubiquitin-related match was a putative protein annotated as a ‘Ubiquitin-
conjugating enzyme E2 L3 (Fragment)’ that has a predicted size of 17 kDa. This 
sequence is an incomplete open reading frame for a UBE2L3 orthologue (Uniprot 
E5S8T6, GI:339240047). UBE2L3, also known as UbcH7 or E2-F1, is a UBCc domain 
ubiquitin conjugating enzyme (E2, [65,303]). The annotated fragment open reading 
frame for TsUBE2L3 is 145 amino acids long and lacks a start codon. The UBCc 
domain of the putative TsUBE2L3 spans the fragment from the first amino acid to the 
140th amino acid (Figure 4.13 D). Peptides matching the putative TsUBE2L3 were 
also found in segment 2 of the gel (Figure 4.13 A). 
When analysed by localisation prediction programmes, the following results for the 
putative TsUBE2L3 were:  
signalP: no signal peptide 
iPSORT: no signal peptide 
wolfPSORT: cyto: 23.0, pero: 3.0, extr: 2.0, nucl: 2.0  
To validate these findings, the experiment was repeated using an even more sensitive 
method of LC/MS/MS (again, carried out by Steve Gygi and Michael Weekes). Day 1 
SP was collected and concentrated as described for the first experiment. This time 
however, proteins were not treated with PNGaseF. This was to minimise protein 
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degradation that can occur during the long incubation at 37°C with PNGaseF. The 
secreted proteins were separated by SDS-PAGE, but in this experiment the running 
time was reduced, to ensure that even the smallest proteins were retained in the gel. 
Efforts to prevent contamination of the gel were also increased. Figure 4.13 B shows 
how the gel was divided up for LC/MS/MS. Again, peptides were identified and 
searched against the T. spiralis protein database using SEQUEST. In total, a smaller 
number of peptides were identified than in the first experiment. Peptides from both the 
first and second experiment were then combined and assembled into proteins. A good 
level of agreement in protein matches was observed (all data can be found in the 
supplementary appendix 4). A total of 333 T. spiralis proteins were identified, of which 
5 are likely to be false positive results or proteins released from dead and dying 
parasites. It is likely that the false positive results are proteins from which only 1 
peptide was identified. Less than 1% of the protein matches were rat proteins, 
demonstrating a clean isolation of the muscle larvae from host muscle tissue. 
Both the putative TsUBE2L3 and the TsRNF13 were identified again in the second 
experiment. More peptides matching the TsUBE2L3 were identified in the second 
experiment than the first. Less peptides matching the TsRNF13 were identified in the 
second experiment than the first. Each protein matched unique peptides, i.e. peptides 
that did not match any other protein. Peptides matching the TsUBE2L3 were all found 
in segment 2 of the second gel, and peptides matching the TsRNF13 were found in 
segment 3 of the second gel. Peptides that matched other proteins as well (to a lesser 
extent) are referred to as razor peptides. In total from both sets of data, 6 unique 
peptides and no razor peptides matched the TsUBE2L3, and 5 unique peptides and 
no razor peptides matched TsRNF13 (Table 4.6). The peptide coverage of the 145 
amino acid sequence of TsUBE2L3 was 22.8%. The coverage of the 525 amino acid 
sequence of TsRNF13 was only 2.5% (Figure 4.13 C and D). When cross-referenced 
with the bioinformatics analyses, both proteins were predicted by wolfPSORT to be 
located extracellularly.  
All T. spiralis sequence matches labelled as ‘uncharacterised’ were further analysed 
using BLAST and SMART, and no other ubiquitin-proteasome-related proteins were 
identified. At this point, the putative TsUBE2L3 and the putative TsRNF13 were 
therefore the only proteins identified by LC/MS/MS that could be attributed to the E2 
and E3 activity observed in T. spiralis secreted proteins. The purpose of experiments 
presented in chapter 5 was to then validate the secretion of these proteins and 
characterise their function. 
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Summary 
 
4.1. The Ub-based inhibitor probe, HA-Ub-VME was produced and purified and its 
reactivity with DUB enzymes was verified using 6His-TsUCH37. 
4.2. Although no deNeddylating activity was detected in T. spiralis secreted proteins 
using FLAG-Nedd8-VS, potential cysteine-dependent activity could be detected using 
HA-Ub-VME. When further analysed using HA-Ub-VME followed by LC/MS/MS, no 
DUB activity could be detected. 
4.3. The lack of deubiquitinating and deNeddylating activity was verified using AMC 
conjugates of Ub and Nedd8. 
4.4. The production of Ub-based inhibitor probes designed to have a higher affinity for 
ubiquitin conjugation enzymes (E1, E2 and E3), was unsuccessful. 
4.5. T. spiralis secreted proteins demonstrated E2 and E3 activity as measured by an 
in vitro ubiquitin conjugation assay. 
4.6. Bioinformatics analysis of T. spiralis annotated proteins identified 130 putative 
ubiquitin-proteasome proteins that were predicted to have an N-terminal signal 
peptide or be located extracellularly. 
4.7. T. spiralis secreted proteins reacted with an antibody raised against a human 
orthologue of a T. spiralis E3 protein predicted to be located extracellularly, NEDD4-L. 
LC/MS/MS however could not confirm the presence of this protein in the secreted 
proteins. 
4.8. Candidates for E2 and E3 activity in the secreted proteins were identified by 
LC/MS/MS, a putative T. spiralis UBE2L3 and a putative T. spiralis RNF13. 
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Discussion	  
 
Experiments in chapter 4 set out to determine whether or not the secreted proteins of 
T. spiralis muscle larvae possess activities of ubiquitin-proteasome system enzymes. 
The investigation began by looking for DUB and deNeddylating activity in T. spiralis 
secreted proteins and this could not be identified. Experiments were then designed to 
look for ubiquitin conjugation activity. 
Initially, production of the Ub-based inhibitor probe, HA-Ub-VME was carried out. 
Expression of the precursor of the inhibitor probe HA-Ub-intein/CBD, and purification 
of HA-Ub-MESNa was successful, however the final yield of purified active HA-Ub-
VME was low. It is possible that some probe may have been lost during ion exchange 
chromatography due to inefficient binding to the column. Although purified active 
probe was detected, some of the fractions collected after ion exchange 
chromatography contained probe of an expected size that was not fully active. The 
VME warhead that eventually forms the covalent bond with the ubiquitin enzyme 
(DUB) contains an ester bond; a chemical group that is sensitive to both acid and 
base catalysed hydrolysis (Figure 4.14 A). Hydrolysis of the VME ester bond could 
occur either before or after ligation with the protein, and in both cases would render 
the probe less active and less able to react with DUBs. In addition, the HA-Ub-MESNa 
could degrade thus preventing ligation, and also reducing the final yield of active 
probe. For future optimisation of yield and activity, buffer conditions during ion 
exchange chromatography and ligation conditions would have to be further 
investigated. Because active inhibitor probes have an extremely high affinity for DUB 
enzymes, a sufficient volume of active HA-Ub-VME was collected for my experiments 
and these issues were not investigated here.  
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Figure 4. 14 The degradation of warheads used to make Ub-based inhibitor probes 
All probe warheads have ester bonds that can hydrolyse under acidic or basic conditions, 
either before or after ligation with the HA-Ub-MESNa. Each warhead reacts differently with the 
sulfhydryl group (SH) of the cysteine of the ubiquitin-specific enzyme. These reactions are not 
necessarily through reaction with the ester bond of the warhead. The diagram shows the 
mechanism of reactivity with a cysteine and the mechanism of the possible hydrolysis, which 
for VME (A) renders the warhead less reactive and for (B) TF3BOK and (C) Lac, renders the 
warheads completely inactive. Curly arrows indicate the movement of an electron pair. Image 
modified from drawings supplied by Jennifer Ward. 
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Although no deNeddylating activity was observed using FLAG-Nedd8-VS, Using HA-
Ub-VME it was not clear if DUB activity was present. By immuno-blot there were some 
suggestions of probe-protein complexes forming. For this reason, the HA-Ub-VME 
reaction with the secreted proteins was scaled-up for a more in-depth analysis. 
Despite 2 biological repeats, LC/MS/MS could not detect any putative T. spiralis DUBs 
in the proteins excised from the gel. Areas of the gel to be excised were selected for 
analysis based on the visual appearance of a band in the NEM-negative sample only. 
Being subjective, this process may not have been exhaustive, and DUBs may have 
been missed. Furthermore, a large number of T. spiralis secreted proteins were 
immuno-precipitated from both the NEM-negative and -positive samples. These 
proteins may have been non-specific contaminants, proteins able to specifically react 
with the probe in a cysteine-independent manner, or probe aggregates. It was 
possible that their LC/MS/MS signal masked signals from any DUB-probe complexes 
present.  
Interestingly, LC/MS/MS did identify 3 ubiquitin-related proteins. One of these was 
ubiquitin itself, the source of which could have been from the probe or from 
ubiquitinated T. spiralis secreted proteins. The second was the putative T. spiralis E2 
UBE2N, however peptides matching this protein were only identified after one of 2 
experiments. They were found in a region of the coomassie-stained gel that did not 
correspond with the size of TsUBE2N in complex with the probe (which would be 
approximately 20 + the 11 probe (31) kDa if the annotation is correct). TsUBE2N was 
not predicted to be secreted by bioinformatics analysis, and although the anti-human 
UBE2N that was tested reacted with T. spiralis proteins in lysate of muscle larvae, it 
did not react with T. spiralis secreted proteins. Taken together, results suggest that it 
is unlikely that TsUBE2N is truly secreted by T. spiralis muscle larvae. It is possible 
that the protein was present as a contaminant released from dead or dying parasites, 
as the secreted proteins were collected after T. spiralis larvae had been cultured for 4 
days by which time a significant reduction in viability is observed.  
The final ubiquitin-related match, an RWD domain protein characterised throughout 
the literature as the 53 kDa excretory-secretory T. spiralis antigen (GI: 805126) was 
also dubious. The 53 kDa excretory-secretory T. spiralis antigen does not contain an 
RWD domain, which is the only ubiquitin-related domain in the sequence. Without the 
RWD domain, it is not clear how it would interact with the Ub of the HA-Ub-VME probe. 
It is therefore unlikely that this protein is transcribed and secreted as annotated, or 
that the annotation is incorrect. To confirm this it would be necessary to carry out 
RACE-PCR and find the true open reading frame of this gene. 
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Thus far, no conclusion could be reached on whether or not T. spiralis muscle larvae 
secrete deubiquitinating or deNeddylating enzymes. In the case of Nedd8 the lack of 
activity with the probe may have been due to differences between the human and T. 
spiralis Nedd8 sequences, and the failure of T. spiralis deNeddylating enzymes to 
recognise the human Nedd8-based probe. To clarify these points, AMC assays were 
carried out. Although lysate of T. spiralis muscle larvae was able to hydrolyse Ub-
AMC and Nedd8-AMC, confirming an ability to interact with the human orthologues, T. 
spiralis secreted proteins were not able to hydrolyse either the Ub or the Nedd8. It 
was therefore concluded that, using the available reagents, no DUB or deNeddylating 
activity could be detected in the T. spiralis secreted proteins. It is therefore unlikely 
that these enzymes are secreted by the parasite.  
Because pathogenic viruses and bacteria express ubiquitin conjugation enzymes (as 
well as DUBs), I next wanted to look for E1, E2 and E3 enzymes in T. spiralis 
secreted proteins. These enzymes ligate more readily with Ub-based inhibitor probes 
that contain more electrophilic warheads [277]. This is possibly due to the increased 
nucleophilicity of the catalytic cysteine of the enzymes, compared to DUB and 
deNeddylating enzymes. Of the warheads previously reported, TF3BOK and Lac 
exhibited reactivity with a diverse list of E1, E2 and E3 enzymes from lysates of 
mouse lymphoma (EL4) and human mammary epithelial cell (HMLE) cells [277]. 
These were therefore chosen for testing the T. spiralis secreted proteins for E1, E2 
and E3 activity.  
Production of the HA-Ub probe, with both the TF3BOK or Lac warheads was 
problematic. When synthesised, the warheads are in a slightly acidic state, in which 
they are more stable. When transferred to the conditions required for ligation (pH 8), 
warhead degradation was significant. This may have been due to hydrolysis of the 
ester bond of the warhead that can undergo acid or base catalysed hydrolysis as 
described earlier for HA-Ub-VME. In these cases, hydrolysis of the warhead at pH 8 
may be happening more rapidly than the ligation reaction with HA-Ub-MESNa (Figure 
4.14). It is also possible that the ligation event occurred, and the warhead underwent 
hydrolysis later, leaving degraded HA-Ub-TF3BOK, or HA-Ub-Lac. When VME is 
degraded its activity is reduced but when TF3BOK and Lac are degraded the 
warheads are rendered completely inactive and can no longer react with target 
proteins. This made their production more problematic than the HA-Ub-VME probe. 
Although Love et al. detected E1, E2 and E3 enzymes using these probes, they were 
not originally designed to specifically capture E1, E2 and E3 enzymes. Ub-based 
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inhibitor probes were designed so that the active-site cysteine of a DUB enzyme 
reacts with the C-terminal end of the probe, thus reacting with the warhead and 
becoming trapped. Conversely, there is some evidence that during ubiquitin 
conjugation, the active-site cysteine of E1, E2 and E3 enzymes doesn’t react with the 
C-terminal residues of Ub, rather with mid-sequence residues of Ub [304,305]. This 
would mean that although ubiquitin conjugation enzymes are able to recognise the Ub 
component of the probe, the cysteine residue of the enzyme that then becomes 
covalently bound to the probe is not the active-site cysteine. This may explain the 
reduced affinity of Ub-based probes with ubiquitin conjugation machinery. Considering 
this, and considering the problems experience with the production of these probes, 
this method was not continued.  
The next experiment, an in vitro ubiquitin conjugation assay, confirmed that T. spiralis 
secreted proteins were not able to ubiquitinate substrate proteins when supplemented 
with the human E1 alone. Interestingly however, ubiquitin conjugation activity was 
observed when T. spiralis secreted proteins were supplemented with either the human 
E2, UBE2L3 or the human E3, parkin. This confirmed that T. spiralis proteins can 
interact with the human E1 which shares 45.7% of residues with the T. spiralis 
putative E1 (GI: 339234521). Although in the presence of UBE2L3, parkin can 
undergo auto-ubiquitination, the T. spiralis secreted proteins also contain hundreds of 
theoretical ubiquitination substrates [306,307]. And since the signal being measured 
was the biotin labelled ubiquitin, the source of the observed signal may not 
necessarily be from auto-ubiquitination of the parkin. Where the secreted proteins 
were supplemented with the human E2 (UBE2L3) and the E1 only (no parkin E3), 
substrates will always be the T. spiralis secreted proteins themselves, unless the E2 
can also auto-ubiquitinate in the presence of T. spiralis secreted proteins. Where the 
secreted proteins were supplemented with the human parkin and the E1 only (no 
UBE2L3), the signal may represent the auto-ubiquitination of the parkin or the 
ubiquitination of the T. spiralis secreted proteins themselves. In conclusion, T. spiralis 
proteins have E2 activity and E3 activity, and are not able to ubiquitinate amongst 
themselves in vitro, but are able to collaborate with the human proteins UBE2L3 and 
parkin. This has very interesting implications, considering that the secreted proteins 
come into contact with host proteins during infection. I hypothesise that these 
enzymes are specifically secreted to only ubiquitinate when in contact with the host 
partner enzyme, and to therefore directly interact with a host ubiquitin-proteasome 
system.  
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The purpose of the follow-up investigation was to confirm the identity of the secreted 
proteins that possess E2 and E3 activities. To try and predict this, the bioinformatics 
programmes iPSORT, wolfPSORT and signalP were used to analyse all annotated T. 
spiralis proteins. In total, 9291 putative T. spiralis proteins were predicted, by one or 
multiple programmes, to have an N-terminal signal peptide or be located 
extracellularly (the sum of all prediction combinations listed in Table 4.3). From 
previous reports and experimental experience, there are possibly a few hundred 
proteins secreted by T. spiralis muscle larvae [196,308-311]. I propose 2 main 
reasons for this vast discrepancy: 
1. T. spiralis secrete proteins at all stages of their life cycle, and these proteins will be 
differentially expressed [115]. Undoubtedly the secreted proteins required for each 
stage will vary, and so for each few hundred proteins secreted at each stage, 
combined, a few thousand may be secreted throughout the entire life cycle.  
2. N-terminal signal peptides do not only target proteins for secretion, but also target 
transmembrane proteins to their membrane destination. They may also serve as 
signals that target proteins to intracellular organelles, such as mitochondria, 
peroxisomes, lysosomes and the nucleus. Many T. spiralis proteins will fall into these 
categories, giving a false positive iPSORT and/or signalP score. Conversely, some T. 
spiralis proteins are secreted without a signal peptide, via an unconventional system 
of secretion that is not well-understood [312]. These proteins would therefore give a 
false negative iPSORT and/or signalP score. 
Proteins predicted to be secreted were therefore analysed based on their wolfPSORT 
score only, and not on their signalP and iPSORT score. These proteins were then 
analysed to isolate only those whose function was annotated as being involved in the 
ubiquitin pathway. 130 sequences were identified. These were further analysed to 
isolate 13 ubiquitin-related sequences whose wolfPSORT score of ‘extracellular’ was 
the highest. Commercial antibodies to 2 of these 13 proteins looked likely to cross-
react with the T. spiralis sequence and so T. spiralis secreted proteins was tested for 
reactivity. Only the anti-NEDD4 antibody reacted with T. spiralis secreted proteins. 
However, LC/MS/MS analysis of the reactive bands from T. spiralis secreted proteins, 
did not return any NEDD4-L matches. It is possible that the signal observed 
represented proteins that are able to non-specifically bind to the antibody, and this 
would explain the size discrepancy. Alternatively, it is possible that the NEDD4-L 
protein was present, but masked by more abundant secreted proteins of a similar size, 
thus failing to be detected by LC/MS/MS. At large, these techniques were not 
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considered fruitful for verifying the identity of the T. spiralis secreted proteins with E2 
and E3 activity.  
In the final attempt to find the enzymes with E2 and E3 activity, LC/MS/MS analysis of 
total T. spiralis secreted proteins was carried out. In 2005 Robinson et al. reported 2D 
electrophoresis and proteomic analysis by MALDI-TOF-MS and LC/MS/MC of 
selected abundant T. spiralis secreted proteins [196,309]. Since then, techniques in 
tandem mass spectrometry have developed and are much more sensitive. Robinson’s 
studies were not exhaustive, only selecting the most abundant proteins from a 2D 
SDS-PAGE gel. Furthermore, in 2005 the available database for matching T. spiralis 
peptides was composed of expressed sequence tag sequences (NCBI dbEST), 
whereas the annotated draft genome (containing structural and functional annotation 
where possible) is now available [232]. Earlier experiments suggested that after 4 
days of culture, proteins from dead or dying larvae might be release into the culture 
supernatant, thus contaminating the secreted proteins. For this reason, methods were 
optimised to ensure that the vast majority of the secreted proteins collected for 
LC/MS/MS analyses were truly secreted, and that any protein released from dead or 
dying parasites was negligible. The experiment was also repeated to enhance the 
credibility of the data. In both experiments peptides matched the same 3 ubiquitin-
related proteins. Interestingly, both the TsUBE2L3 fragment open reading frame, and 
the putative TsRNF13 were also predicted by wolfPSORT to be located extracellularly. 
The mammalian orthologue of the putative E3 ligase RNF13 has a mid-sequence 
transmembrane domain that predominantly localises to the ER and golgi membranes. 
Proteases can cleave the protein from either side of the membrane, releasing either 
the N-terminal portion, which contains a PA domain or the C-terminal RING finger 
portion of the protein [313,314]. It is possible that the T. spiralis orthologue also 
undergoes a form of processing at the transmembrane domain, and that the resulting 
product is released and secreted at a smaller size than the full annotated sequence. 
This could explain why it was consistently found in a portion of the gel that did not 
correspond to its predicted size, suggesting a much smaller protein. It is also worth 
noting, that the peptides identified by LC/MS/MS only covered a small sequence at 
the N-terminus where there is an MIR domain but no RING finger domain. The RING 
finger domain is situated after the transmembrane domain in the C-terminal half of the 
protein. If the protease-processing theory was the true reason for the size discrepancy, 
then the cleaved, secreted portion of the protein would not contain the RING finger 
domain and therefore not be the protein responsible for E3 activity. 
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Peptides matching the E2 TsUBE2L3 were found in both experiments, in a region of 
the gel that would correspond to the predicted size of the protein. The annotated 
TsUBE2L3 sequence is a fragment of a full protein sequence, which translates to a 
protein of 17 kDa. Most orthologous UBE2L3 sequences that align with this fragment 
are proteins of 18 kDa, so it is possible that the fragment is very close to the full 
sequence anyway [65]. Interestingly, the human UBE2L3 was the human E2 used for 
the in vitro ubiquitin conjugation assay. Human UBE2L3 is an E2 partner for the 
human E3 parkin both in vivo and in vitro, and in collaboration with E1 they 
ubiquitinate the Parkinson’s disease-associated proteins synphilin-1 and alpha-
synuclein [306,315,316]. It is therefore plausible that the T. spiralis secreted protein-
derived UBE2L3, can also directly interact with the parkin E3 and the human E1 
during the in vitro ubiquitin conjugation assay, leading to the ubiquitination of 
substrate proteins as were observed by immuno-blot. 
Having identified TsUBE2L3 and TsRNF13 as the only candidates for the E2 and E3 
activity in the T. spiralis secreted proteins, I wanted to validate their secretion, and 
investigate their function. Chapter 5 describes the characterisation of these 
candidates and the functional analysis of the T. spiralis E2, TsUBE2L3.
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Chapter 4 describes how ubiquitin conjugation and ubiquitin ligation activity was 
discovered in the secreted proteins of T. spiralis muscle larvae. A putative T. spiralis 
E2 enzyme, UBE2L3 and a putative T. spiralis E3 enzyme, RNF13 were identified. 
The purpose of the experiments described in chapter 5 was to further characterise 
these secreted T. spiralis enzymes and understand their potential function in host-
parasite interactions during the infection of muscle cells by T spiralis. 
Background	  
 
A comprehensive description of the T. spiralis life cycle can be found in chapter 1 
(section 1.13). Briefly, after the ingestion of T. spiralis contaminated meat, larvae 
develop into adults in the small intestine of their new host. The adults reproduce, 
giving rise to newborn larvae that migrate through the intestinal wall and enter the 
circulation. Newborn larvae are transported in the circulation to skeletal muscle 
tissues, where they invade terminally differentiated skeletal myofibres [127]. The 
parasite does not kill the muscle cell, rather it forms a complex in which the parasite 
develops and the host cell is transformed. It is thought that the T. spiralis surface and 
secreted proteins communicate with the host cell to stimulate its re-entry into the cell 
cycle, thus reversing its differentiation state (dedifferentiation) [156,162,163,169,170]. 
  
A comprehensive description of myogenesis can be found in the chapter 1 (section 
1.14), however it is important to emphasise that there are very few examples in 
nature of terminally differentiated skeletal muscle cells that can dedifferentiate, or re-
enter the cell cycle. It is thought that the spontaneous regeneration of limbs by 
amphibians such as the newt, occurs via the dedifferentiation of terminally 
differentiated muscle cells [147,148]. However mammalian skeletal muscle 
dedifferentiation has only been observed in response to infection by SV40 and 
Polyoma viruses and during the in vitro manipulation of muscle cell cultures [149-
152] [153]. Indeed when T. spiralis newborn larvae invade host myofibres, this is 
exactly what happens. The larvae invade the cell without killing it. Once inside they 
begin to grow and develop into muscle larvae (L1 stage). During this time, the host 
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muscle myofibre begins to lose markers of muscle-specific terminal differentiation 
[131,156]. It also begins to up-regulate cell cycle factors and replicate DNA, in effect 
re-entering the cell cycle [158,159,162,165]. Although the host cell re-enters the cell 
cycle, it does not divide and becomes arrested in the G2/M phase [163]. This 
multinucleated cell has a unique identity, observed only in T. spiralis infection, and 
because it safely harbours the parasite until a chance for transmission occurs, it is 
referred to as a nurse cell. It is thought that these dramatic biological changes are 
induced by the parasite surface and secreted proteins, some of which enter the 
nuclei of the nurse cell [175,201,317]. Very few of these T. spiralis secreted proteins 
have been identified, and even fewer have been functionally characterised 
[197,202,203]. None have been assigned a mechanistic role in nurse cell 
development. 
The differential balance of specific proteins required during each phase of the cell 
cycle, relies heavily on the regulation of protein degradation, which in eukaryotes is 
predominantly controlled by the ubiquitin-proteasome system [52,318]. It is therefore 
conceivable that the ubiquitin-proteasome system plays a role in T. spiralis-induced 
cell cycle re-entry and dedifferentiation of host muscle cells. Chapter 4 presents 
evidence that the secreted proteins of T. spiralis muscle larvae contain ubiquitin 
conjugation and ligation activity. This activity was only observed when the secreted 
proteins came into contact with human ubiquitin conjugation and ligation enzymes, 
UBE2L3 and parkin. Candidates for this E2 and E3 activity were then identified in the 
secreted proteins of T. spiralis muscle larvae by tandem mass spectrometry. 
Orthologues of both ubiquitin pathway enzymes identified have been previously 
linked to the regulation of the cell cycle. The putative T. spiralis E2 is orthologous to 
UBE2L3 (also known as UbcH7, E2-F1, L-UBC, UbcM4), a nuclear and cytoplasmic 
ubiquitin conjugation enzyme that plays a role in polyubiquitination, cell cycle control 
and transcription [306,319-321]. Substrates of this E2 in mammalian systems include 
the tumour suppressor p53, the NFκB precursor p105, the inflammatory cytokine 
TNF (tumour necrosis factor) and the metabolic enzyme glyceraldehyde-3-phosphate 
dehydrogenase [66,67,322-324]. It was also shown to interact with a rabbit E3 ligase 
(E3L) leading to the ubiquitination of some muscle-specific proteins [325]. The 
putative T. spiralis E3 is orthologous to RNF13, a ring finger ubiquitin ligase found to 
be over-expressed in pancreatic cancer [326].  
The final aim of the project was therefore to confirm the identity of the proteins 
responsible for of the E2 and E3 activities, and to try and characterise their effect on 
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muscle cells. Chapter 5 describes how the coding sequences of the candidate E2 
and E3 enzymes were analysed using RACE-PCR. The function of the candidate E2 
enzyme was then investigated in a mammalian skeletal muscle cell line, C2C12 
whereby the effect of TsUBE2L3 on muscle cell morphology, protein synthesis, the 
cell cycle and proliferation was investigated.  
NB: Throughout the text, I use the term myofibre when referring to terminally 
differentiated muscle cells in vivo, and the term myotube when referring to terminally 
differentiated muscle cells developed in vitro. Thus, terminally differentiated C2C12 
cells are always referred to as myotubes. 
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Tandem mass spectrometry identified only 2 ubiquitin-related enzymes in the 
secreted proteins of T. spiralis muscle larvae, a putative T. spiralis E2 enzyme, 
UBE2L3 and a putative T. spiralis E3, RNF15. These proteins were therefore the 
only candidates for the in vitro ubiquitin conjugation and ubiquitin ligation activity 
observed in the T. spiralis SP.  
The putative T. spiralis E3 (TsRNF13) sequence was first aligned with the human 
orthologue for closer analysis, showing 21.6% identity (Figure 5.1 A). The putative 
RNF13 protein was identified during mass spectrometry by peptides covering only 
2.5% of the 525 amino acid sequence. These peptides did not match any of the 
conserved RING finger domain of the sequence as predicted by SMART [210,211]. 
To verify the secretion of TsRNF13 by T. spiralis muscle larvae, a search was carried 
out to find commercial antibodies that were raised against the mammalian orthologue 
that, based on identity between the immunogen sequence and the corresponding T. 
spiralis sequence, appeared likely to cross-react. Because of the low level of identity 
between the mammalian and T. spiralis orthologues, no commercial antibodies could 
be found to fit the criteria and so the secretion of the E3 enzyme by T. spiralis could 
not be verified. 
The putative T. spiralis UBE2L3 sequence however, contains 62.3% of the same 
residues as the human UBE2L3 (Figure 5.1 B). A commercial antibody raised against 
a region of the human protein that has a high identity with the T. spiralis protein was 
purchased. T. spiralis muscle larvae were isolated from infected muscle tissues as 
described (section 2.2, [116]) and cultured for 24 hours before the secreted proteins 
were collected and concentrated. Day 1 T. spiralis SP were analysed by immuno-blot 
using anti-UBE2L3 antibodies. T. spiralis muscle larvae lysate and human cell lysate 
(HEK 293T cells) were also reacted with the anti-UBE2L3 antibodies as positive 
controls (Figure 5.1 C).  
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Figure 5. 1 Analysis of the ubiquitin-related enzymes identified by the proteomic 
analysis of T. spiralis secreted proteins. 
A. Alignment of the putative T. spiralis (Ts) E3 (RNF13) protein sequence with the human 
(Hs) orthologue (homology and identity shaded in grey and dark grey respectively). The MIR 
domain is boxed in green, the transmembrane domain in blue and the RING finger (E3) 
domain in red. The peptide sequence identified by LC/MS/MS (highlighted in yellow) covered 
2.5% of the 524 amino acid sequence. B. Alignment of the putative T. spiralis (Ts) E2 
(TsUBE2L3, GI:316975361) fragment protein sequence with the human isoform 1 (Hs) 
orthologue. The UBCc domain is boxed in red. Peptide sequences identified by LC/MS/MS 
are yellow. Peptides covered 20% of the 145 amino acid sequence. The catalytic cysteine 
residue of the UBCc domain is marked with a star symbol. The immunogen sequence of the 
HsUBE2L3 against which anti-UBE2L3 antibodies were raised, is boxed in black. C. Anti-
UBE2L3 antibodies were reacted with the secreted proteins (SP) of day-1 T. spiralis muscle 
larvae, human (HEK) cell lysate and T. spiralis lysate by immuno-blot (IB). The same samples 
were reacted with anti-tubulin antibodies as a control for secretion.
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In the human cell lysate, one prominent band was observed in the human cell lysate, 
corresponding to the predicted size of the human UBE2L3 isoform 1 that weighs 17.9 
kDa [324]. In the lysate of T. spiralis muscle larvae, 2 prominent bands between 15 
and 25 kDa were observed. Other less prominent bands were also observed. In the T. 
spiralis SP, the most prominent band was observed between 15 and 25 kDa, 
matching the smaller band in the T. spiralis lysate, and the band in HEK cell lysate. 
In the T. spiralis SP, a second less abundant protein was observed just below the 
most prominent band that may have represented a partially degraded from of the 
larger protein. The fragment coding sequence of the putative TsUBE2L3 translates 
into a protein with a predicted molecular weight of 16.9 kDa, which would 
approximately correspond to the most prominent band observed in the T. spiralis SP. 
To test for proteins that might have been release from dead or dying larvae, i.e. not 
actively secreted, the samples were reacted with anti-tubulin antibodies that have a 
high affinity for both the human and the T. spiralis tubulin. Tubulin is a highly 
conserved structural protein that was not found during the proteomic analyses (by 
mass spectrometry) of T. spiralis SP presented in chapter 4. It would therefore only 
be present in the culture supernatant if released from dead or dying larvae.  
Both the mass spectrometry data presented in chapter 4, and the immuno-blot data 
presented here provide evidence for the expression and secretion of the TsUBE2L3 
by T. spiralis muscle larvae. This enzyme may be responsible for the E2 activity 
observed in T. spiralis SP. I therefore wanted to investigate the potential function of 
the E2 in T. spiralis SP, and the potential role for this function in the host-parasite 
interactions during the muscle stages of T. spiralis infection in mammals. To do so, I 
decided to clone the T. spiralis UBE2L3 gene for expression in mammalian muscle 
cells. It was therefore necessary to first confirm the coding sequence for this protein. 
This was done using the RACE-PCR method described in chapter 3 (section 3.1).  
5.2.	  Confirmation	  of	  the	  full	  coding	  sequence	  of	  TsUBE2L3	  by	  RACE-­‐PCR	  
 
Rapid amplification of cDNA ends by PCR (RACE-PCR) is a technique used to 
confirm the full sequence of a gene transcript by amplifying and sequencing the 5’ 
end of the transcript (containing the start codon) and the 3’ end of the transcript 
(containing the stop codon). Multiple attempts to amplify the coding sequence of the 
putative T. spiralis E3, RNF13, failed. Attempts were made to optimise methods until 
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it was concluded that the annotation of the sequence might be incorrect. It was 
therefore not possible to confirm the coding sequence of the T. spiralis E3 candidate 
and, since its secretion could not be verified either, studies continued to focus on the 
T. spiralis E2, TsUBE2L3. 
The annotated coding sequence for TsUBE2L3 exists as a fragment, with a missing 
portion at the 5’ end that does not contain a start codon. The human orthologue of 
UBE2L3 has 3 isoforms, isoform 1 (GI: 373432685, 465 bp, 154 aa, 17.9 kDa) 
isoform 3 (GI: 373432681, 369 bp, 122 aa, 14.1 kDa) and isoform 4 (GI: 373432683, 
639 bp, 212 aa, 24 kDa), although in mice it is thought that isoform 3 and 4 function 
as pseudogenes [327] (Figure 5.2 A). The most abundant protein in HEK 293T cells 
corresponded to the size of isoform 1 at approximately 18 kDa (Figure 5.1 C). The 
human orthologue of UBE2L3 can also be modified with both poly and monoubiquitin 
and is itself degraded by the proteasome (appendix 4) [320,324]. In T. spiralis lysate, 
signals from proteins of 2 distinct sizes were observed during immuno-blot using anti-
UBE2L3 antibodies (Figure 5.1 C). These bands may represent different isoforms of 
the T. spiralis protein or, if the regulation of UBE2L3 by ubiquitination is conserved in 
T. spiralis, may represent ubiquitinated forms of the protein. The full transcript 
sequence expressed by T. spiralis muscle larvae had to be experimentally confirmed 
by RACE-PCR before cloning could be carried out. 
Total RNA was extracted and purified from T. spiralis muscle larvae using Trizol and 
general methods of phenol/chloroform precipitation. Primers for RACE-PCR were 
designed based on the region of the TsUBE2L3 sequence where peptides were 
identified during mass spectrometry of T. spiralis SP. A gene-specific reverse primer 
(GSRP) was designed to amplify the 5’ end, and a gene-specific forward primer 
(GSFP) was designed to amplify the 3’ end (Figure 5.2 and 5.3 respectively). RACE 
was then carried out using the FirstChoice RLM-RACE kit from Ambion and the 
GeneRacer kit from Life Technologies. T. spiralis RNA was processed as instructed 
by the manufacturer and reverse transcribed to cDNA before undergoing 2 rounds of 
nested PCR using the RACE 5’ primers that anneal to the 5’ RACE oligo, paired with 
the gene-specific reverse primers, and the 3’ RACE oligo paired with the gene-
specific forward primers. PCR reactions were carried out using a Taq DNA 
polymerase enzyme that assembles sequences leaving an adenine DNA base 
overhang on each 3’ end of the complementary strands of the PCR product. PCR 
products were separated by agarose gel electrophoresis and visualised under UV 
light after incubation with ethidium bromide (data not shown). DNA bands that 
appeared to correspond with the potential size of the 5’ end fragment (based on 
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orthology with one of the 3 human HsUBE2L3 isoforms), and the potential size of the 
3’ end (based on the annotated TsUBE2L3 sequence), were manually excised from 
the agarose gel. DNA was purified from these bands and ligated into the 
pGEMTeasy cloning vector using methods of TA cloning. The pGEMTeasy vector 
containing the 5’ or 3’ DNA fragment insert was then sequenced by Beckman Coulter 
Genomics.  
The 5’ sequence matched the annotated fragment sequence, and continued 
upstream for 27 bases until an in-frame start codon (Figure 5.2 B). There was then 
another small sequence of 14 bases before the 5’ RACE oligo sequence began. This 
additional sequence aligned with a portion of the same T. spiralis contig sequence 
that the TsUBE2L3 fragment aligned with (contig scaffolds: ABIR00000000.2 [232]). 
This sequence may have represented a 5' untranslated region (5' UTR) of the 
transcript. The sequence that contained the start codon however, aligned much 
further upstream of the contig, suggesting a large splice site in between the 
annotated fragment sequence and the start site of this potential isoform of 
TsUBE2L3. This would explain the difficulty in predicting this gene during the draft 
annotation. The additional 14 bases of this sequence may represent a 5’ 
untranslated region of the transcript, or represent genomic DNA contamination 
(although no introns were present in the coding sequence). The RACE-PCR-
generated 5’ end sequence was aligned with the human sequence for HsUBE2L3 
isoform 1 (Figure 5.2 A), and many other orthologous sequences (data not shown). 
The RACE-PCR-confirmed start site aligned very closely with these orthologous 
sequences.  
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Figure 5. 2 RACE-PCR analysis of the 5’ end of T. spiralis UBE2L3 cDNA 
A. The RACE-PCR sequencing data (RACE-PCR sequence) of the 5’ end of TsUBE2L3 
cDNA aligned with the existing fragment annotated coding sequence. Figure shows the 
position of the RACE oligo, the RACE 5’ forward primer-binding site, the start site of the full 
coding sequence of the gene, the custom gene-specific reverse primer (GSRP)-binding site 
and the cloning vector (pGEMTeasy) sequences.  
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The 3’ end sequence was 100% identical to the annotated fragment sequence, 
including the predicted stop codon. Beyond this was additional sequence that, when 
analysed by BLAST, matched genomic DNA of T. spiralis possibly representing the 
3’ untranslated (UTR) region of the transcript. The full RACE-PCR-confirmed 
sequence, from start to stop, aligned very closely with these orthologous sequences 
(Figure 5.3 B). 
The entire RACE-PCR-generated sequence was matched by BLAST against the T. 
spiralis genome. The sequence was found to match the reverse strand of contig 
0.377. Contig 0.377 was then analysed by AUGUSTUS gene prediction software. 
AUGUSTUS can use informative constraints or ‘hints’ based on the gene 
arrangement in a given organism. When the contig is analysed using T. spiralis as a 
hint, a gene containing part of the RACE-PCR confirmed sequence is predicted. This 
sequence only partially aligns with UBE2L3 orthologues. Brugia malayi is a parasitic 
nematode responsible for lymphatic filariasis in humans. The predicted B. malayi 
UBE2L3 orthologous protein sequence shows 44.7% identity with the T. spiralis 
UBE2L3 (notably less than shared between the human and T. spiralis orthologues). 
When the contig is analysed by AUGUSTUS using Brugia malayi as a hint, 2 gene 
arrangements are predicted. The first and smallest aligns closely with the human 
UBE2L3 isoform 3, translating to a putative T. spiralis protein of 16.6 kDa. The 
second aligns closely with the human UBE2L3 isoform 1, translates to a protein of 18 
kDa and is exactly the same sequence identified by RACE-PCR (data not shown). 
The 2 gene arrangements may represent different T. spiralis UBE2L3 isoforms. 
Alignments of the RACE-PCR confirmed translated sequence with multiple protein 
orthologues, as well as the human isoform 1 protein sequence, showed that the start 
site of the protein was well conserved (Figure 5.3 B). This sequence was therefore 
taken as the true open reading frame for TsUBE2L3 as expressed and secreted by T. 
spiralis muscle larvae.  
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Figure 5. 3 RACE-PCR analysis of the 3’ end of T. spiralis UBE2L3 cDNA 
A. The RACE-PCR sequencing data (RACE-PCR sequence) of the 3’ end of TsUBE2L3 
cDNA aligned with the existing fragment annotated coding sequence. Figure shows the 
position of the RACE oligo, the RACE 3’ forward primer-binding site, the stop site of the full 
coding sequence of the gene, the custom gene-specific forward primer (GSFP)-binding site 
and the cloning vector (pGEMTeasy) sequences. The sequence contained a 3’ continuation 
after the stop codon that was identified as T. spiralis genomic DNA (gDNA). B.The annotated 
fragment (incomplete) coding sequence for TsUBE2L3 (GI:316975344) was aligned with the 
full RACE-PCR confirmed sequence from start to stop, compiled from both 5’ RACE-PCR and 
3’ RACE-PCR data, and with the human isoform 1, 3 and 4 UBE2L3 coding sequences. 
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  C2C12	  mouse	  skeletal	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  line	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  into	  myotubes	  
 
The next aim of the project was to investigate the potential role for the T. spiralis 
UBE2L3 protein in nurse cell formation during muscle stages of T. spiralis infection. 
To do so experiments were carried out to clone the confirmed open reading frame 
and express the protein in a mammalian skeletal muscle cell line. 
C2C12 is a mouse myoblast cell line often used as a laboratory model for studies on 
skeletal muscle cell biology. C2C12 myoblasts were cultured to confluency and 
induced to differentiate using differentiation media (low-serum media lacking in 
growth factors), where they were observed to fuse, forming large elongated 
myotubes that aligned in orientation, representing their successful differentiation in 
culture (Figure 5.4 A). Terminal differentiation of myoblasts into skeletal myotubes is 
characterised by the expression of muscle specific proteins such as the early 
differentiation factor myogenin and the late differentiation factor myosin heavy chain 
(MHC) [328,329]. To verify the differentiation of wild-type C2C12 myoblasts into 
myotubes, anti-myogenin and anti-MHC antibodies were reacted with C2C12 lysates 
by immuno-blot (Figure 5.4 B). Since there are at least 4 different types of MHC 
expressed in mammalian skeletal muscle cells, an antibody was used that reacts 
specifically with MHC IIx/2x. This protein is encoded by the MYH1 gene. Antibodies 
raised against tubulin were also reacted with the lysates as a loading control. Despite 
the expression of tubulin as expected, no myogenin expression was observed in 
undifferentiated C2C12 myoblasts. Both myogenin and MHC expression was 
observed in differentiated C2C12 myotubes, confirming the successful differentiation 
of C2C12 cells in culture using this method. 
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Figure 5. 4 Culture and differentiation of the C2C12 myoblast cell line 
A. C2C12 mouse myoblasts were successfully cultured and differentiated using 
differentiation media. After 4 days mature myotubes were observed. B. The immature state 
of the myoblasts was confirmed by immuno-blot (IB) using anti-myogenin (differentiation 
marker) antibodies. C. The differentiation of myotubes was confirmed by immuno-blot (IB) 
using anti-myogenin and anti-MHC (myosin heavy chain differentiation marker) antibodies. 
The same cell lysate samples were reacted with anti-tubulin antibodies as a protein loading 
control. 
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During infection, T. spiralis newborn larvae invade already terminally differentiated 
myofibres [330]. The larvae then develop into muscle stage larvae (L1 stage) inside 
the myofibre [162]. To understand the effect of the T. spiralis secreted proteins 
(specifically the effect of TsUBE2L3) on the muscle cell, it was necessary to study 
differentiated myotubes rather than undifferentiated myoblasts. Differentiated 
myotubes are in a state of cell cycle arrest and do not divide. It is therefore not 
possible to transfect these cells using conventional methods of cell transfection, 
which require cell division events to take up the vector DNA. Lentiviruses can infect 
and mediate the integration of DNA in both dividing and non-dividing cells such as 
terminally differentiated skeletal muscle cells [331]. For this reason lentiviral vectors 
were chosen for the genetic manipulation of C2C12 myotubes.  
Genetically modified lentiviruses can be produced to package genetic material of 
interest. The packaging process takes place in the packaging cell line HEK 293T 
(Figure 5.5 C). Inside the packaging cell, proteins required for the production of 
lentivirus particles are expressed, and the genetic material of interest is transcribed 
into mRNA. This mRNA is packaged inside the virus particle. Virus particles collected 
from the culture supernatant are then used to infect target cells and deliver the 
mRNA. This is reverse transcribed to DNA before being integrated into the genome 
of the cell for the stable expression of the gene of interest. This process of infection 
is called transduction (rather than transfection).  
The first lentiviral vector to be tested was the HIV-derived pCSGW tdTomato, kindly 
provided by Ilaria Nisoli and Hugh Brady (Imperial College). This (largely ‘home-
made’) vector was chosen because it contains the gene for the fluorescent reporter, 
tdTomato under the translational control of an internal ribosome binding site (IRES) 
sequence. An IRES sequence allows the initiation of transcription of the gene to be 
active at all times. The expression of the bright red fluorescent protein tdTomato, 
allows for visual confirmation that the genetic material packaged into the lentivirus 
has been successfully transduced. The RACE-PCR-confirmed coding sequence of 
TsUBE2L3 with a C-terminal haemagglutinin (HA) tag (18 kDa) was cloned into 
pCSGW (using NotI and BamHI restriction sites) downstream of the HIV LTR 5’ 
promoter sequence and upstream of the IRES tdTomato sequence (Figure 5.5 A) 
[332]. Lentivirus containing pCSGW tdTomato TsUBE2L3-HA RNA and lentivirus 
containing pCSGW tdTomato only RNA (empty vector control, Figure 5.5 B) was 
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produced in HEK 293T cells (Figure 5.5 C). C2C12 myoblasts were grown to 
confluency and induced to differentiate for 3 days using differentiation media. Half of 
the cells were transduced with the TsUBE2L3-HA virus and half of the cells were 
transduced with the empty vector control virus using polybrene and centrifugation to 
enhance transduction efficiency. After 72 hours (allowing time for infection, 
integration and expression) cells were observed using fluorescence microscopy. At 
both the packaging stage in HEK 293T cells (Figure 5.5 D) and the transduction 
stage in C2C12 myotubes (Figure 5.5 E), red fluorescence representing tdTomato 
expression was observed. Using pCSGW tdTomato transduction efficiencies varied 
between experiments, and did not exceed 50% of the total cells (based on the 
proportion of red fluorescent cells). This may have been due to the disruptive 
process of lentivirus transduction. Firstly, polybrene is toxic and although the 
transduction media was removed as soon as possible, C2C12 myotubes appeared 
less healthy after exposure to polybrene. Secondly, cells were centrifuged with the 
lentivirus, this is known as a ‘spinfection’. Although this also greatly improves 
transduction efficiency, C2C12 myotubes were structurally damaged in the process. 
Furthermore, after 3 days of differentiation followed by 72 hours of transduction, 
myotubes began to die. For these reasons this system of transduction was 
discontinued and another lentiviral vector system was employed.  
It was decided that transduction would be greatly enhanced in dividing myoblasts 
because cells could be expanded after transduction. However, the aim of the study 
was to investigate the effect of the T. spiralis protein on myotubes (rather than 
myoblasts) and so I wanted to prevent expression of TsUBE2L3-HA until cells were 
already differentiated. The Lenti-X Tet On Advanced vector system from Clontech 
was chosen for two reasons: 1. because the vectors contain drug selection markers 
which would allow for the development of a stable myoblast cell line and 2. because 
the vectors mediate a doxycycline-controlled inducible system of expression, which 
could be switched on only after differentiation of the cell line.  
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Figure 5. 5 Cloning and expression of TsUBE2L3 in C2C12 myoblasts using a lentiviral 
system 
A. The RACE-confirmed TsUBE2L3 coding sequence with a C-terminal HA tag was cloned 
into pCSGW downstream of the HIV-1 LTR promoter sequence and upstream of an IRES 
(internal ribosome entry site) tdTomato (red fluorescent reporter) sequence. B. The empty 
pCSGW tdTomato vector was used as a control. C. Schematic showing how lentivirus 
particles are produced in HEK 293T cells to package genetic material of interest. These 
lentivirus particles are then used to infect (or transduce) target cells, into which the genetic 
material is injected, becoming reverse transcribed to cDNA that is able to integrate into the 
genome of the target cell for expression of the protein of interest. D. Lentivirus particles 
carrying the TsUBE2L3-HA tdTomato genetic material and the empty vector tdTomato 
genetic material were made in HEK 293T packaging cells that were observed by light and 
fluorescence microscopy. E. Lentivirus particles were used to transduce mature C2C12 
myotubes that were observed by light and fluorescence microscopy. 
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The system involves 2 vectors, a control vector that expresses a doxycycline-
sensitive protein, and an expression vector into which the gene of interest is cloned 
(Figure 5.6 A, B and C). The pLVX Tet On control vector contains a neomycin 
resistance cassette and the pLVX Tight Puro expression vector with a puromycin 
resistance cassette. The coding sequence of TsUBE2L3 with a C-terminal 
haemagglutinin (HA) tag was cloned into the multiple cloning site of pLVX Tight Puro 
expression vector using BamHI and NotI restriction sites. This positions the gene of 
interest downstream of the pTight modified Tet-responsive promoter. The pLVX Tet 
On control vector contains a gene for the transactivator protein rtTA-Advanced. 
RtTA-Advanced contains a DNA-binding TetR domain. In the presence of the drug 
doxycycline (DOX), the rtTA-Advanced protein is activated and binds to the modified 
Tet-responsive promoter of the pLVX Tight Puro expression vector. This drives the 
expression of the gene of interest (either TsUBE2L3-HA or nothing from the empty 
vector Figure 5.6 A, B and C).  
Three lentivirus particle lines were produced in HEK 293T cells: 1. the pLVX Tet On 
control vector, 2. the pLVX Tight TsUBE2L3-HA and 3. the pLVX Tight empty vector 
control (Figure 5.6 D). C2C12 myoblasts were transduced with a mixture of the 
control vector lentivirus paired with each expression vector lentivirus (virus 1+2, 
TsUBE2L3-HA or virus 1+3, empty vector). Cells were then selected for dual 
neomycin and puromycin resistance. Two cell lines were produced, one carrying both 
pLVX Tet On and pLVX Tight empty vector DNA, and another carrying pLVX Tet On 
and pLVX Tight TsUBE2L3-HA DNA. Once selected, myoblast cell lines were 
maintained under a low level of neomycin and puromycin selection. Cells were grown 
to confluency and then induced to differentiate for 3 days using differentiation media. 
Doxycycline was then added to the media to induce the expression of either no 
protein (empty vector) or the recombinant T. spiralis E2 enzyme, TsUBE2L3-HA. 
Expression of the HA-tagged E2 in C2C12 myotubes was confirmed by immuno-blot 
of the HA epitope tag at 4 time-points over a 48-hour period after the addition of 
doxycycline to the culture media (Figure 5.6 D). Reactivity to anti-HA antibodies, 
representing the expression of TsUBE2L3-HA, was observed at the expected size of 
approximately 18 kDa at 18, 22 and 48 hours post-doxycycline induction, but not at 
T0 before doxycycline was added. No anti-HA reactivity was observed in the empty 
vector control cells confirming the specificity of the signal. Anti-tubulin antibodies 
were also reacted as a control for equal protein loading. 
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Figure 5. 6 Cloning and expression of TsUBE2L3 in C2C12 myoblasts using an 
inducible lentiviral system 
A. The Lenti-X Tet-On Advanced Expression System control vector, pLVX-Tet-On containing 
the coding sequence for the rtTA protein under the constitutive control of a CMV promoter. B. 
The RACE-confirmed TsUBE2L3 coding sequence with a C-terminal HA tag was cloned into 
the Lenti-X Tet-On Advanced Expression System expression vector pLVX-Tight-Puro, 
downstream of a doxycycline (DOX)/rtTA responsive pTight promoter and upstream of a 
neomycin resistance cassette. When DOX is added, the DOX/rtTA protein complex binds to 
the pTight promoter inducing transcription of TsUBE2L3-HA C. The empty pLVX Tight-Puro 
vector was used as a control. D. Schematic of the production of lentivirus in HEK 293T cells 
followed by the transduction of C2C12 myotubes, and the selection of neomycin and 
puromycin resistant myoblasts for the generation of stable cell lines. E. Immuno-blot (IB) 
analyses of TsUBE2L3-HA expression in myoblast cell lines, 0, 18, 22 and 48 hours post 
DOX induction using anti-HA antibodies and anti-tubulin antibodies as a loading control.  
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Figure 5. 7 Immuno-fluorescence analysis of inducible TsUBE2L3-HA expression in 
C2C12 myoblast cell lines 
A. Experiment set-up: neomycin and puromycin-selected empty vector and TsUBE2L3-HA 
C2C12 myoblast cell lines. Half the cells were induced using doxycycline for 24 hours (+ 
DOX) and half were not induced. Cells were then analysed by immuno-fluorescence (IFA). B. 
Myoblasts were processed for IFA and incubated with DAPI (to stain nuclei) and anti-HA 
antibodies (with Alexa-488 secondary antibodies). Samples were visualised at 20x 
magnification using confocal microscopy. Figure shows the brightfield image (BF), the DAPI 
(blue) the Alexa-488 (green), the overlay and the overlay plus the BF image. 
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Doxycycline-induced expression of TsUBE2L3-HA, in both undifferentiated 
myoblasts (Figure 5.7) and differentiated myotubes (Figure 5.8), was also confirmed 
by immuno-fluorescence using anti-HA antibodies (raised in rat) and Alexa-488 
(green) conjugated anti-rat antibodies. All immuno-fluorescence experiments were 
visualised by confocal microscopy. Minimal background staining was observed in 
control samples prepared with the anti-rat Alexa-488 secondary antibodies only (no 
anti-HA antibodies, data not shown). No significant fluorescence was observed in the 
empty vector myoblasts or myotubes, before or after induction. Although no 
fluorescence was observed in pLVX Tight TsUBE2L3-HA myoblasts pre-induction, 
some fluorescent signals were observed by immuno-fluorescence in the pLVX Tight 
TsUBE2L3-HA myotubes pre-induction (data not shown). This ‘leaky’ expression was 
not observed at T0 post-induction by immuno-blot using anti-HA antibodies (Figure 
5.6 E). Expression of TsUBE2L3-HA in undifferentiated myoblasts was observed as 
cytoplasmic and in many cells also nuclear (Figure 5.8, 5.9 and 5.10). When 
cytoplasmic, signals were observed throughout the cells, with occasional pockets of 
diminished signal. It was noted that the anti-HA signal was more often nuclear in 
cells that were in the process of dividing. Occasionally, the signal inside the dividing 
nuclei was observed to localise in patches (Figure 5.10). In myotubes, the signal 
appeared to be predominantly cytoplasmic, and rarely nuclear. Finally, not all cells 
reacted with the anti-HA antibodies. This was surprising, considering that the 
myoblasts cell line was selected and maintained using neomycin and puromycin. In 
theory, all cells of the TsUBE2L3-HA cell line should contain the gene for the T. 
spiralis protein. The variation in the intensity of the signal from cell to cell was most 
likely to be an artefact of the IFA process, however some cells contained no signal at 
all suggesting irregular lentivirus transduction or promoter-driven expression. 
Initial observations also suggested that there were subtle differences in the 
morphology of the C2C12 cell line induced to express TsUBE2L3-HA compared with 
the empty vector cell line. This was therefore further investigated. 
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Figure 5. 8 Immuno-fluorescence analysis of inducible TsUBE2L3-HA expression in 
C2C12 myotube cell lines 
A. Experiment set-up: neomycin and puromycin-selected empty vector and TsUBE2L3-HA 
C2C12 myoblast cell lines were differentiated into myotubes. Half the cells were induced 
using doxycycline for 24 hours (+ DOX) and half were not induced. Cells were then analysed 
by immuno-fluorescence (IFA). B. Myotubes were processed for IFA and incubated with DAPI 
(to stain nuclei) and anti-HA antibodies (with Alexa-488 secondary antibodies). Samples were 
visualised at 20x magnification using confocal microscopy. Figure shows the brightfield image 
(BF), the DAPI (blue) the Alexa-488 (green), the overlay and the overlay plus the BF image.  
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In the presence of TsUBE2L3, both myoblasts and myotubes appeared (by light 
microscopy) to have a slightly modified morphology. The effect on myoblasts was 
less predominant (data not shown), but myotubes often appeared less organised and 
uniform, forming more lateral fusions with neighbouring myotubes (Figure 5.9 A). In 
order to visualise the differences in morphology with more clarity, immuno-
fluorescence experiments were carried out using anti-tubulin antibodies, in order to 
visualise the cytoskeletal network and therefore the general structure of the cells.  
Both C2C12 myoblast cell lines, one carrying the pLVX TsUBE2L3-HA expression 
vector and the other carrying the pLVX empty expression vector, were counted and 
seeded at the same density. Half of each cell line was differentiated into myotubes, 
the other half of each cell line passaged as normal and maintained as 
undifferentiated myoblasts. Cells were induced with doxycycline for 24 hours and 
processed for immuno-fluorescence analysis. Cells were incubated with anti-tubulin 
antibodies and anti-HA antibodies and fluorophore-conjugated secondary antibodies 
(Figure 5.9 B). Minimal background staining was observed in control samples 
prepared with the secondary antibodies only (no primary antibodies, data not shown). 
In the presence of TsUBE2L3-HA, undifferentiated myoblasts often contained 
individual cells that were much larger than the majority of the other cells. These 
enlarged cells often contained enlarged nuclei. Although enlarged cells were 
observed in the empty vector myoblasts samples as well, the frequency of enlarged 
cells was greater in the presence of TsUBE2L3-HA. Differentiated myotubes 
expressing TsUBE2L3-HA demonstrated an overall weaker anti-tubulin signal than 
the empty vector control myotubes, however this observation was not reflected in 
immuno-blot analyses of tubulin in cell lysates, which, after normalisation of protein 
concentrations, remained equivalent throughout the study. Myotubes appeared to be 
less well organised in orientation with one-another. In the presence of TsUBE2L3-HA, 
myotubes appeared wider and contained more lateral fusion events.  
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Figure 5. 9 A Analysis of the effect of TsUBE2L3-HA on C2C12 morphology 
A. C2C12 myotubes were induced using doxycycline (+ DOX) for 22 hours. Using light 
microscopy, the morphology of myotube cells expressing TsUBE2L3-HA were compared to 
those carrying empty vector DNA. Red arrows indicate areas of orientation between 
myotubes. Black arrows indicate areas of extensive branching. 
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Figure 5. 9 B Analysis of the effect of TsUBE2L3-HA on C2C12 morphology 
B. C2C12 myoblast and myotube cell lines (empty vector and TsUBE2L3-HA) were harvested 
and processed for immuno-fluorescence (IFA) 24 hours after induction using doxycycline. 
Nuclei were stained using DAPI, and cells were incubated with anti-tubulin antibodies (with 
red Alexa-555 secondary antibodies) and anti-HA antibodies (with green Alexa-488 
secondary antibodies). Samples were visualised using confocal microscopy at 63x 
magnification. Figure shows the brightfield image (BF), the DAPI, tubulin and HA signals, the 
overlay and the overlay plus the BF image.
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Figure 5. 10 Analysis of the subcellular localisation of TsUBE2L3-HA in C2C12 
myoblasts and myotubes 
C2C12 myoblast and myotube TsUBE2L3-HA cell lines were induced using doxycycline for 
24 hours and harvested and processed for immuno-fluorescence (IFA). Nuclei were stained 
using DAPI, and cells were incubated with anti-HA antibodies (with green Alexa-488 
secondary antibodies). Samples were visualised using confocal microscopy at 63x 
magnification and where indicated the manual zoom function was used. Figure shows the 
brightfield image (BF), the DAPI, tubulin and HA signals, the overlay and the overlay plus the 
BF image. Images were taken of (A) a myoblast showing predominant cytoplasmic 
localisation of TsUBE2L3-HA, (B) a dividing myoblast, showing the condensed localisation of 
TsUBE2L3-HA signal inside the nucleus (arrows) and (C) a mature myotube showing 
exclusive cytoplasmic localisation of TsUBE2L3-HA. 
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Unfortunately this data was not quantitative. Due to the variations in phenotype 
observed within individuals of a large population of cells, I was unable to design an 
accurate method of quantification of the differences in morphology. The next aim was 
to try and explain the underlying cause for the changes in morphology observed. 
Since the T. spiralis SP-induced dedifferentiation of muscle cells during infection 
causes a characteristic change in morphology of the host cell, I decided to 
investigate the effect of TsUBE2L3-HA expression on the differentiation state of 
C2C12 myotubes. To do so the effect of TsUBE2L3 on the protein levels of C2C12 
myotube differentiation factors was analysed.  
5.6.	  The	  effect	  of	  TsUBE2L3-­‐HA	  on	  C2C12	  skeletal	  muscle	  cell	  differentiation	  
factors	  
 
Following the invasion of skeletal muscle by T. spiralis during infection, host cell 
expression of muscle-specific proteins such as myosin heavy chain (MHC), 
tropomyosin and myogenin is lost, [131,156,163]. In addition, Bai et al. showed that 
the secreted proteins of T. spiralis muscle larvae are also able to inhibit the 
differentiation process of C2C12 cells when added to them in vitro [160,161]. This 
study also showed a specific inhibition of the early differentiation marker myogenin 
and the late differentiation marker MHC 2x. These proteins were therefore chosen as 
appropriate markers of differentiation in C2C12 cell lines. C2C12 cell lines carrying 
either the pLVX empty expression vector DNA or the pLVX TsUBE2L3-HA 
expression vector DNA were counted and seeded at the same density. Half of each 
cell line was differentiated into myotubes, the other half was passaged as normal and 
maintained as undifferentiated myoblasts. All cells were then induced using 
doxycycline and harvested at the indicated time-points post-induction (Figure 5.11). 
The protein concentrations of the cell lysates were normalised and immuno-blot 
analyses were carried out using anti-MHC and anti-myogenin antibodies. Anti-tubulin 
antibodies were reacted with the same samples as a loading control. Figure 5.11 B is 
representative of 3 biological repeats of this experiment. 
In the myoblast sample, because the cells are rapidly dividing, the cell confluency 
significantly increased over the 48-hour period of induction, allowing more points of 
contact to form between myoblasts. These points of contact promote spontaneous 
differentiation, which involves the up-regulation of tubulin as the cells begin to fuse in 
the early stages of myotube formation. I propose that this is why the tubulin loading 
control signal is observed to increase over time in the myoblast samples. Despite this, 
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no reactivity with anti-myogenin antibodies was observed in myoblast lysates at the 
time of doxycycline induction (T0) or at 18, 22 and 48 hours post-induction (Figure 
5.11 A). In myotubes no changes were observed in the levels of myogenin or MHC 
expression in the presence of TsUBE2L3 until 48 hours post-induction. Here, a 
reduction in myogenin was observed in the TsUBE2L3-HA myotubes when 
compared to the empty vector myotubes (Figure 5.11 B). Although no change was 
observed between 0 and 22 hours, at 48 hours post-induction a slight reduction in 
MHC was also observed in the TsUBE2L3-HA myotubes when compared to the 
empty vector myotubes. This result was not significant, and may have been due to 
small differences in the amount of protein loaded for SDS-PAGE that could not be 
visually detected using the anti-tubulin loading control. In order to draw any 
conclusions about the effect of TsUBE2L3-HA on MHC and myogenin in C2C12 
myotubes, this experiment would need to be repeated. Given more time, it would be 
of interest to repeat the experiment with an extended time-course.  
During this experiment, it was observed that each time a cell sample was lysed, the 
protein concentration (before normalisation) was always higher in the cell line 
carrying the TsUBE2L3-HA vector DNA than in the cell line carrying the empty vector 
DNA. If the total number of cells and the rates of proliferation in each cell line were 
equal, an increase in protein concentration could be caused by an increased rate of 
protein synthesis. Alternatively, an increase in protein concentration could be caused 
by an increased number of cells caused by an increased rate of proliferation. Both of 
these were investigated, starting with a measurement of protein synthesis. 
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Figure 5. 11 Analysis of the effect of TsUBE2L3-HA on muscle differentiation markers 
in C2C12 myoblasts and myotubes 
Empty vector and TsUBE2L3-HA myoblast and myotube cell lines were induced using 
doxycycline for 0, 18, 22, 24 and 48 hours before analysis by immuno-blot (IB) using 
antibodies raised against muscle differentiation markers: myogenin and MHC (myosin heavy 
chain). A. Myoblast cell lines were analysed, and (B) myotube cell lines were analysed. All 
samples were also analysed using anti-tubulin antibodies as a protein loading control. 
 
Chapter 5: Results  
 210 
5.7.	  The	  effect	  of	  TsUBE2L3-­‐HA	  on	  protein	  synthesis	  in	  C2C12	  skeletal	  muscle	  
cells	  
 
Radiolabelled proteins can be detected at very low amounts. The quantification of the 
radioactivity of radiolabelled proteins accurately represents relative protein amount 
and, when measured over time, rates of protein synthesis. To quantify the difference 
observed in protein amounts between empty vector myotubes and TsUBE2L3-HA 
myotubes, both cell lines were counted, seeded at the same density and grown to 
confluency. They were then differentiated for 3 days, before being induced using 
doxycycline. At 20 hours post-induction, the cell culture media was replaced with 
cysteine and methionine-free media for 1 hour. Cysteine and methionine amino acids 
that had been synthesised using the radioactive isotope of sulphur, 35S, were then 
added to the media for 3 hours. Cells were harvested (24 hours post-induction) and 
lysed in equal volumes of lysis buffer and aliquoted in triplicate for each sample. The 
35S radiolabelled protein amounts were analysed by measuring scintillation counts 
per minute (CPM). The experiment was repeated so that 3 biological replicates were 
carried out.  
The amount of 35S radiolabelled cysteine and methionine incorporated into proteins 
during protein synthesis in the 3-hour incubation time was compared between the 2 
cell lines (Figure 5.12 A). The amount of 35S radiolabelled cysteine and methionine 
incorporated into the empty vector cells was consistently lower than in the TsUBE2L3 
cells. The mean scintillation count of all 3 biological replicates was found to be 
significant by a student’s t-test (Figure 5.12 B). Data suggests that protein synthesis 
is significantly increased in C2C12 myotubes expressing the T. spiralis E2, 
TsUBE2L3-HA. This experiment however, does not account for proliferating 
myoblasts. A differentiated skeletal muscle cell culture, is composed of a mixed 
population of myotubes, myoblasts and satellite cells. The life-span of the nuclei of 
myotubes is finite, and as they mature they are replenished with new nuclei from 
surrounding myoblasts that fuse with the myotube. I therefore wanted to investigate 
whether or not the source of the increased protein expression in the C2C12 cells was 
due to an increase in proliferation of the surrounding C2C12 myoblasts, rather than 
an up-regulation of protein synthesis of either the myoblasts and/or the myotubes. To 
do this, the effect of TsUBE2L3 on a panel of cell cycle factors was analysed. 
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Figure 5. 12 Analysis of the effect of TsUBE2L3-HA on the rate of protein synthesis in C2C12 
myotubes 
Empty vector and TsUBE2L3-HA myotube cell lines were induced using doxycycline for 21 
hours before being labeled using 35S cysteine and methionine amino acids for a further 3 
hours. Cells were then harvested and the radioactivity of the cell lysate was measured as 
CPM (counts per minute) in triplicate for each protein sample. A. Three biological repeats 
were carried out, and the mean CPM with standard error of the mean (SEM) is represented 
as error bars. B. The mean of the 3 biological replicates was taken (error bars = SEM) 
showing a 21% increase in the rate of protein synthesis in myotubes expressing TsUBE2L3-
HA compared to the empty vector control. 
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In human cells, UBE2L3 plays an important role in cell cycle regulation, pushing cells 
through S to G2 phase, thus promoting proliferation [320]. Terminally differentiated 
cells such as myotubes exit the cell cycle after a final M phase division and exist in 
an arrested state known as G0 phase where they no longer divide (Figure 5.13 A). 
During nurse cell formation in T. spiralis infection, terminally differentiated skeletal 
muscle cells are induced to re-enter the cell cycle [163]. Here, DNA synthesis occurs, 
indicative of the transition through G1 to S phase. In vitro, it was demonstrated that 
adding the secreted proteins of T. spiralis muscle larvae to C2C12 myoblasts in 
culture up-regulates the expression of the G1-specific cyclin D1 and promotes 
proliferation [160,161]. I therefore decided to look at the effect of the secreted T. 
spiralis E2 TsUBE2L3-HA on the cell cycle state of C2C12 myoblasts and myotubes 
as represented by a panel of cell cycle markers. The protein levels of 4 cell cycle 
factors that are differentially expressed throughout the different stages of the cell 
cycle were investigated. The aim was to observe how each particular stage might be 
affected by the T. spiralis E2. Throughout the cell cycle, cyclin D1 is up-regulated 
during G1 phase, cyclin E is required for G1 to S transition, cyclin B1 is required for 
G2 to M phase transition and the serine 10 residue of the chromatin protein histone 
H3 becomes phosphorylated during chromosome condensation in M phase [333-
336](Figure 5.13 A).  
Both myoblast cell lines, one carrying the pLVX TsUBE2L3-HA expression vector 
DNA and the other carrying the pLVX empty expression vector DNA, were counted 
and seeded at the same density. Half of each cell line was differentiated into 
myotubes, the other half was passaged as normal and maintained as undifferentiated 
myoblasts. Doxycycline was then added to all the cells to induce the expression of 
TsUBE2L3-HA. Cells were harvested after at 0, 18, 22 and 48 hours post-induction. 
Cell samples were lysed and the concentrations of the cell lysates were normalised 
before being analysed by immuno-blot using antibodies raised against cyclin D1, 
cyclin E, cyclin B1 and phospho-histone 3 (Figure 5.13 B and C). The same samples 
were analysed by immuno-blot using anti-tubulin antibodies, providing a loading 
control. Figure 5.13 B and C are representative of 3 biological repeats of these 
experiments. 
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Figure 5. 13 Analysis of the effect of TsUBE2L3-HA on cell cycle factors in C2C12 
myoblasts and myotubes 
A. Graph showing variations in cyclin concentrations throughout the cell cycle. Histone 3 (H3) 
is phosphorylated (pH3) during chromosome condensation in M phase. Empty vector and 
TsUBE2L3-HA myoblast (B) and myotube (C) cell lines were induced using doxycycline for 0, 
18, 22, 24 and 48 hours before analysis by immuno-blot (IB) using antibodies raised against 
cell cycle factors: cyclin D1, cyclin E, cyclin B1 and pH3. All samples were reacted with anti-
tubulin antibodies as a protein loading control.  
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Cyclin D1 protein levels were unaffected by the presence of TsUBE2L3 in myoblasts 
and myotubes. In myoblasts, cyclin E appeared as 2 bands, possibly representative 
of the full length 50 kDa protein and a lower molecular weight isoform, although this 
would need to be confirmed [337]. Although no difference was observed between the 
2 cell lines, at 18 hours post-induction, levels of phospho-histone 3 were specifically 
up-regulated in myoblasts. This may indicate that the 18-hour time-point captured a 
view of a synchronous M-phase event of cell division. The peak expression of cyclin 
B1 levels in myoblasts, observed at 18 hours post induction, mirrored this pattern of 
pH3 expression. No Phosphorylated histone 3 was detected in myotubes of either 
the TsUBE2L3-HA cell line or the empty vector cell line. Since myotube cultures 
mainly contain differentiated cells that have exited the cell cycle, the absence of 
phospho-histone 3 was unsurprising. Finally, cyclin B1, the G2/M-phase-specific 
cyclin, was also unaffected in myoblasts, however it was significantly reduced in the 
presence of TsUBE2L3-HA in myotubes at all time-points. A reduction in cyclin B1 in 
mammalian cells is associated with G2/M arrest and this is one of the mechanisms 
by which the tumour suppressor protein p53 induces cell cycle arrest at the G2/M 
checkpoint [338]. Data therefore suggests a reduction in the proportion of cells in 
G2/M phase (in the presence of TsUBE2L3) that is myotube-specific. Unexpectedly, 
an inhibitory effect on cyclin B1 in myotubes was observed at T0, before doxycycline-
mediated induction. Despite no anti-HA signal at T0, this effect may have been 
caused by leaky expression of TsUBE2L3-HA in myotubes as observed earlier by 
immunofluorescence.  
In order to try and verify differences in the cell cycle states between the 2 cell lines, 
the effect of TsUBE2L3 on C2C12 proliferation was examined. 
5.9.	  The	  effect	  of	  TsUBE2L3-­‐HA	  on	  C2C12	  skeletal	  muscle	  proliferation	  
 
Proliferation of C2C12 cells was analysed by monitoring DNA replication using the 
Click-iT EdU Cell Proliferation Assay (Life Technologies). The modified nucleoside 
base EdU is a thymidine analogue that contains an alkyne modification. EdU is cell 
permeable and can be incorporated into the DNA (in the place of thymidine) of 
dividing cells during DNA replication. The alkyne of EdU can form a covalent bond 
with a fluorophore that contains an azide modification. This method of conjugation of 
chemically modified biological compounds is a form of "Click chemistry' [339].  
Both myoblast cell lines, one carrying the pLVX TsUBE2L3-HA expression vector 
DNA and the other carrying the pLVX empty expression vector DNA, were counted 
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and seeded at the same density. Half of each cell line was differentiated into 
myotubes, the other half was passaged as normal and maintained as undifferentiated 
myoblasts. Doxycycline was then added to all cells to induce expression of 
TsUBE2L3-HA. At the 18-hour time-point post-induction, EdU was added to the cells 
and they were incubated for a further 6 hours before being harvested and processed 
for immuno-fluorescence analysis (24 hours post-induction). The fluorophore Alexa-
647-azide was incubated with the cells as instructed by Life Technologies (Click-iT 
EdU Cell Proliferation Assays). This was to allow nuclei that had undergone a DNA 
replication event, and had therefore incorporated EdU into their DNA, to bind to the 
Alexa Fluor-647-azide fluorophore (red). Cells were then incubated with anti-HA 
antibodies and Alexa-488 fluorophore-conjugated (green) secondary antibodies. All 
nuclei of cells were stained with 4',6-diamidino-2-phenylindole (DAPI), a fluorescent 
compound that binds to A-T rich regions of DNA (Figure 5.14 A). Negative control 
samples were also prepared: 1. Cells from both cell lines that were stained with the 
Alexa-488 fluorophore-conjugated secondary antibodies only (without the anti-HA 
antibodies). 2. Cells from both cell lines that were stained with the Alexa-647-azide 
only (without EdU incubation). 3. Cells from both cell lines that had not been induced 
with doxycycline were also processed with all staining combinations and minimal 
background staining was observed (data not shown). Samples were then visualised 
by confocal microscopy.  
No anti-HA signal was observed in the empty vector myoblast or myotube cells after 
24 hours of induction with doxycycline. Anti-HA signal was observed in the 
TsUBE2L3-HA myoblast and myotube cells after 24 hours of induction with 
doxycycline. Alexa-647 positive nuclei (red) indicated that DNA replication had 
occurred during the 6-hour incubation with EdU. Red nuclei were observed in all 
samples. The presence or absence of red nuclei did not significantly or exclusively 
correlate with TsUBE2L3-HA expression (Alexa-488 signal, green). In other words, 
the red nuclei were evenly distributed amongst cells with and without and anti-HA 
signal. However, nuclei that were red, often demonstrated a higher level of HA 
signal, consistent with the hypothesis that the TsUBE2L3 is recruited to the nucleus 
for replication. Myotubes are in the G0 phase of the cell cycle and would only 
replicate their DNA if pushed into the G1/S phase. In all samples, no red nuclei were 
observed in the myotubes of the empty vector cells or the TsUBE2L3 cells (red nuclei 
were only observed in myoblasts), confirming that TsUBE2L3 was not able to induce 
DNA replication. 
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Six different areas of the empty vector myoblast sample and 6 different areas of the 
TsUBE2L3-HA myoblast sample (at 63x magnification) were chosen at random and 
images were taken. The total number of DAPI-stained nuclei per area (same for each 
image) were counted, and then the number of Alexa-647-stained (EdU positive) 
nuclei per area were counted. The mean number of DAPI-positive nuclei and the 
mean number of Alexa-647-positive nuclei in each sample is presented in Figure 
5.14 B and C. A small reduction in the total number of cells counted was observed in 
the cells expressing TsUBE2L3-HA compared to the empty vector control. The 
percentage of Alexa-647-positive nuclei out of the number of DAPI-positive nuclei 
was calculated. A small reduction in the proportion of Alexa-647 nuclei was observed 
in the cells expressing TsUBE2L3. Data was not calculated to be significant when 
analysed by a student’s t test and more images would have to be counted before a 
conclusion could be drawn.  
To try and verify and more accurately quantify any possible difference in the 
frequency of DNA replication in dividing C2C12 myoblasts in the presence of the T. 
spiralis E2, flow cytometry analyses were carried out. Flow cytometry is the process 
by which single cells are counted and each cell is analysed for its fluorescent profile. 
Molecules of interest within a cell or on the surface of a cell are bound to fluorescent 
markers that can be detected and quantified. In order to compare signals between 
single cells, they must be of a similar (uniform) size and granularity. Differentiated 
myotubes are long thin multinucleated, asymmetrical cells that vary in shape and 
size. They therefore cannot be used for flow cytometry. The effect of TsUBE2L3 on 
proliferation could therefore only be investigated in C2C12 myoblast cell lines.  
Both myoblast cell lines, one carrying the pLVX TsUBE2L3-HA expression vector 
DNA and the other carrying the pLVX empty expression vector DNA, were counted 
and seeded at the same density. Doxycycline was then added to all the cells to 
induce expression of TsUBE2L3-HA. Six hours post-induction, EdU was added to the 
cells and they were incubated for a further 18 hours before being harvested and 
processed for flow cytometry analysis (24 hours post-induction). To observe any non-
specific binding of the Alexa-647-azide fluorophore to the cells, samples that were 
not incubated with EdU were also prepared as a control. Samples were then 
incubated with the Alexa-647-azide fluorophore. Cells were also prepared that had 
been processed for flow cytometry but not incubated with EdU or Alexa-647 azide as 
a guide for cell size and granularity for flow cytometry. Once collected, flow cytometry 
data was analysed using FlowJo software. 
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Figure 5. 14 A. Immuno-fluorescence analysis of the effect of TsUBE2L3-HA on DNA 
replication in C2C12 myoblasts and myotubes  
A. Immuno-fluorescence of C2C12 myoblast and myotube empty vector and TsUBE2L3-HA 
cell lines after 24 hours of doxycycline induction. Cells were incubated with EdU for 6 hours 
before harvesting and processing for IFA and Click chemistry. Cells were incubated with 
Alexa-647-alkyne, DAPI to stain the nuclei, and anti-HA antibodies with Alexa-488 secondary 
antibodies. Figure shows the Brightfield (BF) the DAPI signal (blue) the Alexa-647 signal 
(red), the Alexa-488 signal (green), the overlay and the overlay plus the BF image.  
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Figure 5. 14 B and C. Immuno-fluorescence analysis of the effect of TsUBE2L3-HA on 
DNA replication in C2C12 myoblasts and myotubes  
B. The number of blue (DAPI-positive) and red (Alexa-647-positive, representing DNA 
replication) nuclei were counted in 6x images (63x magnification). The mean number of nuclei 
is presented with standard error of the mean (SEM) as error bars. C. The number of DAPI-
positive cells was taken as the total number of cells (100%) and the proportion of Alexa-647-
positive cells was calculated for the each cell line. The mean percentage with SEM as error 
bars is presented.
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Figure 5.15 A and B show the Alexa-647 signal of the empty vector and TsUBE2L3 
myoblasts presented as flow histograms. In the samples that had been incubated 
with Alexa-647 but not EdU, a small amount of non-specific binding by the 
fluorophore was observed in both cell lines. This was represented as slight increase 
in the percentage of cells with a positive Alexa-647 signal. EdU incorporation during 
DNA synthesis was observed as a significant increase in the percentage of cells with 
a positive Alexa-647 signal. In total, 90.04% of the empty vector cells had an Alexa-
647 positive signal and 88.33% of the TsUBE2L3 cells had an Alexa-647 positive 
signal (Figure 5.15 C). The signal however was split into 3 distinct peaks. Upon 
further analysis of each individual peak, it was observed that the fluorescence 
intensity of peak 2 was almost double that of peak 1, and the fluorescence intensity 
of peak 3 was almost double that of peak 2 Figure 5.15 E. There were 3 different cell 
populations, each representing an exponential increase in the incorporation of EdU. 
The peaks may therefore represent the number of DNA replication rounds and 
therefore the number of cell cycle events through which an individual cell has passed 
in the 18-hour (EdU) incubation period. Cells in peak 1 had undergone 1 round of the 
cell cycle, cells in peak 2 had undergone 2 rounds of the cell cycle and cells in peak 
3 had undergone 3 rounds of the cell cycle. There was not however, a significant 
difference between the empty vector cells and the TsUBE2L3 cells, neither in the 
percentage of cells in each peak, nor in the fluorescence intensity of each peak 
(Figure 5.15 C and D). This data, along with the immuno-fluorescence analysis 
suggests that despite having an inhibitory effect on cyclin B1, TsUBE2L3 does not 
significantly affect DNA replication in C2C12 myoblasts, and does not induce DNA 
replication in C2C12 myotubes.  
As mentioned previously, p53 plays a pivotal role in the terminal differentiation of 
skeletal muscle cells [132,340]. P53 also plays a well-characterised role in cell cycle 
arrest, and at the G2/M checkpoint down-regulates cyclin B1 transcription to this end 
[338]. The mammalian E2, UBE2L3, in collaboration with the E3, E6-AP (E6-
Associated Protein), polyubiquitinates p53 and facilitates the proteasomal 
degradation of the protein thus down-regulating p53 at the protein level [66,341,342]. 
Experiments were therefore designed to analyze the effect of the T. spiralis UBE2L3 
on p53 in C2C12 cells.  
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Figure 5. 15 Flow cytometry analysis of the effect of TsUBE3L3-HA on DNA replication 
in C2C12 myoblasts 
C2C12 empty vector and TsUBE2L3-HA myoblasts were induced with doxycycline for 24 
hours and incubated for 18 hours with EdU before being processed for Click chemistry using 
Alexa-647-azide. Flow histogram showing a shift in florescence intensity at 640-670 nm 
representing Alexa-647-positive nuclei in (A) empty vector cells and (B) TsUBE2L3-HA cells. 
Cells were gated on a forward and side scatter pattern that appeared typical for myoblasts. 
Control cells were not incubated with EdU or Alexa-647. Baseline signal was taken from cells 
that were not incubated with EdU but were treated with Alexa-647-azide. C. The flow 
histograms for empty vector cells and TsUBE2L3-HA cells incubated with EdU and Alexa-
647-azide were overlaid. D. The percentage of the maximum number of cells with a particular 
fluorescence intensity was determined for three distinct peaks within the main peak. E. The 
fluorescence intensity of each peak (1,2 and 3) was calculated for each cell line. 
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In healthy cells, p53-induced cell cycle arrest allows DNA damage or abnormality to 
be repaired during a cell cycle check point before the continuation of the cell cycle. If 
the damage irreparable, p53 induces programmed death (apoptosis) of the cell, 
preventing its replication and thus preventing the inheritance of the damage or 
abnormality. Mutations in the p53 gene are found in various diseases, many of which 
are cancers and cell cycle-related disorders [343-345].  
The effect of TsUBE2L3-HA on wild-type p53 protein levels in C2C12 cells was 
examined. The TsUBE2L3-HA and empty vector cell lines were seeded at equal 
densities. Half of each cell line was grown to confluency and differentiated and the 
other half was passaged and allowed to remain as myoblasts. After 3 days of 
differentiation TsUBE2L3-HA expression was induced with doxycycline. Cells were 
harvested after at 0, 22 and 48 hours post-induction. Cells were lysed, the protein 
concentrations of the cell lysates were normalised and the samples were analysed 
by immuno-blot using anti-p53 antibodies (Figure 5.16 A). The same samples were 
reacted with anti-tubulin antibodies as a protein loading control. Figure 5.16 is 
representative of 3 biological repeats of this experiment. Very low levels of p53 
protein were observed in C2C12 myoblasts throughout the time-course. This is 
expected since the cells have a rapid rate of turnover and few cells will be growth-
arrested. After 48 hours, more p53 was observed, consistent with the fact that as the 
cells become more confluent over time, they begin to spontaneously differentiate. No 
differences were observed between the myoblasts expressing TsUBE2L3 and those 
carrying the empty vector.  
Compared to the myoblasts, the overall p53 expression was significantly up-
regulated in the differentiated myotubes. In the presence of TsUBE2L3-HA however, 
p53 protein was significantly reduced when compared to the empty vector control. 
This down-regulation was observed at T0, suggesting some leaky expression of 
TsUBE2L3-HA before induction with doxycycline. After induction, the expression of 
p53 continued to be significantly reduced in the presence of TsUBE2L3. Minimal 
difference in the reactivity with anti-tubulin antibodies was observed between 
samples, suggesting equal protein loading. These results are representative of more 
than 3 biological replicates of this experiment. 
Since immuno-blot analyses are not accurately quantitative, a radio-immuno-
precipitation of p53 was carried out to verify and quantify the reduction of p53 protein 
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in myotubes expressing TsUBE2L3-HA. Both cell lines were seeded at the same 
density and grown to confluency. They were then differentiated for 3 days, before 
being induced using doxycycline. At 20 hours post-induction, the cell culture media 
was replaced with cysteine and methionine-free media for 1 hour. 35S radiolabelled 
cysteine and methionine amino acids and the proteasome inhibitor MG132 were then 
added to the media for 3 hours. MG132 blocks the core of the proteasome, causing a 
build up of ubiquitinated proteins that would otherwise be degraded. Since p53 is 
highly regulated by ubiquitination and proteasomal degradation, MG132 was used to 
allow the accumulation of all ubiquitinated forms of p53 as well as native p53, thus 
increasing the p53 signal. Cells were harvested (24 hours post-induction), lysed and 
total 35S radiolabelled protein concentrations were analysed by measuring 
scintillation counts per minute (CPM). Radiolabelled lysate concentrations were 
normalised based on their 35S CPM. Protein G suspended anti-p53 antibodies were 
then used to immuno-precipitate p53 from each of the lysates. The input (lysate 
before immuno-precipitation), the immuno-precipitated proteins and the unbound 
(proteins that did not immuno-precipitate), were all separated by SDS-PAGE. 
Proteins were visualised by auto-radiography (Figure 5.16 B).  
Figure 5.16 B represents a short exposure of the auto-radiogram showing that the 
amounts of protein loaded into (input) and recovered from (unbound) the immuno-
precipitation were well normalised between the 2 cell lines. A protein corresponding 
to the expected size of native p53 (53 kDa, Figure 5.16 B red arrow) was immuno-
precipitated from the empty vector lysate. The amount of this protein immuno-
precipitated from the TsUBE2L3-HA lysate was significantly reduced. A slightly larger 
protein was also immuno-precipitated in equal measures from both cell line lysates, 
at 55 kDa. If this band is p53-specific, it may represent mono-ubiquitinated p53. 
Native p53 is actually 43 kDa in size, but runs at 53 kDa when separated by SDS-
PAGE. Therefore, mono-Ub p53 runs very close to native p53. Alternatively, this 
band may represent a modified form of p53 other than ubiquitinated p53, because as 
well as by ubiquitin, p53 is highly regulated by phosphorylation and acetylation [346].  
A very large protein of approximately 250 kDa was also immuno-precipitated from 
the empty vector lysate that was present but greatly reduced in the TsUBE2L3-HA 
lysate sample. When the auto-radiogram was over-exposed, 2 more bands were 
observed to be immuno-precipitated only in the empty vector sample (Figure 5.16 C, 
black arrows). These were between 15 and 35 kDa. The experiment was repeated 
twice and the same pattern of bands was observed (data not shown). The area of the 
3 autoradiograms corresponding to the size of native p53 (53 kDa) were measured 
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for particle gray value (number of pixels with gray value) using gel analysis software 
(Fiji). This allowed for the quantification of the intensity of the band in each immuno-
precipitation sample (Figure 5.16 C). By calculating the mean of the 3 measurements 
from each experiment, native p53 immuno-precipitated from C2C12 myotubes 
expressing TsUBE2L3-HA was significantly less than that immuno-precipitated from 
cells carrying the empty vector DNA. Results strongly agreed with the immuno-blot 
data using anti-p53 antibodies presented earlier.  
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Figure 5. 16 Analysis of the effect of TsUBE2L3-HA on p53 in C2C12 myoblasts and 
myotubes 
A. Immuno-blot analysis of C2C12 empty vector and TsUBE2L3-HA cell lines after 0, 22 and 
48 hours of induction using doxycycline using anti-p53 antibodies. Myotubes were also 
analysed for TsUBE2L3-HA expression using anti-HA antibodies, and all samples were 
analysed using anti-tubulin antibodies as a protein loading control. B. Myotube C2C12 empty 
vector and TsUBE2L3-HA cells were induced for 24 hours, labeled with 35S cysteine and 
methionine amino acids and treated with the proteasome inhibitor MG132. Anti-p53 
antibodies were used to immuno-precipitate p53 from concentration-normalised cell lysates. 
The input, immuno-precipitation products and the proteins that did not immuno-precipitate 
(unbound) were separated by SDS-PAGE and analysed by autoradiography. C. The 
autoradiograph was overexposed to reveal more signals affected by TsUBE2L3-HA. Black 
arrows indicate protein bands affected by TsUBE2L3-HA. The red arrow (1) indicates the 
expected size of mono-ubiquitinated p53 and (2) the expected size of native p53. The 
experiment was repeated. D. The gray value (pixels) of the band representing native p53 was 
measured in the empty vector and TsUBE2L3-HA immuno-precipitation products using Fiji 
image analysis software. The mean of 3 gray values from biological replicates are presented 
with standard error of the mean represented as error bars. A 34% reduction in native p53 was 
observed in the presence of TsUBE2L3-HA. 
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The reduction of a protein observed may have arisen from a post-translational 
inhibitory effect, for example ubiquitin-proteasome-mediated degradation, or from an 
inhibitory effect at the transcriptional level (mRNA). To measure levels of p53 mRNA, 
a quantitative reverse transcriptase PCR (qRT-PCR) was carried out. During qRT-
PCR the amplification by PCR of a reverse transcribed transcript is quantified. The 
levels of specific mRNA transcripts can therefore be measured and compared 
between cell lines. The transcript level of a ‘housekeeping’ gene that is unaffected by 
the experiment variable is measured as a baseline level for transcription. 
Three C2C12 myotube cell lines were cultured: the empty vector, TsUBE2L3-HA and 
an additional inducible cell line that was set up in the same way to express another T. 
spiralis secreted protein called Ts6496. This protein was identified by LC/MS/MS of T. 
spiralis SP as an abundant uncharacterised (T. spiralis-specific) secreted protein 
(supplementary appendix 4). This cell line was assayed as an additional control to 
ensure that the effect on p53 was not simple an artefact of the over-expression of 
any T. spiralis protein in muscle cells, since the empty vector does not contain a 
gene for protein expression. Total RNA was extracted from each myotube cell line 
after the induction of TsUBE2L3 expression using doxycycline for 0, 2, 4, 8, 12 and 
24 hours. RNA was used to synthesise cDNA using the Takara reverse transcriptase 
kit with oligo(dT)12-18 and random primers, according to the manufacturer’s 
instructions (Clontech). Transcript levels of p53 (target gene), myosin heavy chain 
(MHC) and the ‘housekeeping gene’ glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) were analsyed (Figure 5.11). MHC was chosen as an alternative 
(additional) control to GAPDH as no changes in MHC protein levels were observed 
between the 2 cell lines during immuno-blot analysis between 0 and 22 hours post-
induction. For consistency, the gene that encodes the MHC 2x protein (analysed 
previously by immuno-blot), MYH1 was analysed. 
Each sample was quantitatively analysed by real-time PCR (in triplicate) using 
specific TaqMan Gene Expression Assays from Life Technologies. Each sample was 
analysed in triplicate and the mean CT (cycle threshold) value was calculated with 
standard error (SEM). The raw data suggested the expression of GAPDH was not 
affected by TsUBE2L3-HA or Ts6496 expression and the expression of all 3 genes 
was found to be relatively efficient. This allowed for the direct comparison of the 
expression of MHC and p53 to GAPDH using the Comparative CT Method (ΔΔCT) as 
described in the Applied Biosystems ABI PRISM User Bulletin #2. Therefore, the 
expression was calculated relative to GAPDH, and the fold change of each gene at 
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each time-point was calculated relative to the empty vector control cell line sample 
taken at T0 (Figure 5.17). 
The expression of MHC and GAPDH in C2C12 myoblasts was not significantly 
affected by the expression of TsUBE2L3-HA or the expression of Ts6496 at any 
post-induction time-points evaluated. A very small reduction in MHC transcript was 
observed in the TsUBE2L3 samples after 12 and 24 hours. This was in line with a 
slight reduction observed earlier by immuno-blot, however this experiment would 
need to be repeated with an extended time-course to confirm an effect of TsUBE3L3 
on MHC. The expression of Ts6496 or TsUBE2L3-HA in C2C12 myotubes did not 
significantly affect p53 transcript levels at any post-induction time-point that was 
evaluated. This would suggest that the down-regulation of p53 by TsUBE2L3 does 
not occur at the transcript level, rather at the protein level. This reinforced the 
hypothesis that the T. spiralis E2, like its mammalian orthologue UBE2L3 (UbcH7), 
can mediate the ubiquitination and subsequent proteasomal degradation of p53.  
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Figure 5. 17 Analysis of the effect of TsUBE2L3-HA on the transcription of p53 in 
C2C12 myotubes 
Qualitative real-time PCR (qRT-PCR) was carried out on myotube cDNA to assess the effect 
of TsUBE2L3-HA on (A) p53 transcription and (B) myosin heavy chain (MHC) transcription 
normalised to the transcription of the housekeeping gene GAPDH over a 24-hour time-course 
post induction using doxycycline. This was compared to the effect in empty vector cells and in 
cells expressing another T. spiralis unrelated protein, named 6496. The fold change in 
transcription relative to the empty vector time 0 sample is presented. Measurements were 
taken in triplicate and error bars indicate standard error of the mean.  
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Summary	  of	  results	  
 
5.1. The secretion of TsUBE2L3 by T. spiralis muscle larvae was confirmed by 
immuno-blot. The secretion of the putative T. spiralis E3 enzyme, TsRNF13 could not 
be confirmed. 
5.2. RACE-PCR confirmed the full coding sequence for TsUBE2L3. The coding 
sequence for TsRNF13 could not be confirmed. 
5.5. The C2C12 mouse skeletal muscle cell line was successfully cultured and 
differentiated into myotubes. 
5.4. Two lentiviral vector-mediated expression systems were established that allowed 
expression and detection of TsUBE2L3-HA in C2C12 myotubes. 
5.5. The morphology of C2C12 myotubes was affected by the presence of 
TsUBE2L3. More enlarged myoblasts and laterally fused myotubes were observed. 
5.6. TsUBE2L3-HA expression in C2C12 myotubes did not significantly affect the 
skeletal muscle differentiation markers myogenin and myosin heavy chain (MHC). 
5.7. Protein synthesis in C2C12 myotubes was up-regulated by TsUBE2L3. 
5.8. TsUBE2L3-HA expression in C2C12 myotubes did not affect the cell cycle 
factors cyclin D1, cyclin E or phospho-histone 3, but did cause a significant reduction 
in cyclin B1. 
5.9. TsUBE2L3-HA expression in C2C12 myotubes did not affect the rate of 
proliferation as measured by DNA replication in dividing C2C12 myoblasts. 
5.10. TsUBE2L3-HA expression in C2C12 myotubes significantly down-regulated the 
tumour suppressor protein p53 at the protein level, but not at the transcript level. 
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Discussion	  
 
Experiments in chapter 3 showed that the muscle stage larvae of the parasite T. 
spiralis express components of a functional ubiquitin proteasome system, 
components of which have been highly conserved throughout evolution. To ascertain 
if these proteins might be specifically host-targeted, chapter 4 investigated whether 
or not ubiquitin pathway enzymes are secreted by T. spiralis muscle larvae. 
Experiments could not detect deubiquitinating or deNeddylating activity in the 
secreted proteins of T. spiralis muscle larvae, however ubiquitin conjugation (E2) and 
ligation (E3) activity was detected. Proteomic analyses of all of the secreted proteins 
identified a single putative T. spiralis E2 enzyme and a single putative T. spiralis E3 
enzyme. The purpose of experiments presented in chapter 5 was to confirm the 
identity of the proteins responsible for the ubiquitin conjugation activity, and to 
characterise their possible function in host-parasite interactions during T. spiralis 
infection of muscle cells. 
Immuno-blot evidence confirmed the identity of the secreted E2 enzyme as the T. 
spiralis UBE2L3 orthologue. Given 62.3% identity between the T. spiralis and human 
protein sequences, it is not surprising that an anti-human antibody was able to cross 
react with proteins of an expected size in both T. spiralis lysate and the secreted 
proteins. Bands of reactivity however, were multiple in both samples. The 
mammalian UBE2L3 can be mono and polyubiquitinated, and this may explain some 
of the additional bands observed [320]. To confirm this, a pan deubiquitinating 
enzyme such as the murine cytomegalovirus M48, that removes all ubiquitin 
modifications from proteins, could be added to the lysate or secreted proteins before 
immuno-blot with anti-UBE2L3 antibodies [94]. Indeed adding the proteasome 
inhibitor MG132 to C2C12 myotubes expressing TsUBE2L3-HA, caused an 
enrichment of a larger form of HA-tagged protein that would correspond to the size of 
monoubiquitinated TsUBE2L3 (appendix 4).  
The human protein has 3 isoform coding sequences (GI: 373432685, 17.9 kDa, GI: 
373432681, 14.1 kDa, GI: 373432683, 24 kDa) [347,348]. The most abundantly 
expressed form is the 18 kDa isoform 1 [324]. The most predominant anti-UBE2L3-
reactive band in the secreted proteins corresponded to approximately 18 kDa. The 
full sequence for TsUBE2L3 was confirmed by RACE-PCR experiments, and this 
sequence was found to translate to a protein of 18 kDa. This sequence was also 
identified by AUGUSTUS gene prediction software, but only when using gene 
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arrangement information based on the genome of the filarial nematode Brugia malayi 
as a template. During experiments carried out in chapters 3 and 4, evidence of the 
mis-annotation of the T. spiralis draft genome was observed multiple times. This 
suggests that the draft annotation is not a reliable source of data for gene prediction 
in T. spiralis and may explain why another nematode, Brugia malayi, was required for 
a gene prediction that was in agreement with the experimental data. The start codon 
and the beginning portion of the RACE-PCR-confirmed sequence aligned well with 
orthologous sequences from multiple other species including the human sequence 
that has been confirmed experimentally [347]. This sequence was therefore used as 
the basis for cloning the gene encoding the T. spiralis E2 enzyme. The same 
experiments were unable to confirm the identity and secretion of the putative T. 
spiralis E3 (RNF13 orthologue) and studies on this protein were discontinued.  
To try and understand the role the E2 enzyme might play during nurse cell formation, 
I investigated the effect of TsUBE2L3 on muscle cells. Trichinella spiralis infects all 
mammals indiscriminately and the disease phenotype is the same for all species. I 
therefore decided to work with mouse rather than human muscle cells as protocols 
and reagents for the culture and differentiation of C2C12 mouse skeletal muscle cells 
are well established. During infection, T. spiralis newborn larvae invade terminally 
differentiated myofibres, not immature myoblasts [157]. It was therefore important to 
express TsUBE2L3 in already differentiated myotubes. To achieve this, the coding 
sequence of TsUBE2L3-HA was cloned into a lentiviral vector system. The efficiency 
of transduction from the first vector used, pCSGW, did not exceed 50% and methods 
affected the health of the myotubes. Instead, an inducible system allowed for the 
generation of a stable myoblast cell line that could be induced to express the T. 
spiralis E2 after differentiation. 
Immunofluorescence analysis showed that the location of TsUBE2L3-HA within 
myoblasts was both cytoplasmic and nuclear, and even more nuclear in cells that 
were dividing. Being able to determine, by observational microscopy, that a cell is 
actively dividing suggests that the cell is already in a later stage of the cell cycle, 
such as G2 or M. The localisation of TsUBE2L3-HA appeared to be consistently 
more nuclear in cells that were undergoing a division event at the time of harvest. In 
mammalian cells, UBE2L3 is involved in cell cycle progression from S phase to G2 
[320]. Whitcomb et al. show that UBE2L3 is down-regulated in S phase, but becomes 
up-regulated during G2 and M phase. Taken together, data suggests that the up-
regulation and recruitment of TsUBE2L3 to the nucleus may be required for latter 
stages of the cell cycle. In differentiated (non-dividing) C2C12 myotubes, the majority 
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of TsUBE2L3-HA was located cytoplasmically, re-enforcing the hypothesis that 
nuclear recruitment of TsUBE2L3 is a predominant requirement of dividing cells. Due 
to time constraints, this was not confirmed experimentally. Experiments could be 
carried out by blocking the cell cycle at specific stages and analysing the effect on 
the localisation of TsUBE32L3. 
Using lentiviral expression systems, variations in the number of DNA integration 
events and the sites of integration may occur from cell to cell. Levels of regulation of 
either the modified CMV promoter of the pLVX control vector or the pTight promoter 
of the pLVX expression vector may also vary. Finally, differentiated C2C12 cultures 
still contain a mixed population of cells. Myoblasts are present, which can 
differentiate into myocytes and then myotubes. Because cultures were transduced 
and selected before differentiation, cell populations may fluctuate between cell lines, 
and each cell type (myoblast or myotube) may observe different transduction 
efficiencies or regulate integration or promoters differently. This may explain the 
variation in TsUBE2L3-HA expression observed by IFA between individual cells of 
the same line. 
C2C12 cells expressing TsUBE2L3-HA appeared morphologically different to cells 
carrying the empty vector. Differences were subtle and it was difficult to observe 
patterns or quantify changes. A degree of ‘leaky’ expression of TsUBE2L3-HA was 
observed in myotubes, but not myoblasts by immunofluorescence but not by 
immuno-blot. This may explain why some changes in morphology were already 
observed after the differentiation of the cells, but before their induction with 
doxycycline (data not shown). The differentiation process itself, however, did not 
appear to be affected by the leaky TsUBE2L3 expression, and myoblasts fused and 
formed myotubes, albeit with a slightly modified morphology. Immuno-fluorescence 
using anti-tubulin antibodies showed that dividing C2C12 myoblasts expressing 
TsUBE2L3 were sometimes enlarged with enlarged nuclei. Tubulin expression in 
myoblasts was not affected as measured by IB, however by IFA, in the cases where 
cells were enlarged, the tubulin network was larger in order to fill the increased cell 
area. Inside myotubes, the anti-tubulin signal was less intense, suggesting reduced 
tubulin expression. However this was contradicted by immuno-blot experiments 
where tubulin levels were equal between cell lines when protein concentrations were 
normalised. Myotubes expressing TsUBE2L3 appeared as less regular tube shapes, 
and had more lateral fusions, leading them to often appear wider than myotubes 
carrying the empty vector. It is worth noting that all structural abnormalities discussed 
were also observed in the cells carrying the empty vector, but to a much lower 
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frequency. Morphological effects of TsUBE2L3 were not caused by changes in the 
levels of the muscle differentiation markers myogenin and myosin heavy chain 
(MHC) and the cause of the modified morphology remains to be determined. 
The next unexpected observation was that TsUBE2L3-HA expression affected the 
protein concentrations of C2C12 lysates. Each time a cell lysate concentration was 
measured, the protein concentration was higher in the presence of TsUBE2L3. To 
confirm and quantify this observation, time-dependent protein labelling was carried 
out. Results indicated that there was consistently 21% more protein synthesis 
occurring in cells expressing TsUBE2L3. It is unlikely that the over-expression of the 
recombinant TsUBE2L3-HA protein itself was the cause of this, since immuno-blot 
analysis of the HA-tag showed levels of protein comparable to the tubulin protein that 
was analysed as a loading control (although antibody affinities will vary). It was 
hypothesised that the differences in protein concentration was due to a difference in 
the rates of proliferation, leading to differences in population density. Bai et al. 
showed that adding total T. spiralis secreted proteins to C2C12 myoblasts in culture, 
increased their rate of proliferation and in parallel, increased cyclin D1 and 
proliferating cell nuclear antigen levels [160,161]. I therefore decided to test the effect 
of TsUBE2L3 expression on the cell cycle of C2C12 cells. 
Differentiated C2C12 myotubes are in G0 phase, having exited the cell cycle after M 
phase. They are therefore not expected to express high levels of cyclin proteins that 
are specifically up-regulated during the cell cycle. No effect of TsUBE2L3 was 
observed on cyclin D1 (G1 phase), cyclin E (G1/S phase) or phospho-histone 3 
(chromosome condensation during M phase). Cyclin B1 however, was significantly 
reduced in the presence of TsUBE2L3. Cyclin B1 is expressed during the G2/M 
phase and its transcriptional down-regulation by the tumour suppressor protein p53 
causes G2 cell cycle arrest [338,349]. Down regulation of cyclin B1 can lead to an 
inhibition of proliferation and tumour growth [350,351]. In order to investigate if the 
down-regulation of cyclin B1 in the presence of TsUBE2L3, was able to affect the cell 
cycle of C2C12 cells, a proliferation assay was carried out. By IFA, no significant 
differences were observed between cells carrying the empty vector DNA and cells 
expressing TsUBE2L3-HA. In addition, no significant or exclusive correlation was 
observed between cells that had undergone a DNA replication event and those that 
were HA- (TsUBE2L3-HA) positive. In other words, the proportion of cells that had 
undergone a DNA replication event was no higher in HA-positive cells than in HA-
negative cells. As expected, no terminally differentiated myotube cells had replicated 
their DNA in either cell line. The data was quantified and the proportion of replicating 
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cells was not significantly different in the presence of TsUBE2L3. Preliminary flow 
cytometry experiments on myoblasts confirmed this result, showing that the 
proportion of cycling cells was almost identical in the 2 cell lines, and suggesting that 
over 18 hours some cells had undergone 3 rounds of replication. To increase the 
confidence of this data, flow cytometry analyses would need to be repeated using 
optimised parameters. It would be preferable to synchronise the myoblast cell cycle 
by drug treatment first, and use different DNA replication labels such as propidium 
iodide (PI). Rather than labelling only newly synthesised strands of DNA, which is the 
principle of thymidine analogues such as EdU, PI is an intercalating agent that labels 
both DNA strands during replication. Flow cytometry-based PI assays therefore allow 
for a more accurate quantification of the number of replication events of a cell. I 
would also measure the cell cycle over a shorter period of time, or during a time-
course, to try and capture only single cell cycle events, and to more accurately 
compare DNA replication between the 2 cell lines. Due to their shape, asymmetry 
and the fact that they are multinucleated, flow cytometry analysis could not be carried 
out using myotubes. To observe changes other than DNA replication events, in the 
cell cycle state of myotubes, another method of cell cycle phase detection would 
have to be used. Immuno-blot or microarray analyses on a greater panel of cell cycle 
markers would be informative.  
Data suggests that the increased rate of protein synthesis in the presence of 
TsUBE2L3, is therefore not due to an increased rate of proliferation of myoblasts in 
the culture. However, this data does not represent what is happening in cell cycle 
arrested myotubes in the culture. Myotubes exist in a mixed population of cells that 
contains myoblasts. This consistently limits the myotube-specific signal from any 
assay. It would be ideal if myotubes could be efficiently isolated (en mass), so that 
signals would not be masked by those from the myoblast population of a culture. 
Preliminary efforts using the compound cytosine arabinoside (AraC, which kills 
replicating cells) were not effective because myotubes began to die before the 
experiment was finished (data not shown). It makes sense that the health of the 
myotube depends on the presence of the surrounding satellite cells and myoblasts, 
as was also discussed by Hinterberger et al. [352]. 
Another cell cycle factor, p53, has been previously shown to be a specific substrate 
for ubiquitination of the mammalian UBE2L3 [66,353]. Polyubiquitination of p53 by 
UBE2L3 leads to its degradation by the proteasome [65]. It was therefore 
hypothesised the highly conserved T. spiralis UBE2L3 would also be able to 
ubiquitinate p53. Initial immuno-blot analyses showed that p53 was significantly 
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down-regulated by TsUBE2L3 in myotubes and this was confirmed by radio-immuno-
precipitation, showing a significant p53 reduction in the presence of the T. spiralis E2 
enzyme. This reduction however, was not caused by a reduction in the transcript 
levels of p53, which remained largely unaffected by TsUBE2L3-HA expression over a 
24-hour period.  
It was therefore proposed that the reduction in p53 must occur at the protein level, 
and may be mediated by ubiquitination and proteasomal degradation. 
Monoubiquitination of p53 by the p53-specific E3 ligase MDM2, is usually a signal for 
nuclear export [354,355]. Nuclear accumulation of p53 above a certain level can lead 
to polyubiquitination by MDM2 and degradation of p53 by the nuclear proteasome 
[356]. Monoubiquitin-mediated nuclear export and cytoplasmic accumulation of p53 
can also lead to cytoplasmic polyubiquitination of p53, which in turn targets the 
protein for degradation by the cytoplasmic proteasome [357]. Further analysis of 
ubiquitinated forms of p53 in the presence and absence of the T. spiralis E2 would 
allow clarification of the mechanism of TsUBE2L3-mediated p53 depression. 
During the G2/M checkpoint, p53 is activated in response to DNA damage, leading to 
a transcriptional reduction in cyclin B1 that contributes to G2 arrest [338,349]. 
TsUBE2L3 expression also led to a reduction of cyclin B1 in myotubes. A 
TsUBE2L3-mediated reduction in p53 would be expected to lead to a rise in cyclin 
B1, which is the opposite of what was observed. Results therefore suggested that the 
effect of TsUBE2L3 on p53 is not linked to the effect on cyclin B1. The cyclinB1-cdK1 
complex is essential for mitosis, and so an inhibition of cyclin B1 can lead to cell 
cycle arrest before M phase [358]. When it is no longer needed after mitosis, the 
anaphase promoting complex E3 ligase is responsible for the ubiquitination of cyclin 
B1, leading to its degradation. The question therefore remains: how can TsUBE2L3 
down-regulate the tumour suppressor p53 and at the same time the promoter of 
proliferation cyclin B1. It appears likely that the mechanism of cyclin B1 suppression 
by TsUBE2L3 in C2C12 myotubes is a p53-independent process. Considering the 
complexity of cell signalling, it is also possible that the effect of the T. spiralis E2 on 
both proteins is indirect. For example, TsUBE2L3 may specifically ubiquitinate other 
proteins, having an indirect downstream effect on p53 or cyclin B1. 
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Chapter	  6:	  
Final	  Discussion	  
Significance	  of	  study	  
 
The disruption of the ubiquitin pathway is associated with various human diseases 
and has been directly implicated in the process of infection by viruses and bacteria 
[93,96,97,99,100,228,272-275,359]. Since these prokaryotic organisms do not 
express their own ubiquitin pathway, viral and bacterial-derived ubiquitin pathway 
proteins are thought to be specifically host targeted and indeed this has been 
previously demonstrated [97,98]. However, the importance of the ubiquitin pathway 
in infection extends beyond viruses and bacteria. Considering the importance of this 
pathway in eukaryotic cell biology, and its conservation throughout evolution, this 
study began with the hypothesis that eukaryotic parasites also manipulate the 
ubiquitin pathway to their advantage during infection. Because eukaryotic parasites 
express their own ubiquitin pathway, for this study the proposed contribution of this 
pathway to the process of parasitic infection was divided into 2 categories:  
1. The role of the parasite ubiquitin pathway in parasite biology. 
2. The role of the ubiquitin pathway in direct host-parasite interactions. 
The purpose of studying the parasite ubiquitin pathway during infection (thus 
addressing point 1) is two-fold. Firstly research can shed light on the evolution of the 
function of particular ubiquitin pathway components from non-parasitic to parasitic 
organisms and from lower eukaryotes to higher eukaryotes. This can help us 
understand the role of these components in important biological processes and how 
they are involved when these processes are disrupted, for example in disease. 
Secondly, it can help us identify proteins that are essential for parasite survival, thus 
identifying potential drug targets for the development of therapeutics aimed at 
blocking infection [112,230,360,361]. The importance of the ubiquitin pathway in a 
vast number of cellular processes means that certain ubiquitin pathway components 
must be essential for parasite survival during all life cycle stages. If so, targeting 
these proteins would lead to broad treatments capable of disrupting all stages during 
infection. In addition, the high conservation of ubiquitin pathway proteins amongst 
different species of the same genus, could result in therapeutics with even farther 
reaching efficacy. 
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The purpose of studying the role of the ubiquitin pathway in direct host-parasite 
interactions (thus addressing point 2) is to identify ubiquitin pathway components that 
are parasite-derived but specifically host-targeted. In the case of helminths, these will 
likely be the proteins that come into direct contact with the host during infection; the 
parasite surface or secreted proteins [2,115]. If these proteins are found to have 
antigenic potency, they may serve as novel candidates for the development of 
vaccines aimed at preventing infection. In addition, studying helminth-derived host-
targeted ubiquitin components may identify proteins that have an interesting 
modulatory effect on the biology of the host cell. These studies can be used as 
model systems to help us to dissect the mechanisms underlying the particular 
biology of the host cell that is affected by the helminth protein. This will contribute to 
our greater understanding of mammalian cell biology, its regulation and deregulation 
and provide ideas on how it may be deliberately manipulated for therapeutic benefit.  
During the infective stages, helminths require their host for survival. They therefore 
do not usually intend to kill the host, rather to evade immune recognition by down-
regulating host immunity until transmission occurs. These helminth-induced immuno-
modulatory effects can therefore, in some instances, be beneficial to the host as well. 
These beneficial effects predominantly stem from the enhanced and often sustained 
anti-inflammatory T helper 2 (TH2) immune response that gives rise to the release of 
protective cytokines [362]. This protective immune response can reverse elevated 
and pathogenic immune responses that are characteristic of allergy and autoimmune 
disease [363,364]. Various studies now show that whole parasitic nematodes can be 
administered to treat ulcerative colitis, asthma, rheumatoid arthritis, multiple sclerosis 
and type 1 diabetes amongst others [365-369]. Furthermore, human clinical trials 
have shown that infection with whole parasitic nematodes can provide relief and 
even remission from autoimmune disorders (reviewed by [370] and [371]). For 
example, ingesting pig whipworm (Trichuris suis) eggs can significantly reduce the 
symptoms of Chrohn’s disease [372,373] and the symptoms of allergic rhinitis [374]. 
All of these examples use whole parasites to stimulate a therapeutic effect. Instead, 
this study aimed to address the idea of isolated helminth effectors, with a view to the 
exploitation of helminth-derived proteins, rather than whole parasites, for therapeutic 
purposes. In contrast to the widely studied immuno-modulation by intestinal 
helminths, the purpose of this project was to look at muscle cell modulation by 
proteins of the intramuscular parasite T. spiralis, with a particular focus on the worm's 
ubiquitin pathway. 
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To date, no parasite-derived ubiquitin pathway proteins had been determined to be 
specifically host targeted. The main reason for this is technical. For many parasites, 
especially those that exist inside the host cell, it is extremely challenging to uncouple 
the parasite’s own ubiquitin pathway proteins from those that are host targeted. 
Helminths provide a solution for this problem since they secrete an abundance of 
proteins that modulate their immediate niches in the host. In some lucky cases, such 
as with T. spiralis, these secretions can be isolated from parasites in culture at high 
purity.  
I initially investigated the role of the T. spiralis ubiquitin pathway, focusing on the 
function of the deubiquitinating enzyme TsUCH37. Following this, I investigated the 
role of the ubiquitin pathway in direct host-parasite interactions during infection by T. 
spiralis, with a particular interest in identifying parasite-derived ubiquitin pathway 
modulators and dissecting their mechanism of modulation. Because T. spiralis 
doesn't kill the host muscle cell, this worm was ideal for using as a model to study the 
mechanisms underlying the reprogramming of muscle cells. 
Key	  findings	  and	  future	  work	  
 
The first significant finding was that the function of the T. spiralis DUB, TsUCH37, 
has been highly conserved throughout evolution, from nematodes to humans [1]. In 
mammals, this ubiquitin hydrolase enzyme is the only ubiquitin-C-terminal hydrolase 
(UCH) domain DUB to be associated with the proteasome [32,33,233]. It therefore 
plays a unique and crucial role in the removal of Ub from substrate proteins that have 
been targeted to the proteasome for degradation. The orthologue of this protein has 
been shown to be essential for the survival of mice and Drosophila [36,264]. 
Although I was unable to show if TsUCH37 alone is essential for the survival of T. 
spiralis in culture, this study does present evidence that the inhibition of the UCH 
domain family of enzymes leads to the death of cultured larvae. This data contributes 
to on-going work that sets precedence for the further investigation of UCH37 as a 
drug target in disease. This includes work by other members of our group that are 
studying the human malaria parasite (Plasmodium falciparum) orthologue, PfUCH54 
[102] whose knockout in blood-stage P. falciparum, is lethal (unpublished data, 
Sachiko Miyata). It has also been previously shown that despite their level of 
conservation, UCH family enzymes can be individually targeted by drugs [246-
248,267]. Further analyses of the crystal structure of TsUCH37, solved in 
collaboration with Chittaranjan Das' laboratory at Purdue University, will contribute to 
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our understanding of the structural differences between UCH DUBs and their 
orthologues that may be exploited in drug discovery [3].  
Having proven that biological tools based on human ubiquitin could be successfully 
used to study the ubiquitin pathway of T. spiralis, I wanted to use these tools to study 
the T. spiralis components that are directly involved in host-parasite interaction 
during infection, the secreted proteins. Specifically, due to their fascinating ability to 
remodel terminally differentiated skeletal muscle cells, I wanted to investigate the 
proteins involved in nurse cell formation during the invasion of muscle tissue by T. 
spiralis larvae. The T. spiralis-induced remodelling of the host cell involves changes 
in host cell transcription, differentiation and the cell cycle, biological processes for 
which the ubiquitin pathway is a major player [5,52]. It was therefore hypothesised 
that T. spiralis may secrete ubiquitin pathway components into the muscle cell that 
target and modulate the host ubiquitin pathway, contributing to nurse cell formation.  
Initially, it was found that secreted proteins of T. spiralis muscle larvae possess in 
vitro ubiquitin conjugation (E2) and ubiquitin ligation (E3) activity that was only 
activated when supplied with the human recombinant E1 and human E3 and E2 
partners, namely the E2, UBE2L3 and the E3, parkin. Efforts were then made to 
identify the proteins responsible for this activity, and after many methodologies were 
unsuccessfully explored, a proteomic analysis of all the T. spiralis secreted proteins 
was carried out. During this process, an entire putative secretome for T. spiralis was 
compiled (supplementary appendix 4). Of the 333 annotated proteins identified, 
some are redundant sequences. Data therefore suggests that in total there are less 
than 333 total proteins secreted by T. spiralis muscle larvae. Some of these proteins 
contained conserved domains and could be categorised into the various known 
processes in which they function in other organisms. Some of these functions are 
relevant to nurse cell formation, such as inflammation, angiogenesis, cytoskeletal 
arrangement, collagen production and differentiation and some are also related to 
processes that are highly regulated by the ubiquitin pathway such as the cell cycle.  
During this analysis, only 2 ubiquitin-related enzymes were identified in the T. spiralis 
secreted proteins. Interestingly, the putative T. spiralis UBE2L3, was the only E2 
identified, the orthologue of the human UBE2L3 that was able to activate the 
ubiquitination activity of T. spiralis secreted proteins in vitro. Unfortunately the protein 
initially thought to be responsible for E3 activity could not be characterised, leaving 
an interesting avenue open for further investigation. Since the E3 activity was 
confirmed but not identified using techniques based on known protein orthology, 
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there is always a chance that the source of the E3 activity may be T. spiralis specific. 
In other words, T. spiralis may express a novel domain with ubiquitin ligation activity 
that is thus far uncharacterised.  
It is worth noting that C2C12 myotubes express the mouse UBE2L3 orthologue, 
which is 68.4% identical in sequence to the T. spiralis protein (appendix 5). If T. 
spiralis secrete the E2 into a host cell that already expresses a conserved version of 
the E2, three hypotheses are viable. 1. that the function of the T. spiralis E2 is to 
collaborate with the host E1 and E3 to ubiquitinate other T. spiralis secreted proteins 
that are not recognised by the host E2, 2. that the increased concentration of 
UBE2L3 due to the addition of TsUBE2L3 enhances the function of the host E2 that 
is already present, or 3. that the T. spiralis E2 possesses novel functional activity and 
is able to recognise and ubiquitinate host protein substrates that are not recognised 
by the host orthologue. Although the evidence presented here for the secretion of 
TsUBE2L3 by muscle larvae in culture is robust, its secretion into the nurse cell was 
not confirmed. I designed 2 specific anti-TsUBE2L3 antibodies that were produced 
by Davids Biotechnology (Germany). I also prepared histological sections of nurse 
cells in rat muscle tissue for immuno-histochemical analyses [204] (appendix 6). 
However due to time constraints I was unable to complete these experiments and 
confirm the secretion of TsUBE2L3 into the nurse cell complex. This would therefore 
require completion before a role of TsUBE2L3 in nurse cell formation could be 
assigned. Nonetheless, in the interest of finding parasite-derived muscle cell 
modulators that may serve a therapeutic purpose, this detail is irrelevant. In other 
words, T. spiralis may express and secrete proteins that are not directly involved in 
parasite biology, the infection of muscle cells or nurse cell formation, but are 
nonetheless able to beneficially modulate a muscle cell phenotype. This effect could 
then be harnessed for its therapeutic potential.  
As mentioned earlier, parasite ubiquitin pathway enzymes have been previously 
characterised, however to date none have been proven to be specifically host-
targeted [102-104,113,231,375]. This study therefore presents evidence for the first 
parasite-derived host-targeted ubiquitin pathway enzyme, the T. spiralis UBE2L3. 
This ubiquitin conjugating enzyme (E2) is highly conserved and plays an important 
role in the regulation of the cell cycle in mammalian cells [319,320]. UBE2L3 is 
involved in both the passage of a cell through S phase, and the regulation by 
ubiquitination of the tumour suppressor protein p53. P53 is required for the terminal 
differentiation of skeletal muscle cells and for the cell cycle arrest that occurs during 
the G2/M checkpoint in response to DNA damage [134,338,340]. Interestingly, during 
Chapter 6: Final Discussion 
 241 
nurse cell formation T. spiralis muscle larvae induce cell cycle re-entry followed by a 
sustained state of G2/M arrest of infected myofibres via an unknown mechanism.  
To determine the potential involvement of TsUBE2L3 in these processes, I set out to 
develop a system for the characterisation of the T. spiralis secreted E2 in muscle 
cells. Many helminths including T. spiralis are refractory to established methods of 
genetic manipulation. It was therefore not possible to characterise the function of 
TsUBE2L3 by manipulating its expression in vivo and looking at the subsequent 
effect on nurse cell formation in the host. Instead, I developed an in vitro system for 
the (over) expression of the T. spiralis E2 enzyme in a skeletal muscle cell line 
C2C12. A lentiviral-mediated expression system was adopted and stable myoblast 
cell lines were generated that could be differentiated and then induced to express the 
T. spiralis protein in a timely manner. This system could potentially be employed in 
the future for characterising other T. spiralis secreted proteins of interest, such as 
those identified by the proteomic study presented here. 
C2C12 muscle cells expressing TsUBE2L3 were observed to differentiate and fuse 
forming myotubes at the same rate as the control cells. Their morphology however 
was altered. This alteration was not a result of a loss of skeletal muscle 
differentiation markers and did not affect the life span of the cells. Whitcomb et al. 
showed that the human UBE2L3 plays an important role in the progression of cells 
through S phase, but despite an unexplained rise in the rate of protein synthesis, the 
T. spiralis E2 did not enhance the rate of proliferation of C2C12 myoblasts [319,320]. 
The reason for the enhanced nuclear localisation of TsUBE2L3 in actively dividing 
myoblasts could therefore not be determined and I propose that a more robust 
investigation into the effect of the T. spiralis E2 on proliferation would be required 
before a role could be completely ruled out.  
During infection, T. spiralis-induced cell cycle re-entry of host myofibres involves 
DNA replication, and myofibre nuclei remain thereafter as 4n [162]. I speculate that 
the process of forced DNA replication, in cells that would ordinarily never again 
replicate their DNA, causes DNA damage and mutation that may activate the G2/M 
checkpoint which induces the following arrest. Inducing DNA replication in terminally 
differentiated cells is a major feat. I therefore propose that during infection, this 
process requires a complex of T. spiralis secreted proteins acting in synergy. It is 
therefore unsurprising that TsUBE2L3 alone was unable to induce DNA replication in 
terminally differentiated myotubes. It was however able to down-regulate the G2/M 
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specific cell cycle protein cyclin B1. The mechanism and consequence of this effect 
on cyclin B1 remains to be determined. 
The final finding was that TsUBE2L3 significantly down-regulates native p53 in 
C2C12 myotubes. This was surprising, since cyclin B1 down-regulation is usually 
concomitant with p53 activation and subsequent G2/M arrest, a phenotype that is 
induced by T. spiralis. It is therefore likely that either the mechanisms of p53 and 
cyclin B1 down-regulation in response to TsUBE2L3 occur independently of each 
other, or that they occur in a highly regulated time-dependent fashion. For example 
p53-induced down-regulation of cyclin B1 occurs first and is sustained, and then p53 
itself is down-regulated. This study was not able to determine the mechanism of 
either. It did conclude that the p53 depression did not occur at the transcript level, 
and therefore must occur at the protein level. It was therefore plausible that, since 
UBE2L3 is a p53-specific E2 enzyme in mammalian cells, the mechanism of p53 
down-regulation at the protein level was via proteasomal degradation.  
Some of the final experiments presented in chapter 5 would need expanding before a 
firm conclusion on the function of the T. spiralis E2 in skeletal myotubes could be 
confirmed. Future studies will be able to expand on the techniques presented here to 
further characterise TsUBE2L3 and its effect on p53. For example, the methods 
presented in this thesis could be used to develop a C2C12 cell line that expresses 
HA-tagged Ub upon induction. This could be used to analyse the entire ubiquitome of 
the muscle cell and how it may be perturbed by the T. spiralis E2. Following this with 
proteomics analyses may identify ubiquitination substrates that are specific to the T. 
spiralis E2, including p53. Using methods such as microarray and co-precipitation 
could highlight altered gene expression patterns and interaction partners and 
therefore pathways in which the protein may be involved in muscle cells. 
In summary, this thesis demonstrates viable methods for the characterisation of T. 
spiralis ubiquitin pathway proteins. Furthermore, this thesis demonstrates the 
successful development of a system for the characterisation of T. spiralis secreted 
proteins in terminally differentiated skeletal muscle cells in vitro, with a multitude of 
possible experimental read-outs.  
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Implications	  and	  future	  work	  
 
T. spiralis infection in humans is not considered a public health emergency because 
nowadays infection and mortality are rare [118]. T. spiralis however does infect 
mammals indiscriminately, posing an agricultural problem that affects livestock, and 
especially due to the nature of transmission, animals reared for meat production 
[376,377]. The treatment of muscle stage T. spiralis larvae during chronic infection is 
extremely challenging, due to the resilience of the nurse cell complex [179]. The 
initial intestinal phase of the life cycle however, is amenable to drug treatment. An 
intestinal phase of development is common to many parasitic nematodes, and in 
many cases this is the ultimate target tissue. Considering the high level of 
conservation of the ubiquitin pathway, prospective ubiquitin pathway drug targets in T. 
spiralis may also be expressed by other helminths. This could lead to the 
development of novel anthelmintics also active against parasites that pose a more 
widespread risk to human life [378].  
The ubiquitin pathway is emerging as effective target for the treatment of diseases 
such as cancer. Due to its predominant role in the regulation of the cell cycle, its 
potential as a drug target for treating cancer has been considered for some time. 
Proteasome inhibitors have reached clinical trials, DUB inhibitors have shown anti-
cancer potential in animal models, and ubiquitin conjugation machinery is being 
characterised with a view to identifying additional ubiquitin pathway targets [82,379]. 
Although thus far the ubiquitin pathway as a drug target in infectious disease has 
been largely overlooked, these studies contribute to the theory that it shows great 
potential. 
The development of the nurse cell during the infection of muscle cells by T. spiralis 
involves the manipulation of many processes that require a functional ubiquitin 
pathway. It was therefore hypothesised that some of the T. spiralis host-targeted 
proteins might be themselves ubiquitin pathway enzymes. Studying the secreted 
proteins of T. spiralis muscle larvae allowed for the distinction to be made between 
the host-targeted and the ‘parasite’s own’ proteins. It is likely that many other 
parasitic nematodes express and secrete orthologues of these proteins, and the full 
proteomic analysis of T. spiralis secreted proteins will therefore be informative to the 
helminthology community. Likewise, by identifying proteins that are involved in the 
processes required for the reprogramming of skeletal muscle cells, this study 
contributes to our understanding of the role of the ubiquitin pathway in muscle cell 
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biology, and how it may be disrupted. This information is relevant in the fields of 
regenerative medicine and muscle cell cycle disorders. Understanding how T. spiralis 
is able to re-program terminally differentiated mammalian skeletal muscle cells will 
provide insight into potential methods of manipulation of muscle cells for medically 
beneficial purposes.  
Firstly, as shown by Bai et al. the secreted proteins of T. spiralis muscle larvae are 
able to promote the proliferation of C2C12 myoblasts in culture [160,161]. Although 
the T. spiralis E2 alone did not mimic this effect, this demonstrates promise that T. 
spiralis may be used as a model for skeletal muscle-specific degenerative disorders 
such as muscular dystrophy [380]. In healthy muscle tissue, when myofibres die 
either due to age or physical injury to the tissue, satellite cells become activated to 
differentiate into myoblasts and myocytes which fuse into multinucleated, terminally 
differentiated myofibres [137,381]. One important feature of Duchenne muscular 
dystrophy is the failure of satellite cells to continue to self-renew, a feature important 
for maintaining the satellite cell pool. Over time the myoblast capacity to differentiate 
when required for the repair and regeneration of the myofibres diminishes [382]. 
Being able to isolate proteins that have the capacity to induce the proliferation of 
skeletal myoblasts may help identify pathways and mechanisms involved in 
stabilising the regenerative capacity of skeletal muscle tissue.  
Secondly, during infection by T. spiralis the secreted proteins are able to force 
terminally differentiated skeletal muscle cells to re-enter the cell cycle, indicating that 
the secreted proteins have the capacity to reverse the differentiation status of 
myofibres. This also proves that the myofibre has the molecular capacity to re-enter 
the cell cycle. During infection by SV40 and Polyoma viruses, myofibres re-enter the 
cell cycle and also undergo mitosis [172]. This shows that the myofibre also has the 
capacity to divide. Although in the case of T. spiralis, the process of cell cycle re-
entry terminates in G2/M arrest, it may be possible to separate the T. spiralis 
secreted proteins that induce the initial stages of cell cycle re-entry from those that 
induce the subsequent G2/M cell cycle arrest.  
Dissecting the mechanisms involved in the deregulation of the myofibre will help us 
understand the molecular basis of terminal differentiation, how it is sustained and 
how it may be manipulated for the purposes of tissue regeneration and repair [152]. 
This may even be through the use of T. spiralis-derived muscle cell modulators. 
During infection, helminths such as T. spiralis occupy specialised niches within the 
host, often eliciting minimal pathogenicity. The T. spiralis muscle tissue niche is a 
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perfect example of how a helminth can strike a delicate balance between host 
manipulation and host protection. The parasite modulates cell cycle differentiation 
state, angiogenesis, collagen production and many other interesting biological 
processes. Understanding how these changes occur, may lead to the discovery or 
development of parasite-derived or parasite-inspired therapeutics, with the aim of 
treating disease. This may not be restricted to muscle or cell cycle-related disorders, 
nor to the T. spiralis niche as a model. This thesis therefore ends with the proposal 
that host-targeted proteins of parasites may one day become parasite-derived 
therapeutics.
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Appendices	  
Appendix	  1.	  Co-­‐precipitation	  of	  6His-­‐TsUCH37	  with	  T.	  spiralis	  lysate 	  
# 
Identified Proteins (109) 
Accession 
Number 
(alternative no.) 
Predicted 
molecular 
weight 
No. of 
unique 
peptides Band 
Conserved 
proteasome-
related 
domain 
Proteasome 
subunit 
BLAST human 
homologue 
1 
putative proteasome activator 
complex subunit 3 [Trichinella 
spiralis] 
gi|316965573 
(+1) 
28 kDa 13 
4, 5, 6, 
10, 12, 
16 
PA28 immuno-
proteasome 
PSME3 
2 
26S proteasome non-ATPase 
regulatory subunit 2 [Trichinella 
spiralis] 
gi|316977340 
(+1) 102 kDa 28 2 RPN1 19S base 
proteasome 
(prosome, 
macropain) 26S 
subunit, non-
ATPase, 2 
3 
26S proteasome non-ATPase 
regulatory subunit 1 [Trichinella 
spiralis] 
gi|316971878 
(+1) 156 kDa 18 1 RPN2 19S base 
26S proteasome 
non-ATPase 
regulatory subunit 
1  
4 
26S protease regulatory subunit 
4 [Trichinella spiralis] 
gi|316975801 
(+1) 74 kDa 18 8 RPT1 19S base 
26S protease 
regulatory subunit 
8 
5 
putative 26S proteasome non-
ATPase regulatory subunit 8 
[Trichinella spiralis] 
gi|316974557 
(+1) 31 kDa 7 7 RPT1 19S base 
26S protease 
regulatory subunit 
7 
6 
26S proteasome non-ATPase 
regulatory subunit 4 [Trichinella 
spiralis] 
gi|316973936 
(+1) 45 kDa 4 4, 9 RPN10 19S base 
proteasome 
(prosome, 
macropain) 26S 
subunit, non-
ATPase, 4 
7 26S protease regulatory subunit 6A [Trichinella spiralis] 
gi|316979457 
(+1) 51 kDa 8 ? RPT1 19S base 
26S protease 
regulatory subunit 
6A 
8 
proteasome subunit alpha type-1 
[Trichinella spiralis] 
gi|316971831 
(+1) 218 kDa 4 8 
proteasome 
subunit alpha 
type-1 
20S 
proteasome 
subunit alpha type-
1  
9 
proteasome subunit beta type-1 
[Trichinella spiralis] 
gi|316971688 
(+1) 34 kDa 2 8 
Ntn 
hydrolase 20S 
proteasome beta 1 
subunit variant 
10 proteasome activator complex 
subunit 3 [Trichinella spiralis] 
gi|316969768 
(+1) 
16 kDa 3 7, 8 PA28 immuno-
proteasome 
PSME3 
11 proteasome subunit alpha type-6 [Trichinella spiralis] 
gi|316976218 
(+1) 13 kDa 2 8 
Ntn 
hydrolase 20s 
proteasome 
subunit alpha type-
6 
12 
proteasome subunit beta type-6 
[Trichinella spiralis] 
gi|316976433 
(+1) 62 kDa 3 12, 13 
Ntn 
hydrolase 20s 
proteasome 
subunit beta type-
6 
13 
proteasome subunit alpha type-
2-A [Trichinella spiralis] 
gi|316973439 
(+1) 26 kDa 4 10 
Ntn 
hydrolase 20s 
proteasome 
subunit alpha type-
2 
14 
26S proteasome non-ATPase 
regulatory subunit 11 [Trichinella 
spiralis] 
gi|316975446 
(+1) 
50 kDa 4 4 RPN6 19S lid 
26S proteasome 
non-ATPase 
regulatory subunit 
11 
15 protein ADRM1 [Trichinella spiralis] 
gi|316977948 
(+1) 
46 kDa 3 9 Rpn13, 
UCH37_bd 
19S base ADRM1 
16 
26S proteasome non-ATPase 
regulatory subunit 3 [Trichinella 
spiralis] 
gi|316974493 59 kDa 6 7 PCI, Rpn3_C 19S lid 
Proteasome 
(prosome, 
macropain) 26S 
subunit, non-
ATPase, 3 
17 
26S proteasome non-ATPase 
regulatory subunit 4 [Trichinella 
spiralis] 
gi|316973936 45 kDa 6 9 RPN10 19S base 
proteasome 
(prosome, 
macropain) 26S 
subunit, non-
ATPase, 4 
18 
26S protease regulatory subunit 
6B [Trichinella spiralis] gi|316968151 39 kDa 4 11 RPT1 19S base 
26S protease 
regulatory subunit 
6B  
19 26S protease regulatory subunit 
8 [Trichinella spiralis] gi|316972496 39 kDa 4 12 RPT1 19S base 
26S protease 
regulatory subunit 
8 
 
Appendix 1. Co-precipitation of 6His-TsUCH37 with T. spiralis lysate 
Table of all putative T. spiralis proteasome subunits identified by LC/MS/MS of the co-
precipitation of 6His-TsUCH37 with lysate of T. spiralis muscle larvae. 
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Appendix	  2.	  Bioinformatics	  prediction	  of	  T.	  spiralis	  secreted	  proteins	  
Programme  GI accession # Description 
iPSORT, wolfPSORT 
and signalP 
339242525 E3 ubiquitin-protein ligase 
339238271 E3 ubiquitin-protein ligase RNF34 
339237319 RING finger protein 13 
339245151 RWD domain protein 
iPSORT only 339261774 BTB/POZ domain-containing protein KCTD17 
iPSORT and wolfPSORT 
339235861 E3 ubiquitin-protein ligase synoviolin-A 
339262132 E3 ubiquitin-protein ligase sia-1 
339237381 ubiquitin-conjugating enzyme E2 2 
339233898 ubiquitin-conjugating enzyme E2 
339264723 RING-H2 finger protein ATL1D 
339245539 polycomb group RING finger protein 3 
339236113 polycomb group RING finger protein 1 
339264545 bromodomain and WD repeat-containing protein 2 
339237985 WD domain, G-beta repeat-containing domain protein 
339234805 putative WD repeat-containing protein 85 
339239945 putative WD repeat-containing protein 3 
339238813 WD domain, G-beta repeat-containing domain protein (WD48) 
339242135 bromodomain and WD repeat-containing protein 2 
339253068 putative HECT-domain protein (NEDD4-L) 
339246471 putative HECT-domain protein 
iPSORT and signalP 
339235583 E3 ubiquitin-protein ligase synoviolin-A 
339234781 putative HECT-domain protein 
wolfPSORT only 
339235337 ubiquitin-conjugating enzyme E2-21 protein 
339233478 ubiquitin-conjugating enzyme E2 K  
339236213 ubiquitin-conjugating enzyme E2 O 
339238007  ubiquitin carboxyl- hydrolase, family 1 
339248837 ubiquitin-conjugating enzyme E2 variant 2 
339244557 ubiquitin carboxyl- hydrolase 7 
339236793 ubiquitin-conjugating enzyme E2 Q1 
339250668 ubiquitin-conjugating enzyme E2 G2 
339252782 ubiquitin-conjugating enzyme 
339242301 ubiquitin-fold modifier 1 
339233154 putative ubiquitin associated and SH3 domain-containing protein A 
339253040 ubiquitin-conjugating enzyme E2 1 
339252718 ubiquitin-conjugating enzyme E2 1 
339243657 putative ubiquitin associated and SH3 domain-containing protein B 
339257344 ubiquitin-conjugating enzyme E22  
339232770 E3 ubiquitin-protein ligase UBR3 
339246159 putative ubiquitin carboxyl- hydrolase CYLD  
339260542 putative ubiquitin associated and SH3 domain-containing protein B 
339261298 putative ubiquitin family protein 
339239021  ubiquitin-conjugating enzyme E2-18 kDa 
339235805 E3 ubiquitin-protein ligase synoviolin-A 
339240047 ubiquitin-conjugating enzyme E2 L3  
339241693 ubiquitin-related modifier 1 
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339262230 putative ubiquitin family protein 
339253028 ubiquitin-conjugating enzyme E2 1 
339257342 ubiquitin-conjugating enzyme E22 
339259260 ubiquitin carboxyl- hydrolase 4 
339247039 ubiquitin carboxyl- hydrolase 20 
339265467 ubiquitin conjugation factor E4 B 
339257152 ubiquitin-conjugating enzyme E22 
339255776 ubiquitin carboxyl- hydrolase superfamily 
339252976 ubiquitin-conjugating enzyme E2 1 
339232982  ubiquitin family protein 
339265657 putative ubiquitin associated and SH3 domain-containing protein B 
339259274 E3 ubiquitin-protein ligase UBR5 
339265187 putative ubiquitin-conjugating enzyme E2 S 
339252692 ubiquitin-conjugating enzyme E2 1 
339252686 ubiquitin-conjugating enzyme E2 1 
339235675 E3 ubiquitin-protein ligase Siah1 
339258098 putative ubiquitin associated and SH3 domain-containing protein B 
339232958 ubiquitin family protein 
339263734 ubiquitin associated and SH3 domain-containing protein B 
339239901 putative ubiquitin associated and SH3 domain-containing protein B 
339252980 ubiquitin-conjugating enzyme E2 1 
339232996 ubiquitin family protein 
339246865 ubiquitin carboxyl- hydrolase 14 
339263786 putative ubiquitin family protein 
339258236 putative ubiquitin associated and SH3 domain-containing protein B 
339247273 ubiquitin carboxyl- hydrolase BAP1  
339257336 ubiquitin-conjugating enzyme E22 
339252978 ubiquitin-conjugating enzyme E2 1 
339256894 ubiquitin-related modifier 1 
339258230 putative ubiquitin associated and SH3 domain-containing protein B 
339258130 putative ubiquitin associated and SH3 domain-containing protein B 
339253044 ubiquitin-conjugating enzyme E2 1 
339257338 ubiquitin-conjugating enzyme E22 
339236215 putative ubiquitin-conjugating enzyme protein 17 
339252880 E3 ubiquitin-protein ligase 
339250174 BTB/POZ domain-containing protein KCTD12 
339236281 putative BTB/POZ domain protein  
339259936 BTB/POZ domain-containing protein TNFAIP1 
339246047 BTB/POZ domain-containing protein KCTD2 
339250176 BTB/POZ domain-containing protein KCTD8 
339246107 BTB/POZ domain-containing protein KCTD3 
339243199 putative BTB/POZ domain protein 
339250172 BTB/POZ domain-containing protein KCTD16 
339249469 putative UBA/TS-N domain protein 
339265151 cullin-4B 
339240427 cullin family protein 
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339250980 RING finger protein 44 
339243635 putative MIZ/SP-RING zinc finger 
339252988 RING-H2 finger protein ATL2A 
339253520 SUMO-conjugating enzyme UBC9 
339235373 WD repeat-containing protein 68 
339261602 putative WD repeat-containing protein 54 
339248885 WD repeat-containing protein 82 
339246903 putative WD repeat-containing protein 43 
339247185 WD repeat-containing protein 20 
339247269 WD repeat-containing protein 74 
339248763 katanin p80 WD40-containing subunit B1 
339234581 WD repeat-containing protein 51A 
339261652 putative bromodomain and WD repeat-containing protein 2 
339262962 WD repeat-containing protein 51A 
339237779 WD domain, G-beta repeat-containing domain protein 
339238527 WD domain, G-beta repeat-containing domain protein 
339265355 WD repeat-containing protein 47 
339264228 bromodomain and WD repeat-containing protein 2 
339238381 WD domain, G-beta repeat-containing domain protein 
339242147 bromodomain and WD repeat-containing protein 2 (WDR11) 
339246265 WD domain, G-beta repeat-containing domain protein 
339242167 putative bromodomain and WD repeat-containing protein 2 
339240803 WD repeat-containing protein 19 
339237047 putative WD repeat-containing protein 55 
339262234 WD domain, G-beta repeat-containing domain protein 
339264901 WD repeat-containing protein 82 
339242171 putative bromodomain and WD repeat-containing protein 2 
339241089 WD repeat-containing protein 24 
339241997 WD repeat-containing protein 24 
339261604 putative ThiF family protein 
339253356 putative HECT-domain protein 
339250272 putative HECT-domain protein 
339253450 putative HECT-domain protein 
339261350 E3 SUMO-protein ligase SIZ2 
339253520 SUMO-conjugating enzyme UBC9 
339264292 E3 SUMO-protein ligase PIAS4 
wolfPSORT and signalP 
339235867 E3 ubiquitin-protein ligase synoviolin-A 
339263624 putative ubiquitin--protein ligase 
signalP only 339246163 cullin-4B 
 
Appendix 2. Bioinformatics prediction of T. spiralis secreted proteins 
All ubiquitin-related putative T. spiralis proteins predicted by iPSORT, signalP and 
wolfPSORT to be secreted  
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Appendix	  3.	  Proteomic	  analysis	  of	  anti-­‐NEDD4-­‐L	  reactive	  T.	  spiralis	  SP	  
  
Identified Proteins (29) Accession Number 
Molecular 
Weight 
Band excised (numbered) 
# 1 2 3 4 5 6 
1 serine protease [Trichinella spiralis] gi|168805931 35 kDa 17 93 55 0 92 15 
2 serine protease [Trichinella spiralis] gi|168805933 
(+2) 
48 kDa 79 31 55 0 47 41 
3 multi cystatin-like domain protein precursor [Trichinella spiralis] 
gi|111183175 
(+3) 46 kDa 2 21 145 0 39 5 
4 
secreted 5'-nucleotidase [Trichinella 
spiralis] gi|22656349 62 kDa 31 0 0 0 2 37 
5 conserved hypothetical protein 
[Trichinella spiralis] 
gi|316972936 
(+1) 
59 kDa 3 0 0 35 2 10 
6 conserved hypothetical protein [Trichinella spiralis] 
gi|316974176 
(+1) 41 kDa 2 0 0 30 0 0 
7 
RWD domain protein [Trichinella 
spiralis] 
gi|316972581 
(+3) 77 kDa 2 0 0 31 0 7 
8 putative sulfhydryl oxidase 1 
[Trichinella spiralis] 
gi|316977588 
(+1) 
73 kDa 7 0 0 0 0 22 
9 large tegument protein [Trichinella spiralis] 
gi|316971025 
(+1) 84 kDa 19 0 0 0 0 4 
10 
putative Low-density lipoprotein 
receptor repeat class B [Trichinella 
spiralis] 
gi|316971109 
(+1) 168 kDa 0 5 6 0 10 0 
11 conserved hypothetical protein [Trichinella spiralis] 
gi|316966482 
(+1) 58 kDa 0 0 0 11 0 6 
12 
putative sodium/potassium-
transporting ATPase subunit beta-1 
[Trichinella spiralis] 
gi|316971027 
(+1) 
91 kDa 8 3 2 0 3 3 
13 conserved hypothetical protein [Trichinella spiralis] gi|339258164 29 kDa 0 3 5 0 7 0 
14 
conserved hypothetical protein 
[Trichinella spiralis] 
gi|316972588 
(+1) 51 kDa 0 0 0 32 0 10 
15 putative fasciclin domain protein 
[Trichinella spiralis] 
gi|316968555 
(+1) 
66 kDa 3 0 0 0 0 5 
16 putative ISDet3, transposase OrfA [Trichinella spiralis] 
gi|316975125 
(+1) 50 kDa 4 0 0 0 0 6 
17 DNase II [Trichinella spiralis] gi|117581955 (+3) 38 kDa 0 0 3 0 2 0 
18 
48 kDa poly-cysteine and histidine 
tailed protein precursor [Trichinella 
spiralis] 
gi|291170388 
(+5) 48 kDa 0 0 0 0 2 0 
19 
putative calcium binding EGF domain 
protein [Trichinella spiralis] 
gi|316975135 
(+1) 280 kDa 4 0 0 0 0 0 
20 conserved hypothetical protein 
[Trichinella spiralis] 
gi|316974192 
(+1) 
57 kDa 0 0 0 21 0 0 
21 
putative nudix hydrolase [Trichinella 
spiralis] gi|164521920 46 kDa 0 0 0 27 0 0 
22 
putative Fe-S protein assembly co-
chaperone HscB [Trichinella spiralis] 
gi|316965621 
(+1) 119 kDa 2 0 0 0 0 0 
23 adenosylhomocysteinase [Trichinella spiralis] 
gi|316966393 
(+1) 
47 kDa 0 0 0 0 4 0 
24 enolase [Trichinella spiralis] gi|13937125 (+3) 48 kDa 0 0 4 0 0 0 
25 
DNA polymerase (Pol2) superfamily 
[Trichinella spiralis] 
gi|316969308 
(+1) 134 kDa 2 0 0 0 0 0 
26 UNC45 protein [Trichinella spiralis] gi|316971886 
(+1) 
138 kDa 0 0 0 0 2 0 
27 papilin [Trichinella spiralis] gi|316976630 (+1) 231 kDa 3 0 0 0 0 0 
28 
conserved hypothetical protein 
[Trichinella spiralis] 
gi|316964581 
(+1) 30 kDa 0 0 0 13 0 0 
29 conserved hypothetical protein 
[Trichinella spiralis] 
gi|316978836 
(+1) 
52 kDa 0 2 0 0 0 0 
 
Appendix 3. Proteomic analysis of anti-NEDD4-L reactive T. spiralis SP 
LC/MS/MS results of 6 anti-NEDD4-L reactive protein bands manually excised for analysis  
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Appendix	  4.	  Analysis	  of	  the	  effect	  of	  MG132	  on	  TsUBE2L3-­‐HA	  expression	  in	  
C2C12	  myotubes.	  
 
 
 
Appendix 4. Analysis of the effect of MG132 on TsUBE2L3-HA expression in C2C12 
myotubes.  
Myotube empty vector and TsUBE2L3-HA cell lines were grown in the presence and absence 
of MG132 before analysis by immuno-blot (IB) of the effect of MG132 on TsUBE2L3-HA using 
anti-HA antibodies. The same samples were analysed using anti-tubulin antibodies as a 
protein loading control. 
Appendices 
 270 
Appendix	  5.	  Analysis	  of	  UBE2L3	  expression	  in	  C2C12	  myotube	  empty	  vector	  
and	  TsUBE2L3-­‐HA	  cell	  lines.	  
 
 
 
Appendix 5. Analysis of UBE2L3 expression in C2C12 myotube empty vector and 
TsUBE2L3-HA cell lines.  
Myotube empty vector and TsUBE2L3-HA cell lines were induced using doxycycline for 24 
hours before analysis by immuno-blot (IB) using anti-human UBE2L3 antibodies. The same 
samples were analysed by coomassie staining as a protein loading control. 
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Appendix	  6.	  Paraffin	  sections	  of	  T.	  spiralis	  infected	  rat	  muscle	  tissue	  
 
Appendix  6
 
 
Appendix 6. Paraffin sections of T. spiralis infected rat muscle tissue 
T. spiralis infected rat tissue (triceps, tongue and diaphragm) was collected 1 month after 
infection and 12 months after infection. Tissues were dissected and fixed in 10% neutral 
buffered formalin overnight at 4°C. Tissues were embedded in paraffin and 4 µm sections 
were cut and stained using Hematoxylin and eosin, all using standard protocols [194]. Arrows 
indicate the outer collagen capsule.
Appendices 
 272 
Appendix	  7.	  Structural analysis of the catalytic domain of TsUCH37	  
 
Appendix 7. Structural analysis of the catalytic domain of TsUCH37 
The crystal structure of TsUCH37cat-Ub-VME (Morrow et al. Biochemistry 2013 [3]). A. The 
crystal structure of TsUCH37cat (blue) in complex with Ub-VME (orange) with the structure of 
human UCH37 (olive, PDB 3RIS) superimposed. The crossover loop location of each DUB is 
boxed in red. B. A close-up of the active-site residues of the TsUCH37cat-Ub-VME and human 
UCH37 superimposition. Positions of the active-site residues Gln, Cys, His, and Asp and their 
bond distances are shown. C. Electrostatic charge map of the active-site clefts of human 
UCH37 (left) with Ub modelled into the binding position (grey) and TsUCH37cat (right) bound 
to Ub-VME (orange). The catalytic cleft is circled and the active-site cysteine is highlighted in 
yellow. Positive charges are red, negative charges are blue and neutral charged are white. 
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